Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,24954342,T1/2,"Diclofenac potassium had the lowest T1/2 and the highest mean Css, muscle/Css, plasma (1.9 hours and 0.85±0.53, respectively).",Concentration of non-steroidal anti-inflammatory drugs in the pelvic floor muscles: an experimental comparative rat model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24954342/),h,1.9,2086,DB00814,Meloxicam
,24954342,"Css, muscle/Css","Diclofenac potassium had the lowest T1/2 and the highest mean Css, muscle/Css, plasma (1.9 hours and 0.85±0.53, respectively).",Concentration of non-steroidal anti-inflammatory drugs in the pelvic floor muscles: an experimental comparative rat model. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24954342/),,0.85,2087,DB00814,Meloxicam
,29057473,Terminal half-life,"Terminal half-life (6.88 ± 2.96 hr), volume of distribution at steady-state (186.53 ± 61.20 ml/Kg) and clearance (27.91 ± 5.72 ml kg-1 hr-1 ) were similar to those reported in literature for healthy horses.",Postoperative pharmacokinetics of meloxicam in horses after surgery for colic syndrome. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29057473/),h,6.88,5532,DB00814,Meloxicam
,29057473,volume of distribution at steady-state,"Terminal half-life (6.88 ± 2.96 hr), volume of distribution at steady-state (186.53 ± 61.20 ml/Kg) and clearance (27.91 ± 5.72 ml kg-1 hr-1 ) were similar to those reported in literature for healthy horses.",Postoperative pharmacokinetics of meloxicam in horses after surgery for colic syndrome. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29057473/),[ml] / [kg],186.53,5533,DB00814,Meloxicam
,29057473,clearance,"Terminal half-life (6.88 ± 2.96 hr), volume of distribution at steady-state (186.53 ± 61.20 ml/Kg) and clearance (27.91 ± 5.72 ml kg-1 hr-1 ) were similar to those reported in literature for healthy horses.",Postoperative pharmacokinetics of meloxicam in horses after surgery for colic syndrome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29057473/),[ml] / [h·kg],27.91,5534,DB00814,Meloxicam
,20425727,peak plasma concentration,"A mean peak plasma concentration of 3.10 microg/ml (range, 2.64 to 3.79 microg/ml) was recorded at 11.64 hours (range, 10 to 12 hours) with a half-life of 27.54 hours (range, 19.97 to 43.29 hours) after oral meloxicam administration.",Pharmacokinetics of intravenous and oral meloxicam in ruminant calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20425727/),[μg] / [ml],3.10,8041,DB00814,Meloxicam
,20425727,half-life,"A mean peak plasma concentration of 3.10 microg/ml (range, 2.64 to 3.79 microg/ml) was recorded at 11.64 hours (range, 10 to 12 hours) with a half-life of 27.54 hours (range, 19.97 to 43.29 hours) after oral meloxicam administration.",Pharmacokinetics of intravenous and oral meloxicam in ruminant calves. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20425727/),h,27.54,8042,DB00814,Meloxicam
,20425727,bioavailability,"The bioavailability of oral meloxicam corrected for dose was 1.00 (range, 0.64 to 1.66).",Pharmacokinetics of intravenous and oral meloxicam in ruminant calves. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20425727/),,1.00,8043,DB00814,Meloxicam
,34333251,Cmax,"The Cmax values of MEL were 1.92 ± 0.34 μg/ml and 3.03 ± 1.25 μg/ml at dosages of 0.8 and 2 mg/kg b.w. while the tmax values were 3.25 ± 1.04 h and 4.00 ± 1.26 h, respectively.",Comparative pharmacokinetics of meloxicam oil suspension in pigs at different dosages following intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34333251/),[μg] / [ml],1.92,10756,DB00814,Meloxicam
,34333251,Cmax,"The Cmax values of MEL were 1.92 ± 0.34 μg/ml and 3.03 ± 1.25 μg/ml at dosages of 0.8 and 2 mg/kg b.w. while the tmax values were 3.25 ± 1.04 h and 4.00 ± 1.26 h, respectively.",Comparative pharmacokinetics of meloxicam oil suspension in pigs at different dosages following intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34333251/),[μg] / [ml],3.03,10757,DB00814,Meloxicam
,34333251,tmax,"The Cmax values of MEL were 1.92 ± 0.34 μg/ml and 3.03 ± 1.25 μg/ml at dosages of 0.8 and 2 mg/kg b.w. while the tmax values were 3.25 ± 1.04 h and 4.00 ± 1.26 h, respectively.",Comparative pharmacokinetics of meloxicam oil suspension in pigs at different dosages following intramuscular administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34333251/),h,3.25,10758,DB00814,Meloxicam
,34333251,tmax,"The Cmax values of MEL were 1.92 ± 0.34 μg/ml and 3.03 ± 1.25 μg/ml at dosages of 0.8 and 2 mg/kg b.w. while the tmax values were 3.25 ± 1.04 h and 4.00 ± 1.26 h, respectively.",Comparative pharmacokinetics of meloxicam oil suspension in pigs at different dosages following intramuscular administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34333251/),h,4.00,10759,DB00814,Meloxicam
,17395544,t(1/2beta),"The mean+/-S.E. values of t(1/2beta), MRT, AUC and Cl(B) in sheep were 10.85+/-1.21 h, 15.13+/-1.67 h, 31.88+/-2.97 microg h mL(-1) and 0.016+/-0.002 L h(-1) kg(-1), respectively whereas the respective values in goats were 6.73+/-0.58 h, 9.37+/-0.83 h, 19.23+/-2.23 microg h mL(-1) and 0.03+/-0.01 L h(-1) kg(-1).",Comparative plasma pharmacokinetics of meloxicam in sheep and goats following intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17395544/),h,10.85,10900,DB00814,Meloxicam
,17395544,MRT,"The mean+/-S.E. values of t(1/2beta), MRT, AUC and Cl(B) in sheep were 10.85+/-1.21 h, 15.13+/-1.67 h, 31.88+/-2.97 microg h mL(-1) and 0.016+/-0.002 L h(-1) kg(-1), respectively whereas the respective values in goats were 6.73+/-0.58 h, 9.37+/-0.83 h, 19.23+/-2.23 microg h mL(-1) and 0.03+/-0.01 L h(-1) kg(-1).",Comparative plasma pharmacokinetics of meloxicam in sheep and goats following intravenous administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17395544/),h,15.13,10901,DB00814,Meloxicam
,17395544,AUC,"The mean+/-S.E. values of t(1/2beta), MRT, AUC and Cl(B) in sheep were 10.85+/-1.21 h, 15.13+/-1.67 h, 31.88+/-2.97 microg h mL(-1) and 0.016+/-0.002 L h(-1) kg(-1), respectively whereas the respective values in goats were 6.73+/-0.58 h, 9.37+/-0.83 h, 19.23+/-2.23 microg h mL(-1) and 0.03+/-0.01 L h(-1) kg(-1).",Comparative plasma pharmacokinetics of meloxicam in sheep and goats following intravenous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17395544/),h,15.13,10902,DB00814,Meloxicam
,17395544,Cl(B),"The mean+/-S.E. values of t(1/2beta), MRT, AUC and Cl(B) in sheep were 10.85+/-1.21 h, 15.13+/-1.67 h, 31.88+/-2.97 microg h mL(-1) and 0.016+/-0.002 L h(-1) kg(-1), respectively whereas the respective values in goats were 6.73+/-0.58 h, 9.37+/-0.83 h, 19.23+/-2.23 microg h mL(-1) and 0.03+/-0.01 L h(-1) kg(-1).",Comparative plasma pharmacokinetics of meloxicam in sheep and goats following intravenous administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17395544/),[l] / [h·kg],0.016,10903,DB00814,Meloxicam
,17395544,Cl(B),"The mean+/-S.E. values of t(1/2beta), MRT, AUC and Cl(B) in sheep were 10.85+/-1.21 h, 15.13+/-1.67 h, 31.88+/-2.97 microg h mL(-1) and 0.016+/-0.002 L h(-1) kg(-1), respectively whereas the respective values in goats were 6.73+/-0.58 h, 9.37+/-0.83 h, 19.23+/-2.23 microg h mL(-1) and 0.03+/-0.01 L h(-1) kg(-1).",Comparative plasma pharmacokinetics of meloxicam in sheep and goats following intravenous administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17395544/),h,9.37,10904,DB00814,Meloxicam
,25314827,peak plasma concentration,"After oral administration, a peak plasma concentration of 1.03 microg/mL was achieved at approximately 11 hr.",Pharmacokinetics of single dose oral meloxicam in bottlenose dolphins (Tursiops truncatus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25314827/),[μg] / [ml],1.03,11278,DB00814,Meloxicam
,25314827,elimination half-life,"However, the elimination of meloxicam in cetaceans was slower than in other species, with an elimination half-life of almost 70 hr, and detectable drug concentrations up to 7 days.",Pharmacokinetics of single dose oral meloxicam in bottlenose dolphins (Tursiops truncatus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25314827/),h,70,11279,DB00814,Meloxicam
,15379436,S:R ratio,(S)-(+)-KTP was the predominant enantiomer; the S:R ratio in the plasma increased from 2.58 +/- 0.38 at 15 min to 5.72 +/- 2.35 at 1 h.,A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379436/),,2.58,13592,DB00814,Meloxicam
,15379436,S:R ratio,(S)-(+)-KTP was the predominant enantiomer; the S:R ratio in the plasma increased from 2.58 +/- 0.38 at 15 min to 5.72 +/- 2.35 at 1 h.,A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379436/),,5.72,13593,DB00814,Meloxicam
,15379436,Tmax,"The mean (+/- SD) pharmacokinetic parameters for (S)-(+)-KTP were characterized as Tmax = 0.76 +/- 0.19 h, Cmax = 2.02 +/- 0.41 microg/ml, t1/2el = 1.65 +/- 0.48 h, AUC = 6.06 +/- 1.16 microg.h/ml, Vd/F = 0.39 +/- 0.07 L/kg, Cl/F = 170 +/- 39 ml/(kg.h).",A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379436/),h,0.76,13594,DB00814,Meloxicam
,15379436,Cmax,"The mean (+/- SD) pharmacokinetic parameters for (S)-(+)-KTP were characterized as Tmax = 0.76 +/- 0.19 h, Cmax = 2.02 +/- 0.41 microg/ml, t1/2el = 1.65 +/- 0.48 h, AUC = 6.06 +/- 1.16 microg.h/ml, Vd/F = 0.39 +/- 0.07 L/kg, Cl/F = 170 +/- 39 ml/(kg.h).",A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379436/),[μg] / [ml],2.02,13595,DB00814,Meloxicam
,15379436,t1/2el,"The mean (+/- SD) pharmacokinetic parameters for (S)-(+)-KTP were characterized as Tmax = 0.76 +/- 0.19 h, Cmax = 2.02 +/- 0.41 microg/ml, t1/2el = 1.65 +/- 0.48 h, AUC = 6.06 +/- 1.16 microg.h/ml, Vd/F = 0.39 +/- 0.07 L/kg, Cl/F = 170 +/- 39 ml/(kg.h).",A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379436/),h,1.65,13596,DB00814,Meloxicam
,15379436,AUC,"The mean (+/- SD) pharmacokinetic parameters for (S)-(+)-KTP were characterized as Tmax = 0.76 +/- 0.19 h, Cmax = 2.02 +/- 0.41 microg/ml, t1/2el = 1.65 +/- 0.48 h, AUC = 6.06 +/- 1.16 microg.h/ml, Vd/F = 0.39 +/- 0.07 L/kg, Cl/F = 170 +/- 39 ml/(kg.h).",A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379436/),[h·μg] / [ml],6.06,13597,DB00814,Meloxicam
,15379436,Vd/F,"The mean (+/- SD) pharmacokinetic parameters for (S)-(+)-KTP were characterized as Tmax = 0.76 +/- 0.19 h, Cmax = 2.02 +/- 0.41 microg/ml, t1/2el = 1.65 +/- 0.48 h, AUC = 6.06 +/- 1.16 microg.h/ml, Vd/F = 0.39 +/- 0.07 L/kg, Cl/F = 170 +/- 39 ml/(kg.h).",A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379436/),[l] / [kg],0.39,13598,DB00814,Meloxicam
,15379436,Cl/F,"The mean (+/- SD) pharmacokinetic parameters for (S)-(+)-KTP were characterized as Tmax = 0.76 +/- 0.19 h, Cmax = 2.02 +/- 0.41 microg/ml, t1/2el = 1.65 +/- 0.48 h, AUC = 6.06 +/- 1.16 microg.h/ml, Vd/F = 0.39 +/- 0.07 L/kg, Cl/F = 170 +/- 39 ml/(kg.h).",A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379436/),[ml] / [h·kg],170,13599,DB00814,Meloxicam
,15379436,Tmax,"The mean (+/- SD) pharmacokinetic parameters of MLX were Tmax = 8.5 +/- 1.91 h, Cmax = 0.82 +/- 0.29 microg/ml, t1/2lambda(z) = 12.13 +/- 2.15 h, AUCinf = 15.41 +/- 1.24 microg.h/ml, Vd/F = 0.23 +/- 0.03 L/ kg, and Cl/F = 10 +/- 1.4 ml/(kg.h).",A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379436/),h,8.5,13600,DB00814,Meloxicam
,15379436,Cmax,"The mean (+/- SD) pharmacokinetic parameters of MLX were Tmax = 8.5 +/- 1.91 h, Cmax = 0.82 +/- 0.29 microg/ml, t1/2lambda(z) = 12.13 +/- 2.15 h, AUCinf = 15.41 +/- 1.24 microg.h/ml, Vd/F = 0.23 +/- 0.03 L/ kg, and Cl/F = 10 +/- 1.4 ml/(kg.h).",A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379436/),[μg] / [ml],0.82,13601,DB00814,Meloxicam
,15379436,t1/2lambda(z),"The mean (+/- SD) pharmacokinetic parameters of MLX were Tmax = 8.5 +/- 1.91 h, Cmax = 0.82 +/- 0.29 microg/ml, t1/2lambda(z) = 12.13 +/- 2.15 h, AUCinf = 15.41 +/- 1.24 microg.h/ml, Vd/F = 0.23 +/- 0.03 L/ kg, and Cl/F = 10 +/- 1.4 ml/(kg.h).",A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379436/),h,12.13,13602,DB00814,Meloxicam
,15379436,AUCinf,"The mean (+/- SD) pharmacokinetic parameters of MLX were Tmax = 8.5 +/- 1.91 h, Cmax = 0.82 +/- 0.29 microg/ml, t1/2lambda(z) = 12.13 +/- 2.15 h, AUCinf = 15.41 +/- 1.24 microg.h/ml, Vd/F = 0.23 +/- 0.03 L/ kg, and Cl/F = 10 +/- 1.4 ml/(kg.h).",A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379436/),[h·μg] / [ml],15.41,13603,DB00814,Meloxicam
,15379436,Vd/F,"The mean (+/- SD) pharmacokinetic parameters of MLX were Tmax = 8.5 +/- 1.91 h, Cmax = 0.82 +/- 0.29 microg/ml, t1/2lambda(z) = 12.13 +/- 2.15 h, AUCinf = 15.41 +/- 1.24 microg.h/ml, Vd/F = 0.23 +/- 0.03 L/ kg, and Cl/F = 10 +/- 1.4 ml/(kg.h).",A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379436/),[l] / [kg],0.23,13604,DB00814,Meloxicam
,15379436,Cl/F,"The mean (+/- SD) pharmacokinetic parameters of MLX were Tmax = 8.5 +/- 1.91 h, Cmax = 0.82 +/- 0.29 microg/ml, t1/2lambda(z) = 12.13 +/- 2.15 h, AUCinf = 15.41 +/- 1.24 microg.h/ml, Vd/F = 0.23 +/- 0.03 L/ kg, and Cl/F = 10 +/- 1.4 ml/(kg.h).",A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15379436/),[ml] / [h·kg],10,13605,DB00814,Meloxicam
,21034318,terminal half-life,"There were no significant differences between PO and IV administration with regard to terminal half-life (mean ± SD, 12.96 ± 8.05 hours and 9.93 ± 4.92 hours, respectively), mean area under the curve to the last measured concentration (5.08 ± 1.62 μg•h/mL and 5.83 ± 2.49 μg•h/mL), volume of distribution (745 ± 475 mL/kg and 487 ± 266 mL/kg), or clearance (40.17 ± 10.35 mL/kg/h and 37.17 ± 16.08 mL/kg/h).",Pharmacokinetics of meloxicam following intravenous and oral administration in green iguanas (Iguana iguana). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034318/),h,12.96,14119,DB00814,Meloxicam
,21034318,terminal half-life,"There were no significant differences between PO and IV administration with regard to terminal half-life (mean ± SD, 12.96 ± 8.05 hours and 9.93 ± 4.92 hours, respectively), mean area under the curve to the last measured concentration (5.08 ± 1.62 μg•h/mL and 5.83 ± 2.49 μg•h/mL), volume of distribution (745 ± 475 mL/kg and 487 ± 266 mL/kg), or clearance (40.17 ± 10.35 mL/kg/h and 37.17 ± 16.08 mL/kg/h).",Pharmacokinetics of meloxicam following intravenous and oral administration in green iguanas (Iguana iguana). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034318/),h,9.93,14120,DB00814,Meloxicam
,21034318,area under the curve to the last measured concentration,"There were no significant differences between PO and IV administration with regard to terminal half-life (mean ± SD, 12.96 ± 8.05 hours and 9.93 ± 4.92 hours, respectively), mean area under the curve to the last measured concentration (5.08 ± 1.62 μg•h/mL and 5.83 ± 2.49 μg•h/mL), volume of distribution (745 ± 475 mL/kg and 487 ± 266 mL/kg), or clearance (40.17 ± 10.35 mL/kg/h and 37.17 ± 16.08 mL/kg/h).",Pharmacokinetics of meloxicam following intravenous and oral administration in green iguanas (Iguana iguana). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034318/),[h·μg] / [ml],5.08,14121,DB00814,Meloxicam
,21034318,area under the curve to the last measured concentration,"There were no significant differences between PO and IV administration with regard to terminal half-life (mean ± SD, 12.96 ± 8.05 hours and 9.93 ± 4.92 hours, respectively), mean area under the curve to the last measured concentration (5.08 ± 1.62 μg•h/mL and 5.83 ± 2.49 μg•h/mL), volume of distribution (745 ± 475 mL/kg and 487 ± 266 mL/kg), or clearance (40.17 ± 10.35 mL/kg/h and 37.17 ± 16.08 mL/kg/h).",Pharmacokinetics of meloxicam following intravenous and oral administration in green iguanas (Iguana iguana). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034318/),[h·μg] / [ml],5.83,14122,DB00814,Meloxicam
,21034318,volume of distribution,"There were no significant differences between PO and IV administration with regard to terminal half-life (mean ± SD, 12.96 ± 8.05 hours and 9.93 ± 4.92 hours, respectively), mean area under the curve to the last measured concentration (5.08 ± 1.62 μg•h/mL and 5.83 ± 2.49 μg•h/mL), volume of distribution (745 ± 475 mL/kg and 487 ± 266 mL/kg), or clearance (40.17 ± 10.35 mL/kg/h and 37.17 ± 16.08 mL/kg/h).",Pharmacokinetics of meloxicam following intravenous and oral administration in green iguanas (Iguana iguana). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034318/),[ml] / [kg],745,14123,DB00814,Meloxicam
,21034318,volume of distribution,"There were no significant differences between PO and IV administration with regard to terminal half-life (mean ± SD, 12.96 ± 8.05 hours and 9.93 ± 4.92 hours, respectively), mean area under the curve to the last measured concentration (5.08 ± 1.62 μg•h/mL and 5.83 ± 2.49 μg•h/mL), volume of distribution (745 ± 475 mL/kg and 487 ± 266 mL/kg), or clearance (40.17 ± 10.35 mL/kg/h and 37.17 ± 16.08 mL/kg/h).",Pharmacokinetics of meloxicam following intravenous and oral administration in green iguanas (Iguana iguana). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034318/),[ml] / [kg],487,14124,DB00814,Meloxicam
,21034318,clearance,"There were no significant differences between PO and IV administration with regard to terminal half-life (mean ± SD, 12.96 ± 8.05 hours and 9.93 ± 4.92 hours, respectively), mean area under the curve to the last measured concentration (5.08 ± 1.62 μg•h/mL and 5.83 ± 2.49 μg•h/mL), volume of distribution (745 ± 475 mL/kg and 487 ± 266 mL/kg), or clearance (40.17 ± 10.35 mL/kg/h and 37.17 ± 16.08 mL/kg/h).",Pharmacokinetics of meloxicam following intravenous and oral administration in green iguanas (Iguana iguana). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034318/),[ml] / [h·kg],40.17,14125,DB00814,Meloxicam
,21034318,clearance,"There were no significant differences between PO and IV administration with regard to terminal half-life (mean ± SD, 12.96 ± 8.05 hours and 9.93 ± 4.92 hours, respectively), mean area under the curve to the last measured concentration (5.08 ± 1.62 μg•h/mL and 5.83 ± 2.49 μg•h/mL), volume of distribution (745 ± 475 mL/kg and 487 ± 266 mL/kg), or clearance (40.17 ± 10.35 mL/kg/h and 37.17 ± 16.08 mL/kg/h).",Pharmacokinetics of meloxicam following intravenous and oral administration in green iguanas (Iguana iguana). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034318/),[ml] / [h·kg],37.17,14126,DB00814,Meloxicam
,21034318,Maximum plasma concentration,Maximum plasma concentration was significantly greater following IV (0.63 ± 0.17 μg/mL) versus PO (0.19 ± 0.07 μg/mL) administration.,Pharmacokinetics of meloxicam following intravenous and oral administration in green iguanas (Iguana iguana). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034318/),[μg] / [ml],0.63,14127,DB00814,Meloxicam
,21034318,Maximum plasma concentration,Maximum plasma concentration was significantly greater following IV (0.63 ± 0.17 μg/mL) versus PO (0.19 ± 0.07 μg/mL) administration.,Pharmacokinetics of meloxicam following intravenous and oral administration in green iguanas (Iguana iguana). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034318/),[μg] / [ml],0.19,14128,DB00814,Meloxicam
,34405424,Total run time,Total run time was 4.0 min.,Using a stable isotope-labeled internal standard for liquid chromatography-tandem mass spectrometry quantitation of meloxicam in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34405424/),min,4.0,14781,DB00814,Meloxicam
,34405424,Cmax,"After a single-dose oral administration of 7.5 mg meloxicam, the main pharmacokinetic parameters were as follows: Cmax , 814.79 ± 201.37 ng mL-1 ; Tmax , 4.54 ± 1.42 h; AUC0-t , 24,572.04 ± 5766.93 ng·h mL-1 ; AUC0-∞ , 25,810.89 ± 6796.60 ng·h mL-1 and t1/2 , 21.11 ± 5.35 h.",Using a stable isotope-labeled internal standard for liquid chromatography-tandem mass spectrometry quantitation of meloxicam in human plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34405424/),[ng] / [ml],814.79,14782,DB00814,Meloxicam
,34405424,Tmax,"After a single-dose oral administration of 7.5 mg meloxicam, the main pharmacokinetic parameters were as follows: Cmax , 814.79 ± 201.37 ng mL-1 ; Tmax , 4.54 ± 1.42 h; AUC0-t , 24,572.04 ± 5766.93 ng·h mL-1 ; AUC0-∞ , 25,810.89 ± 6796.60 ng·h mL-1 and t1/2 , 21.11 ± 5.35 h.",Using a stable isotope-labeled internal standard for liquid chromatography-tandem mass spectrometry quantitation of meloxicam in human plasma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34405424/),h,4.54,14783,DB00814,Meloxicam
,34405424,AUC0-t,"After a single-dose oral administration of 7.5 mg meloxicam, the main pharmacokinetic parameters were as follows: Cmax , 814.79 ± 201.37 ng mL-1 ; Tmax , 4.54 ± 1.42 h; AUC0-t , 24,572.04 ± 5766.93 ng·h mL-1 ; AUC0-∞ , 25,810.89 ± 6796.60 ng·h mL-1 and t1/2 , 21.11 ± 5.35 h.",Using a stable isotope-labeled internal standard for liquid chromatography-tandem mass spectrometry quantitation of meloxicam in human plasma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34405424/),[h·ng] / [ml],"24,572.04",14784,DB00814,Meloxicam
,34405424,AUC0-∞,"After a single-dose oral administration of 7.5 mg meloxicam, the main pharmacokinetic parameters were as follows: Cmax , 814.79 ± 201.37 ng mL-1 ; Tmax , 4.54 ± 1.42 h; AUC0-t , 24,572.04 ± 5766.93 ng·h mL-1 ; AUC0-∞ , 25,810.89 ± 6796.60 ng·h mL-1 and t1/2 , 21.11 ± 5.35 h.",Using a stable isotope-labeled internal standard for liquid chromatography-tandem mass spectrometry quantitation of meloxicam in human plasma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34405424/),[h·ng] / [ml],"25,810.89",14785,DB00814,Meloxicam
,34405424,t1/2,"After a single-dose oral administration of 7.5 mg meloxicam, the main pharmacokinetic parameters were as follows: Cmax , 814.79 ± 201.37 ng mL-1 ; Tmax , 4.54 ± 1.42 h; AUC0-t , 24,572.04 ± 5766.93 ng·h mL-1 ; AUC0-∞ , 25,810.89 ± 6796.60 ng·h mL-1 and t1/2 , 21.11 ± 5.35 h.",Using a stable isotope-labeled internal standard for liquid chromatography-tandem mass spectrometry quantitation of meloxicam in human plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34405424/),h,21.11,14786,DB00814,Meloxicam
,12151025,half-life,"Preliminary pharmacokinetics, determined by isocratic high-performance liquid chromatography (HPLC), revealed no difference in the half-life of paracetamol (2.5+/-0.3 h) vs. meloxicam (3.4+/-0.4 h).",Observer-blinded comparison of two nonopioid analgesics for postoperative pain in piglets. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12151025/),h,2.5,15741,DB00814,Meloxicam
,12151025,half-life,"Preliminary pharmacokinetics, determined by isocratic high-performance liquid chromatography (HPLC), revealed no difference in the half-life of paracetamol (2.5+/-0.3 h) vs. meloxicam (3.4+/-0.4 h).",Observer-blinded comparison of two nonopioid analgesics for postoperative pain in piglets. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12151025/),h,3.4,15742,DB00814,Meloxicam
,31579940,clearance,"The clearance was slow (0.00975 L/hr*Kg), the volume of distribution small (0.0487 L/kg), and the IV half-life was 5.06 ± 2.32 hr.",Pharmacokinetic profiles of meloxicam after single IV and PO administration in Bilgorajska geese. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31579940/),[l] / [h·kg],0.00975,19095,DB00814,Meloxicam
,31579940,volume of distribution,"The clearance was slow (0.00975 L/hr*Kg), the volume of distribution small (0.0487 L/kg), and the IV half-life was 5.06 ± 2.32 hr.",Pharmacokinetic profiles of meloxicam after single IV and PO administration in Bilgorajska geese. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31579940/),[l] / [kg],0.0487,19096,DB00814,Meloxicam
,31579940,IV half-life,"The clearance was slow (0.00975 L/hr*Kg), the volume of distribution small (0.0487 L/kg), and the IV half-life was 5.06 ± 2.32 hr.",Pharmacokinetic profiles of meloxicam after single IV and PO administration in Bilgorajska geese. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31579940/),h,5.06,19097,DB00814,Meloxicam
,31579940,bioavailability,The average absolute PO bioavailability was 64.2 ± 24.0%.,Pharmacokinetic profiles of meloxicam after single IV and PO administration in Bilgorajska geese. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31579940/),%,64.2,19098,DB00814,Meloxicam
up to,23542493,solubility,"Due to nanonization the solubility of meloxicam elevated up to 1.2mg/mL, additionally the extent of dissolution also increased, complete dissolution was observed in 15 min.",In vitro and in vivo characterization of meloxicam nanoparticles designed for nasal administration. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23542493/),[mg] / [ml],1.2,19806,DB00814,Meloxicam
,21219346,terminal half-life,"In the adult goats after intravenous administration the terminal half-life was 10.9 ± 1.7 h, steady-state volume of distribution was 0.245 ± 0.06 L/kg, and total body clearance was 17.9 ± 4.3 mL/h/kg.",Pharmacokinetics of meloxicam in adult goats and its analgesic effect in disbudded kids. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219346/),h,10.9,23319,DB00814,Meloxicam
,21219346,steady-state volume of distribution,"In the adult goats after intravenous administration the terminal half-life was 10.9 ± 1.7 h, steady-state volume of distribution was 0.245 ± 0.06 L/kg, and total body clearance was 17.9 ± 4.3 mL/h/kg.",Pharmacokinetics of meloxicam in adult goats and its analgesic effect in disbudded kids. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219346/),[l] / [kg],0.245,23320,DB00814,Meloxicam
,21219346,total body clearance,"In the adult goats after intravenous administration the terminal half-life was 10.9 ± 1.7 h, steady-state volume of distribution was 0.245 ± 0.06 L/kg, and total body clearance was 17.9 ± 4.3 mL/h/kg.",Pharmacokinetics of meloxicam in adult goats and its analgesic effect in disbudded kids. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219346/),[ml] / [h·kg],17.9,23321,DB00814,Meloxicam
,21219346,bioavailability,"After oral administration bioavailability was 79 ± 19%, C(max) was 736 ± 184 ng/mL, T(max) was 15 ±5 h, although the terminal half-life was similar to the intravenous value, 11.8 ± 1.7 h.",Pharmacokinetics of meloxicam in adult goats and its analgesic effect in disbudded kids. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219346/),%,79,23322,DB00814,Meloxicam
,21219346,C(max),"After oral administration bioavailability was 79 ± 19%, C(max) was 736 ± 184 ng/mL, T(max) was 15 ±5 h, although the terminal half-life was similar to the intravenous value, 11.8 ± 1.7 h.",Pharmacokinetics of meloxicam in adult goats and its analgesic effect in disbudded kids. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219346/),[ng] / [ml],736,23323,DB00814,Meloxicam
,21219346,T(max),"After oral administration bioavailability was 79 ± 19%, C(max) was 736 ± 184 ng/mL, T(max) was 15 ±5 h, although the terminal half-life was similar to the intravenous value, 11.8 ± 1.7 h.",Pharmacokinetics of meloxicam in adult goats and its analgesic effect in disbudded kids. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219346/),h,15,23324,DB00814,Meloxicam
,21219346,terminal half-life,"After oral administration bioavailability was 79 ± 19%, C(max) was 736 ± 184 ng/mL, T(max) was 15 ±5 h, although the terminal half-life was similar to the intravenous value, 11.8 ± 1.7 h.",Pharmacokinetics of meloxicam in adult goats and its analgesic effect in disbudded kids. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219346/),h,11.8,23325,DB00814,Meloxicam
,26612429,peak plasma concentrations,Mean peak plasma concentrations were greater (1.91 (SD 0.39) vs. 0.71 (SD 0.17) µg/mL) and the time to reach them shorter (3.20 (SD 1.64) vs. 14.33 (SD 2.19) hours) following S/C compared with oral administration (p<0.05).,"Pharmacokinetics of meloxicam in adult goats: a comparative study of subcutaneous, oral and intravenous administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612429/),[μg] / [ml],1.91,26419,DB00814,Meloxicam
,26612429,peak plasma concentrations,Mean peak plasma concentrations were greater (1.91 (SD 0.39) vs. 0.71 (SD 0.17) µg/mL) and the time to reach them shorter (3.20 (SD 1.64) vs. 14.33 (SD 2.19) hours) following S/C compared with oral administration (p<0.05).,"Pharmacokinetics of meloxicam in adult goats: a comparative study of subcutaneous, oral and intravenous administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612429/),[μg] / [ml],0.71,26420,DB00814,Meloxicam
,26612429,time to reach them,Mean peak plasma concentrations were greater (1.91 (SD 0.39) vs. 0.71 (SD 0.17) µg/mL) and the time to reach them shorter (3.20 (SD 1.64) vs. 14.33 (SD 2.19) hours) following S/C compared with oral administration (p<0.05).,"Pharmacokinetics of meloxicam in adult goats: a comparative study of subcutaneous, oral and intravenous administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612429/),h,3.20,26421,DB00814,Meloxicam
,26612429,time to reach them,Mean peak plasma concentrations were greater (1.91 (SD 0.39) vs. 0.71 (SD 0.17) µg/mL) and the time to reach them shorter (3.20 (SD 1.64) vs. 14.33 (SD 2.19) hours) following S/C compared with oral administration (p<0.05).,"Pharmacokinetics of meloxicam in adult goats: a comparative study of subcutaneous, oral and intravenous administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612429/),h,14.33,26422,DB00814,Meloxicam
,26612429,terminal half-life,"The terminal half-life was longer (15.16 (SD 4.74) vs. 10.69 (SD 1.49) hours) and the MRT was shorter (15.67 (SD 2.37) vs. 24.33 (SD 3.12) hours) following S/C than oral administration (p<0.05), but bioavailability was similar (98.24 (SD 9.62) vs. 96.49 (SD 10.71)%).","Pharmacokinetics of meloxicam in adult goats: a comparative study of subcutaneous, oral and intravenous administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612429/),h,15.16,26423,DB00814,Meloxicam
,26612429,terminal half-life,"The terminal half-life was longer (15.16 (SD 4.74) vs. 10.69 (SD 1.49) hours) and the MRT was shorter (15.67 (SD 2.37) vs. 24.33 (SD 3.12) hours) following S/C than oral administration (p<0.05), but bioavailability was similar (98.24 (SD 9.62) vs. 96.49 (SD 10.71)%).","Pharmacokinetics of meloxicam in adult goats: a comparative study of subcutaneous, oral and intravenous administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612429/),h,10.69,26424,DB00814,Meloxicam
,26612429,MRT,"The terminal half-life was longer (15.16 (SD 4.74) vs. 10.69 (SD 1.49) hours) and the MRT was shorter (15.67 (SD 2.37) vs. 24.33 (SD 3.12) hours) following S/C than oral administration (p<0.05), but bioavailability was similar (98.24 (SD 9.62) vs. 96.49 (SD 10.71)%).","Pharmacokinetics of meloxicam in adult goats: a comparative study of subcutaneous, oral and intravenous administration. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612429/),h,15.67,26425,DB00814,Meloxicam
,26612429,MRT,"The terminal half-life was longer (15.16 (SD 4.74) vs. 10.69 (SD 1.49) hours) and the MRT was shorter (15.67 (SD 2.37) vs. 24.33 (SD 3.12) hours) following S/C than oral administration (p<0.05), but bioavailability was similar (98.24 (SD 9.62) vs. 96.49 (SD 10.71)%).","Pharmacokinetics of meloxicam in adult goats: a comparative study of subcutaneous, oral and intravenous administration. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612429/),h,24.33,26426,DB00814,Meloxicam
,26612429,bioavailability,"The terminal half-life was longer (15.16 (SD 4.74) vs. 10.69 (SD 1.49) hours) and the MRT was shorter (15.67 (SD 2.37) vs. 24.33 (SD 3.12) hours) following S/C than oral administration (p<0.05), but bioavailability was similar (98.24 (SD 9.62) vs. 96.49 (SD 10.71)%).","Pharmacokinetics of meloxicam in adult goats: a comparative study of subcutaneous, oral and intravenous administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612429/),%,98.24,26427,DB00814,Meloxicam
,26612429,bioavailability,"The terminal half-life was longer (15.16 (SD 4.74) vs. 10.69 (SD 1.49) hours) and the MRT was shorter (15.67 (SD 2.37) vs. 24.33 (SD 3.12) hours) following S/C than oral administration (p<0.05), but bioavailability was similar (98.24 (SD 9.62) vs. 96.49 (SD 10.71)%).","Pharmacokinetics of meloxicam in adult goats: a comparative study of subcutaneous, oral and intravenous administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612429/),%,96.49,26428,DB00814,Meloxicam
,8838440,absolute bioavailability,3. Following i.m. administration meloxicam was rapidly and completely absorbed (mean absolute bioavailability 102%).,Pharmacokinetics and tolerability of meloxicam after i.m. administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8838440/),%,102,26959,DB00814,Meloxicam
,8838440,initial plasma concentrations,"4. Intravenous administration of meloxicam (15 mg) resulted in higher initial plasma concentrations (C3min, i.e. concentration in plasma 3 min after start of injection = 2.99 +/- 0.75 microgram.ml-1) than after i.m. injection (Cmax: 1.62 +/- 0.20 mg ml-1).",Pharmacokinetics and tolerability of meloxicam after i.m. administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8838440/),[μg] / [ml],2.99,26960,DB00814,Meloxicam
,8838440,Cmax,"4. Intravenous administration of meloxicam (15 mg) resulted in higher initial plasma concentrations (C3min, i.e. concentration in plasma 3 min after start of injection = 2.99 +/- 0.75 microgram.ml-1) than after i.m. injection (Cmax: 1.62 +/- 0.20 mg ml-1).",Pharmacokinetics and tolerability of meloxicam after i.m. administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8838440/),[mg] / [ml],1.62,26961,DB00814,Meloxicam
,8838440,apparent elimination half-life,All other pharmacokinetic parameters were similar for both routes of administration (apparent elimination half-life = 15-22 h; plasma clearance = 7-9 ml min-1).,Pharmacokinetics and tolerability of meloxicam after i.m. administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8838440/),h,15-22,26962,DB00814,Meloxicam
,8838440,plasma clearance,All other pharmacokinetic parameters were similar for both routes of administration (apparent elimination half-life = 15-22 h; plasma clearance = 7-9 ml min-1).,Pharmacokinetics and tolerability of meloxicam after i.m. administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8838440/),[ml] / [min],7-9,26963,DB00814,Meloxicam
,21635268,terminal elimination half-life (t(1/2β) ),The results obtained (mean ± SD) were as follows: the terminal elimination half-life (t(1/2β) ) was 40.2 ± 16.8 h and total body clearance (Cl(T) ) was 1.94 ± 0.66 mL·kg/h.,The pharmacokinetics and metabolism of meloxicam in camels after intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21635268/),h,40.2,28238,DB00814,Meloxicam
,21635268,total body clearance (Cl(T) ),The results obtained (mean ± SD) were as follows: the terminal elimination half-life (t(1/2β) ) was 40.2 ± 16.8 h and total body clearance (Cl(T) ) was 1.94 ± 0.66 mL·kg/h.,The pharmacokinetics and metabolism of meloxicam in camels after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21635268/),[kg·ml] / [h],1.94,28239,DB00814,Meloxicam
,21635268,volume of distribution at steady state (V(SS)),The volume of distribution at steady state (V(SS)) was 92.8 ± 13.7 mL/kg.,The pharmacokinetics and metabolism of meloxicam in camels after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21635268/),[ml] / [kg],92.8,28240,DB00814,Meloxicam
,21883284,rate of drug absorption,"The rate of drug absorption was faster (P<0.01) in PRF (0.237±0.0478/h) than RG calves (0.0815±0.0188/h), while absorption in PRG calves (0.153±0.128/h) was not different from other groups.",Pharmacokinetics of oral meloxicam in ruminant and preruminant calves. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21883284/),1/[h],0.237,31940,DB00814,Meloxicam
,21883284,rate of drug absorption,"The rate of drug absorption was faster (P<0.01) in PRF (0.237±0.0478/h) than RG calves (0.0815±0.0188/h), while absorption in PRG calves (0.153±0.128/h) was not different from other groups.",Pharmacokinetics of oral meloxicam in ruminant and preruminant calves. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21883284/),1/[h],0.0815,31941,DB00814,Meloxicam
,21883284,absorption,"The rate of drug absorption was faster (P<0.01) in PRF (0.237±0.0478/h) than RG calves (0.0815±0.0188/h), while absorption in PRG calves (0.153±0.128/h) was not different from other groups.",Pharmacokinetics of oral meloxicam in ruminant and preruminant calves. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21883284/),1/[h],0.153,31942,DB00814,Meloxicam
,21883284,C(max),"C(max) was lower (P=0.03) in PRF (1.27±0.430 μg/mL) than in PRG calves (2.20±0.467 μg/mL), while C(max) of RG calves (1.95±0.955 μg/mL) was not different from other groups.",Pharmacokinetics of oral meloxicam in ruminant and preruminant calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21883284/),[μg] / [ml],1.27,31943,DB00814,Meloxicam
,21883284,C(max),"C(max) was lower (P=0.03) in PRF (1.27±0.430 μg/mL) than in PRG calves (2.20±0.467 μg/mL), while C(max) of RG calves (1.95±0.955 μg/mL) was not different from other groups.",Pharmacokinetics of oral meloxicam in ruminant and preruminant calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21883284/),[μg] / [ml],2.20,31944,DB00814,Meloxicam
,21883284,C(max),"C(max) was lower (P=0.03) in PRF (1.27±0.430 μg/mL) than in PRG calves (2.20±0.467 μg/mL), while C(max) of RG calves (1.95±0.955 μg/mL) was not different from other groups.",Pharmacokinetics of oral meloxicam in ruminant and preruminant calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21883284/),[μg] / [ml],1.95,31945,DB00814,Meloxicam
,21883284,V/F,"V/F was higher in PRF calves (365±57 mL/kg) than either PRG (177±63 mL/kg, P<0.01) or RG (232±83 mL/kg, P=0.01) calves.",Pharmacokinetics of oral meloxicam in ruminant and preruminant calves. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21883284/),[ml] / [kg],365,31946,DB00814,Meloxicam
,21883284,V/F,"V/F was higher in PRF calves (365±57 mL/kg) than either PRG (177±63 mL/kg, P<0.01) or RG (232±83 mL/kg, P=0.01) calves.",Pharmacokinetics of oral meloxicam in ruminant and preruminant calves. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21883284/),[ml] / [kg],177,31947,DB00814,Meloxicam
,21883284,V/F,"V/F was higher in PRF calves (365±57 mL/kg) than either PRG (177±63 mL/kg, P<0.01) or RG (232±83 mL/kg, P=0.01) calves.",Pharmacokinetics of oral meloxicam in ruminant and preruminant calves. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21883284/),[ml] / [kg],232,31948,DB00814,Meloxicam
,11867967,peak plasma drug concentration (C(max)),The pharmacokinetic studies showed peak plasma drug concentration (C(max)) of 48.48 +/- 6.57 microg/ml at 2 h (T(max)) after topical application of 500 mg of meloxicam gel formulation.,Comparison of analgesic and anti-inflammatory activity of meloxicam gel with diclofenac and piroxicam gels in animal models: pharmacokinetic parameters after topical application. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11867967/),[μg] / [ml],48.48,32035,DB00814,Meloxicam
,11867967,T(max),The pharmacokinetic studies showed peak plasma drug concentration (C(max)) of 48.48 +/- 6.57 microg/ml at 2 h (T(max)) after topical application of 500 mg of meloxicam gel formulation.,Comparison of analgesic and anti-inflammatory activity of meloxicam gel with diclofenac and piroxicam gels in animal models: pharmacokinetic parameters after topical application. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11867967/),h,2,32036,DB00814,Meloxicam
,11867967,area under the curve,The area under the curve as calculated from 0 to 6 h was found to be 114.18 +/- 4.23 and 194.13 +/- 3.78 microg x h/ml for 0 to infinity.,Comparison of analgesic and anti-inflammatory activity of meloxicam gel with diclofenac and piroxicam gels in animal models: pharmacokinetic parameters after topical application. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11867967/),[h·μg] / [ml],114.18,32037,DB00814,Meloxicam
,11867967,area under the curve,The area under the curve as calculated from 0 to 6 h was found to be 114.18 +/- 4.23 and 194.13 +/- 3.78 microg x h/ml for 0 to infinity.,Comparison of analgesic and anti-inflammatory activity of meloxicam gel with diclofenac and piroxicam gels in animal models: pharmacokinetic parameters after topical application. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11867967/),[h·μg] / [ml],194.13,32038,DB00814,Meloxicam
,16032972,flow-rate,A flow-rate of 2 mL/min achieves a complete chromatographic run (including column equilibration) within 12 min.,A non-extracting procedure for the determination of meloxicam in plasma samples by HPLC-diode array detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16032972/),[ml] / [min],2,32479,DB00814,Meloxicam
,32420638,elimination half-life (t1/2 ʎz ),"In the control group following the administration of meloxicam, mean elimination half-life (t1/2 ʎz ), area under the concentration-time curve (AUC0-∞ ), total body clearance (ClT ), and volume of distribution at steady-state (Vdss ) were 13.50 ± 0.62 hr, 41.10 ± 2.86 hr µg/ml, 24.43 ± 1.75 ml hr-1 kg-1 , and 0.45 ± 0.03 L/kg, respectively.",Effect of castration procedure on the pharmacokinetics of meloxicam in goat kids. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32420638/),h,13.50,32670,DB00814,Meloxicam
,32420638,area under the concentration-time curve (AUC0-∞ ),"In the control group following the administration of meloxicam, mean elimination half-life (t1/2 ʎz ), area under the concentration-time curve (AUC0-∞ ), total body clearance (ClT ), and volume of distribution at steady-state (Vdss ) were 13.50 ± 0.62 hr, 41.10 ± 2.86 hr µg/ml, 24.43 ± 1.75 ml hr-1 kg-1 , and 0.45 ± 0.03 L/kg, respectively.",Effect of castration procedure on the pharmacokinetics of meloxicam in goat kids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32420638/),[h·μg] / [ml],41.10,32671,DB00814,Meloxicam
,32420638,area under the concentration-time curve (AUC0-∞ ),"In the control group following the administration of meloxicam, mean elimination half-life (t1/2 ʎz ), area under the concentration-time curve (AUC0-∞ ), total body clearance (ClT ), and volume of distribution at steady-state (Vdss ) were 13.50 ± 0.62 hr, 41.10 ± 2.86 hr µg/ml, 24.43 ± 1.75 ml hr-1 kg-1 , and 0.45 ± 0.03 L/kg, respectively.",Effect of castration procedure on the pharmacokinetics of meloxicam in goat kids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32420638/),[ml] / [h·kg],24.43,32672,DB00814,Meloxicam
,32420638,total body clearance (ClT ),"In the control group following the administration of meloxicam, mean elimination half-life (t1/2 ʎz ), area under the concentration-time curve (AUC0-∞ ), total body clearance (ClT ), and volume of distribution at steady-state (Vdss ) were 13.50 ± 0.62 hr, 41.10 ± 2.86 hr µg/ml, 24.43 ± 1.75 ml hr-1 kg-1 , and 0.45 ± 0.03 L/kg, respectively.",Effect of castration procedure on the pharmacokinetics of meloxicam in goat kids. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32420638/),[h·μg] / [ml],41.10,32673,DB00814,Meloxicam
,32420638,volume of distribution at steady-state (Vdss ),"In the control group following the administration of meloxicam, mean elimination half-life (t1/2 ʎz ), area under the concentration-time curve (AUC0-∞ ), total body clearance (ClT ), and volume of distribution at steady-state (Vdss ) were 13.50 ± 0.62 hr, 41.10 ± 2.86 hr µg/ml, 24.43 ± 1.75 ml hr-1 kg-1 , and 0.45 ± 0.03 L/kg, respectively.",Effect of castration procedure on the pharmacokinetics of meloxicam in goat kids. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32420638/),[l] / [kg],0.45,32674,DB00814,Meloxicam
,15566093,Plasma clearance,"Plasma clearance was low (mean +/- SD; 34 +/- 0.5 mL/kg/h), steady-state volume of distribution was limited (0.12 +/- 0.018 L/kg), and terminal half-life was 8.54 +/- 3.02 hours.",Pharmacokinetics of meloxicam in plasma and urine of horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15566093/),[ml] / [h·kg],34,32915,DB00814,Meloxicam
,15566093,steady-state volume of distribution,"Plasma clearance was low (mean +/- SD; 34 +/- 0.5 mL/kg/h), steady-state volume of distribution was limited (0.12 +/- 0.018 L/kg), and terminal half-life was 8.54 +/- 3.02 hours.",Pharmacokinetics of meloxicam in plasma and urine of horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15566093/),[l] / [kg],0.12,32916,DB00814,Meloxicam
,15566093,terminal half-life,"Plasma clearance was low (mean +/- SD; 34 +/- 0.5 mL/kg/h), steady-state volume of distribution was limited (0.12 +/- 0.018 L/kg), and terminal half-life was 8.54 +/- 3.02 hours.",Pharmacokinetics of meloxicam in plasma and urine of horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15566093/),h,8.54,32917,DB00814,Meloxicam
,15566093,bioavailability,"After oral administration, bioavailability was nearly total regardless of feeding status (98 +/- 12% in fed horses and 85 +/- 19% in nonfed horses).",Pharmacokinetics of meloxicam in plasma and urine of horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15566093/),%,98,32918,DB00814,Meloxicam
,15566093,bioavailability,"After oral administration, bioavailability was nearly total regardless of feeding status (98 +/- 12% in fed horses and 85 +/- 19% in nonfed horses).",Pharmacokinetics of meloxicam in plasma and urine of horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15566093/),%,85,32919,DB00814,Meloxicam
,23380429,tmax,"Test product was characterized by a slightly earlier tmax than the reference, i.e., 4.9 ± 1.1 vs.",Bioequivalence study of a novel orodispersible tablet of meloxicam in a porous matrix after single-dose administration in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23380429/),,4.9,33917,DB00814,Meloxicam
,31153785,time to maximal plasma concentration,Meloxicam in guinea pigs exhibited a moderate absorption rate after oral dosing (time to maximal plasma concentration 3.7 ± 1.7 hours) and maximal plasma concentration was 0.92 ± 0.30 μg mL-1.,Pharmacokinetics and absolute oral bioavailability of meloxicam in guinea pigs (Cavia porcellus). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31153785/),h,3.7,34268,DB00814,Meloxicam
,31153785,maximal plasma concentration,Meloxicam in guinea pigs exhibited a moderate absorption rate after oral dosing (time to maximal plasma concentration 3.7 ± 1.7 hours) and maximal plasma concentration was 0.92 ± 0.30 μg mL-1.,Pharmacokinetics and absolute oral bioavailability of meloxicam in guinea pigs (Cavia porcellus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31153785/),[μg] / [ml],0.92,34269,DB00814,Meloxicam
,31153785,total body clearance,"After IV administration, total body clearance and volume of distribution were 0.13 ± 0.04 and 0.72 ± 0.36 L kg-1, respectively.",Pharmacokinetics and absolute oral bioavailability of meloxicam in guinea pigs (Cavia porcellus). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31153785/),[l] / [kg],0.13,34270,DB00814,Meloxicam
,31153785,volume of distribution,"After IV administration, total body clearance and volume of distribution were 0.13 ± 0.04 and 0.72 ± 0.36 L kg-1, respectively.",Pharmacokinetics and absolute oral bioavailability of meloxicam in guinea pigs (Cavia porcellus). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31153785/),[l] / [kg],0.72,34271,DB00814,Meloxicam
,31153785,Terminal half-life,"Terminal half-life was 3.7 ± 0.7 hours and 3.5 ± 1.1 hours after IV and oral administration, respectively.",Pharmacokinetics and absolute oral bioavailability of meloxicam in guinea pigs (Cavia porcellus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31153785/),h,3.7,34272,DB00814,Meloxicam
,31153785,Terminal half-life,"Terminal half-life was 3.7 ± 0.7 hours and 3.5 ± 1.1 hours after IV and oral administration, respectively.",Pharmacokinetics and absolute oral bioavailability of meloxicam in guinea pigs (Cavia porcellus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31153785/),h,3.5,34273,DB00814,Meloxicam
,31153785,Body extraction ratio,Body extraction ratio was 0.0087 and mean absorption time was 3.8 ± 1.7 hours.,Pharmacokinetics and absolute oral bioavailability of meloxicam in guinea pigs (Cavia porcellus). ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31153785/),,0.0087,34274,DB00814,Meloxicam
,31153785,mean absorption time,Body extraction ratio was 0.0087 and mean absorption time was 3.8 ± 1.7 hours.,Pharmacokinetics and absolute oral bioavailability of meloxicam in guinea pigs (Cavia porcellus). ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31153785/),h,3.8,34275,DB00814,Meloxicam
,31153785,absolute oral bioavailability,The absolute oral bioavailability was 0.54 ± 0.14 in unfasted guinea pigs.,Pharmacokinetics and absolute oral bioavailability of meloxicam in guinea pigs (Cavia porcellus). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31153785/),,0.54,34276,DB00814,Meloxicam
,31491858,half-life,"The predicted half-life (12.5 ± 2.0 vs. 28.5 ± 2.0 h), Cmax (1.59 ± 0.15 vs. 1.95 ± 0.16 μg/mL), Tmax (5.33 vs. 11.7 h), and AUC0→∞ (39.6 ± 7.4 vs. 115.6 ± 19 h * µg/mL) differed significantly between MET and MOS cows, respectively.",A Comparative Pharmacokinetic Analysis of Oral and Subcutaneous Meloxicam Administered to Postpartum Dairy Cows. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31491858/),h,12.5,36037,DB00814,Meloxicam
,31491858,half-life,"The predicted half-life (12.5 ± 2.0 vs. 28.5 ± 2.0 h), Cmax (1.59 ± 0.15 vs. 1.95 ± 0.16 μg/mL), Tmax (5.33 vs. 11.7 h), and AUC0→∞ (39.6 ± 7.4 vs. 115.6 ± 19 h * µg/mL) differed significantly between MET and MOS cows, respectively.",A Comparative Pharmacokinetic Analysis of Oral and Subcutaneous Meloxicam Administered to Postpartum Dairy Cows. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31491858/),h,28.5,36038,DB00814,Meloxicam
,31491858,Cmax,"The predicted half-life (12.5 ± 2.0 vs. 28.5 ± 2.0 h), Cmax (1.59 ± 0.15 vs. 1.95 ± 0.16 μg/mL), Tmax (5.33 vs. 11.7 h), and AUC0→∞ (39.6 ± 7.4 vs. 115.6 ± 19 h * µg/mL) differed significantly between MET and MOS cows, respectively.",A Comparative Pharmacokinetic Analysis of Oral and Subcutaneous Meloxicam Administered to Postpartum Dairy Cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31491858/),[μg] / [ml],1.59,36039,DB00814,Meloxicam
,31491858,Cmax,"The predicted half-life (12.5 ± 2.0 vs. 28.5 ± 2.0 h), Cmax (1.59 ± 0.15 vs. 1.95 ± 0.16 μg/mL), Tmax (5.33 vs. 11.7 h), and AUC0→∞ (39.6 ± 7.4 vs. 115.6 ± 19 h * µg/mL) differed significantly between MET and MOS cows, respectively.",A Comparative Pharmacokinetic Analysis of Oral and Subcutaneous Meloxicam Administered to Postpartum Dairy Cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31491858/),[μg] / [ml],1.95,36040,DB00814,Meloxicam
,31491858,Tmax,"The predicted half-life (12.5 ± 2.0 vs. 28.5 ± 2.0 h), Cmax (1.59 ± 0.15 vs. 1.95 ± 0.16 μg/mL), Tmax (5.33 vs. 11.7 h), and AUC0→∞ (39.6 ± 7.4 vs. 115.6 ± 19 h * µg/mL) differed significantly between MET and MOS cows, respectively.",A Comparative Pharmacokinetic Analysis of Oral and Subcutaneous Meloxicam Administered to Postpartum Dairy Cows. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31491858/),h,5.33,36041,DB00814,Meloxicam
,31491858,Tmax,"The predicted half-life (12.5 ± 2.0 vs. 28.5 ± 2.0 h), Cmax (1.59 ± 0.15 vs. 1.95 ± 0.16 μg/mL), Tmax (5.33 vs. 11.7 h), and AUC0→∞ (39.6 ± 7.4 vs. 115.6 ± 19 h * µg/mL) differed significantly between MET and MOS cows, respectively.",A Comparative Pharmacokinetic Analysis of Oral and Subcutaneous Meloxicam Administered to Postpartum Dairy Cows. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31491858/),h,11.7,36042,DB00814,Meloxicam
,31491858,AUC0→∞,"The predicted half-life (12.5 ± 2.0 vs. 28.5 ± 2.0 h), Cmax (1.59 ± 0.15 vs. 1.95 ± 0.16 μg/mL), Tmax (5.33 vs. 11.7 h), and AUC0→∞ (39.6 ± 7.4 vs. 115.6 ± 19 h * µg/mL) differed significantly between MET and MOS cows, respectively.",A Comparative Pharmacokinetic Analysis of Oral and Subcutaneous Meloxicam Administered to Postpartum Dairy Cows. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31491858/),[h·μg] / [ml],39.6,36043,DB00814,Meloxicam
,31491858,AUC0→∞,"The predicted half-life (12.5 ± 2.0 vs. 28.5 ± 2.0 h), Cmax (1.59 ± 0.15 vs. 1.95 ± 0.16 μg/mL), Tmax (5.33 vs. 11.7 h), and AUC0→∞ (39.6 ± 7.4 vs. 115.6 ± 19 h * µg/mL) differed significantly between MET and MOS cows, respectively.",A Comparative Pharmacokinetic Analysis of Oral and Subcutaneous Meloxicam Administered to Postpartum Dairy Cows. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31491858/),[h·μg] / [ml],115.6,36044,DB00814,Meloxicam
,31491858,half-life,"After controlling for the treatment group, first lactation cows had a significantly higher half-life (4.1 ± 2.1 h), Cmax (0.56 ± 0.2 µg/mL), and AUC0→∞ (21.6 ± h * µg/mL) relative to second lactation or greater cows, respectively.",A Comparative Pharmacokinetic Analysis of Oral and Subcutaneous Meloxicam Administered to Postpartum Dairy Cows. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31491858/),h,4.1,36045,DB00814,Meloxicam
,31491858,Cmax,"After controlling for the treatment group, first lactation cows had a significantly higher half-life (4.1 ± 2.1 h), Cmax (0.56 ± 0.2 µg/mL), and AUC0→∞ (21.6 ± h * µg/mL) relative to second lactation or greater cows, respectively.",A Comparative Pharmacokinetic Analysis of Oral and Subcutaneous Meloxicam Administered to Postpartum Dairy Cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31491858/),[μg] / [ml],0.56,36046,DB00814,Meloxicam
,31491858,AUC0→∞,"After controlling for the treatment group, first lactation cows had a significantly higher half-life (4.1 ± 2.1 h), Cmax (0.56 ± 0.2 µg/mL), and AUC0→∞ (21.6 ± h * µg/mL) relative to second lactation or greater cows, respectively.",A Comparative Pharmacokinetic Analysis of Oral and Subcutaneous Meloxicam Administered to Postpartum Dairy Cows. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31491858/),,21.6,36047,DB00814,Meloxicam
,1868324,t1/2 alpha,Mean values for pharmacokinetic parameters for the five ponies were: t1/2 alpha 0.40 h; t1/2 beta 2.70 h; Vd area 0.158 l/kg; ClB 41.87 ml/kg/h.,Pharmacodynamics and pharmacokinetics of miloxicam in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1868324/),h,0.40,36551,DB00814,Meloxicam
,1868324,t1/2 beta,Mean values for pharmacokinetic parameters for the five ponies were: t1/2 alpha 0.40 h; t1/2 beta 2.70 h; Vd area 0.158 l/kg; ClB 41.87 ml/kg/h.,Pharmacodynamics and pharmacokinetics of miloxicam in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1868324/),h,2.70,36552,DB00814,Meloxicam
,1868324,Vd area,Mean values for pharmacokinetic parameters for the five ponies were: t1/2 alpha 0.40 h; t1/2 beta 2.70 h; Vd area 0.158 l/kg; ClB 41.87 ml/kg/h.,Pharmacodynamics and pharmacokinetics of miloxicam in the horse. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1868324/),[l] / [kg],0.158,36553,DB00814,Meloxicam
,1868324,ClB,Mean values for pharmacokinetic parameters for the five ponies were: t1/2 alpha 0.40 h; t1/2 beta 2.70 h; Vd area 0.158 l/kg; ClB 41.87 ml/kg/h.,Pharmacodynamics and pharmacokinetics of miloxicam in the horse. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1868324/),[ml] / [h·kg],41.87,36554,DB00814,Meloxicam
,11108435,Peak concentrations,Peak concentrations were reached approximately 6 hours postdose in both plasma (842 microg/L) and synovial fluid (320 microg/L).,Articular diffusion of meloxicam after a single oral dose: relationship to cyclo-oxygenase inhibition in synovial cells. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11108435/),[μg] / [l],842,38002,DB00814,Meloxicam
,11108435,Peak concentrations,Peak concentrations were reached approximately 6 hours postdose in both plasma (842 microg/L) and synovial fluid (320 microg/L).,Articular diffusion of meloxicam after a single oral dose: relationship to cyclo-oxygenase inhibition in synovial cells. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11108435/),[μg] / [l],320,38003,DB00814,Meloxicam
,11108435,ratio of drug concentration,"A plateau was observed after the distribution phase (6 hours), corresponding to a constant ratio of drug concentration between synovial fluid and plasma of about 0.47.",Articular diffusion of meloxicam after a single oral dose: relationship to cyclo-oxygenase inhibition in synovial cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11108435/),,0.,38004,DB00814,Meloxicam
,11108435,50% inhibitory concentrations (IC50),"The 50% inhibitory concentrations (IC50) for basal and stimulated COX activity in human synovial cells were 33.7 nmol/L (11.8 microg/L) and 2.0 nmol/L (0.70 microg/L), respectively.",Articular diffusion of meloxicam after a single oral dose: relationship to cyclo-oxygenase inhibition in synovial cells. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11108435/),[nM] / [l],33.7,38005,DB00814,Meloxicam
,11108435,50% inhibitory concentrations (IC50),"The 50% inhibitory concentrations (IC50) for basal and stimulated COX activity in human synovial cells were 33.7 nmol/L (11.8 microg/L) and 2.0 nmol/L (0.70 microg/L), respectively.",Articular diffusion of meloxicam after a single oral dose: relationship to cyclo-oxygenase inhibition in synovial cells. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11108435/),[μg] / [l],11.8,38006,DB00814,Meloxicam
,11108435,50% inhibitory concentrations (IC50),"The 50% inhibitory concentrations (IC50) for basal and stimulated COX activity in human synovial cells were 33.7 nmol/L (11.8 microg/L) and 2.0 nmol/L (0.70 microg/L), respectively.",Articular diffusion of meloxicam after a single oral dose: relationship to cyclo-oxygenase inhibition in synovial cells. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11108435/),[nM] / [l],2.0,38007,DB00814,Meloxicam
,11108435,50% inhibitory concentrations (IC50),"The 50% inhibitory concentrations (IC50) for basal and stimulated COX activity in human synovial cells were 33.7 nmol/L (11.8 microg/L) and 2.0 nmol/L (0.70 microg/L), respectively.",Articular diffusion of meloxicam after a single oral dose: relationship to cyclo-oxygenase inhibition in synovial cells. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11108435/),[μg] / [l],0.70,38008,DB00814,Meloxicam
,9105543,elimination half-life (t1/2),Meloxicam is metabolized to four biologically inactive metabolites and excreted in urine and faeces with an elimination half-life (t1/2) of around 20 h.,Clinical pharmacokinetics of meloxicam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105543/),h,20,38284,DB00814,Meloxicam
,9105543,total plasma clearance,This is reflected in a total plasma clearance of 7 to 8 ml/min.,Clinical pharmacokinetics of meloxicam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105543/),[ml] / [min],7 to 8,38285,DB00814,Meloxicam
,19825327,Cmax,"The mean Cmax was 1,027.32 +/- 251.91 and 1,151.89 +/- 282.58 ng/ml while the mean AUC0-t was 34,024.31 +/- 11,811.68 and 35,137.66 +/- 11,970.47 ng x h/ml for the test and reference formulation, respectively.",Bioequivalence study of two meloxicam tablet formulations after single-dose administration in healthy Thai male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825327/),[ng] / [ml],"1,027.32",40674,DB00814,Meloxicam
,19825327,Cmax,"The mean Cmax was 1,027.32 +/- 251.91 and 1,151.89 +/- 282.58 ng/ml while the mean AUC0-t was 34,024.31 +/- 11,811.68 and 35,137.66 +/- 11,970.47 ng x h/ml for the test and reference formulation, respectively.",Bioequivalence study of two meloxicam tablet formulations after single-dose administration in healthy Thai male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825327/),[ng] / [ml],"1,151.89",40675,DB00814,Meloxicam
,19825327,AUC0-t,"The mean Cmax was 1,027.32 +/- 251.91 and 1,151.89 +/- 282.58 ng/ml while the mean AUC0-t was 34,024.31 +/- 11,811.68 and 35,137.66 +/- 11,970.47 ng x h/ml for the test and reference formulation, respectively.",Bioequivalence study of two meloxicam tablet formulations after single-dose administration in healthy Thai male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825327/),[h·ng] / [ml],"34,024.31",40676,DB00814,Meloxicam
,19825327,AUC0-t,"The mean Cmax was 1,027.32 +/- 251.91 and 1,151.89 +/- 282.58 ng/ml while the mean AUC0-t was 34,024.31 +/- 11,811.68 and 35,137.66 +/- 11,970.47 ng x h/ml for the test and reference formulation, respectively.",Bioequivalence study of two meloxicam tablet formulations after single-dose administration in healthy Thai male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825327/),[h·ng] / [ml],"35,137.66",40677,DB00814,Meloxicam
,19825327,AUC0-infinity,"In addition, the mean AUC0-infinity for test formulation was 37,241.44 +/- 14,888.85 ng x h/ml and for the reference formulation was 39,541.04 +/- 16,624.64 ng x h/ml.",Bioequivalence study of two meloxicam tablet formulations after single-dose administration in healthy Thai male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825327/),[h·ng] / [ml],"37,241.44",40678,DB00814,Meloxicam
,19825327,AUC0-infinity,"In addition, the mean AUC0-infinity for test formulation was 37,241.44 +/- 14,888.85 ng x h/ml and for the reference formulation was 39,541.04 +/- 16,624.64 ng x h/ml.",Bioequivalence study of two meloxicam tablet formulations after single-dose administration in healthy Thai male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825327/),[h·ng] / [ml],"39,541.04",40679,DB00814,Meloxicam
,19825327,tmax,"The median tmax for the test and reference formulation was 4.50 (range 2.00 - 12.00) and 4.50 (range 3.00 - 10.00), respectively.",Bioequivalence study of two meloxicam tablet formulations after single-dose administration in healthy Thai male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825327/),,4.50,40680,DB00814,Meloxicam
,19825327,tmax,"The median tmax for the test and reference formulation was 4.50 (range 2.00 - 12.00) and 4.50 (range 3.00 - 10.00), respectively.",Bioequivalence study of two meloxicam tablet formulations after single-dose administration in healthy Thai male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825327/),,4.50,40681,DB00814,Meloxicam
,27227503,Maximum bupivacaine plasma concentration,"Maximum bupivacaine plasma concentration was 1,030 ± 497.5 ng/mL at a mean ± SD value of 30 ± 24 minutes after administration.",Pharmacokinetics of bupivacaine after intraperitoneal administration to cats undergoing ovariohysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27227503/),[ng] / [ml],"1,030",40903,DB00814,Meloxicam
,27227503,elimination half-life,Mean elimination half-life was 4.79 ± 2.7 hours.,Pharmacokinetics of bupivacaine after intraperitoneal administration to cats undergoing ovariohysterectomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27227503/),h,4.79,40904,DB00814,Meloxicam
,27227503,clearance,"Mean clearance indexed by bioavailability and volume of distribution indexed by bioavailability were 0.35 ± 0.18 L•h/kg and 2.10 ± 0.84 L/kg, respectively.",Pharmacokinetics of bupivacaine after intraperitoneal administration to cats undergoing ovariohysterectomy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27227503/),[h·l] / [kg],0.35,40905,DB00814,Meloxicam
,27227503,volume of distribution,"Mean clearance indexed by bioavailability and volume of distribution indexed by bioavailability were 0.35 ± 0.18 L•h/kg and 2.10 ± 0.84 L/kg, respectively.",Pharmacokinetics of bupivacaine after intraperitoneal administration to cats undergoing ovariohysterectomy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27227503/),[h·l] / [kg],0.35,40906,DB00814,Meloxicam
,27227503,volume of distribution,"Mean clearance indexed by bioavailability and volume of distribution indexed by bioavailability were 0.35 ± 0.18 L•h/kg and 2.10 ± 0.84 L/kg, respectively.",Pharmacokinetics of bupivacaine after intraperitoneal administration to cats undergoing ovariohysterectomy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27227503/),[l] / [kg],2.10,40907,DB00814,Meloxicam
,34125605,terminal half-life,"Mean ± SD terminal half-life, maximum concentration, and time to maximum concentration were 5.53 ± 1.37 hours, 6.25 ± 1.53 μg/mL, and 3.25 ± 2.12 hours, respectively.",Breed differences in the pharmacokinetics of orally administered meloxicam in domestic chickens (Gallus domesticus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34125605/),h,5.53,41936,DB00814,Meloxicam
,34125605,maximum concentration,"Mean ± SD terminal half-life, maximum concentration, and time to maximum concentration were 5.53 ± 1.37 hours, 6.25 ± 1.53 μg/mL, and 3.25 ± 2.12 hours, respectively.",Breed differences in the pharmacokinetics of orally administered meloxicam in domestic chickens (Gallus domesticus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34125605/),[μg] / [ml],6.25,41937,DB00814,Meloxicam
,34125605,time to maximum concentration,"Mean ± SD terminal half-life, maximum concentration, and time to maximum concentration were 5.53 ± 1.37 hours, 6.25 ± 1.53 μg/mL, and 3.25 ± 2.12 hours, respectively.",Breed differences in the pharmacokinetics of orally administered meloxicam in domestic chickens (Gallus domesticus). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34125605/),h,3.25,41938,DB00814,Meloxicam
,30336288,half-life,"In the plasma meloxicam was characterised by a half-life, mean residence time, clearance and volume of distribution at steady state of 0.37 ± 0.10 h, 0.90 ± 0.12 h, 0.02 ± 0.00 l/h kg and 0.02 ± 0.00 l/kg respectively (presented as geometric mean).",Percentage of faecal excretion of meloxicam in the Cape vultures (Gyps corprotheres). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30336288/),h,0.37,48650,DB00814,Meloxicam
,30336288,volume of distribution at steady state,"In the plasma meloxicam was characterised by a half-life, mean residence time, clearance and volume of distribution at steady state of 0.37 ± 0.10 h, 0.90 ± 0.12 h, 0.02 ± 0.00 l/h kg and 0.02 ± 0.00 l/kg respectively (presented as geometric mean).",Percentage of faecal excretion of meloxicam in the Cape vultures (Gyps corprotheres). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30336288/),[l] / [kg],0.02,48651,DB00814,Meloxicam
,29755192,plasma concentrations (Cmax),"Maximum bupivacaine plasma concentrations (Cmax) for BE and BD were 1155 ± 168 ng/mL and 1678 ± 364 ng/mL (P = 0.29) at 67 ± 13 min (Tmax) and 123 ± 59 min (P = 0.17), respectively.",Efficacy and pharmacokinetics of bupivacaine with epinephrine or dexmedetomidine after intraperitoneal administration in cats undergoing ovariohysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29755192/),[ng] / [ml],1155,48784,DB00814,Meloxicam
,29755192,plasma concentrations (Cmax),"Maximum bupivacaine plasma concentrations (Cmax) for BE and BD were 1155 ± 168 ng/mL and 1678 ± 364 ng/mL (P = 0.29) at 67 ± 13 min (Tmax) and 123 ± 59 min (P = 0.17), respectively.",Efficacy and pharmacokinetics of bupivacaine with epinephrine or dexmedetomidine after intraperitoneal administration in cats undergoing ovariohysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29755192/),[ng] / [ml],1678,48785,DB00814,Meloxicam
,29755192,Tmax,"Maximum bupivacaine plasma concentrations (Cmax) for BE and BD were 1155 ± 168 ng/mL and 1678 ± 364 ng/mL (P = 0.29) at 67 ± 13 min (Tmax) and 123 ± 59 min (P = 0.17), respectively.",Efficacy and pharmacokinetics of bupivacaine with epinephrine or dexmedetomidine after intraperitoneal administration in cats undergoing ovariohysterectomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29755192/),min,67,48786,DB00814,Meloxicam
,31774176,bioavailability,"The IM bioavailability of meloxicam was relatively lower in lactating (75.3 ± 18.6%) than nonlactating goats (103.8 ± 34.7%); however, the difference was not statistically significant.",Impact of lactation on pharmacokinetics of meloxicam in goats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31774176/),%,75.3,50562,DB00814,Meloxicam
,31774176,bioavailability,"The IM bioavailability of meloxicam was relatively lower in lactating (75.3 ± 18.6%) than nonlactating goats (103.8 ± 34.7%); however, the difference was not statistically significant.",Impact of lactation on pharmacokinetics of meloxicam in goats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31774176/),%,103.8,50563,DB00814,Meloxicam
less,31774176,AUC ratio,"Moreover, AUC ratio between milk and plasma, which represent drug milk penetration, for both IV and IM administrations was less than 1 (about 0.3).",Impact of lactation on pharmacokinetics of meloxicam in goats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31774176/),,1,50564,DB00814,Meloxicam
,31774176,AUC ratio,"Moreover, AUC ratio between milk and plasma, which represent drug milk penetration, for both IV and IM administrations was less than 1 (about 0.3).",Impact of lactation on pharmacokinetics of meloxicam in goats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31774176/),,0.3,50565,DB00814,Meloxicam
,23627392,elimination half-life,"Following IV administration (n = 5), the geometric mean (range) elimination half-life was 14.0 hours (10.5 to 17.0 hours), volume of distribution was 0.204 L/kg (0.171 to 0.272 L/kg), and clearance was 0.17 mL/min/kg (0.12 to 0.27 mL/min/kg).",Pharmacokinetics of intravenously and orally administered meloxicam in sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23627392/),h,14.0,54521,DB00814,Meloxicam
,23627392,volume of distribution,"Following IV administration (n = 5), the geometric mean (range) elimination half-life was 14.0 hours (10.5 to 17.0 hours), volume of distribution was 0.204 L/kg (0.171 to 0.272 L/kg), and clearance was 0.17 mL/min/kg (0.12 to 0.27 mL/min/kg).",Pharmacokinetics of intravenously and orally administered meloxicam in sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23627392/),[l] / [kg],0.204,54522,DB00814,Meloxicam
,23627392,clearance,"Following IV administration (n = 5), the geometric mean (range) elimination half-life was 14.0 hours (10.5 to 17.0 hours), volume of distribution was 0.204 L/kg (0.171 to 0.272 L/kg), and clearance was 0.17 mL/min/kg (0.12 to 0.27 mL/min/kg).",Pharmacokinetics of intravenously and orally administered meloxicam in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23627392/),[ml] / [kg·min],0.17,54523,DB00814,Meloxicam
,23627392,maximum serum concentration,"Following oral administration (n = 6), maximum serum concentration was 1.72 μg/mL (1.45 to 1.93 μg/mL), time to maximum serum concentration was 19.0 hours (12.0 to 24.0 hours), clearance per bioavailability was 0.22 mL/min/kg (0.16 to 0.30 mL/min/kg), and terminal half-life was 15.4 hours (13.2 to 17.7 hours).",Pharmacokinetics of intravenously and orally administered meloxicam in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23627392/),[μg] / [ml],1.72,54524,DB00814,Meloxicam
,23627392,time to maximum serum concentration,"Following oral administration (n = 6), maximum serum concentration was 1.72 μg/mL (1.45 to 1.93 μg/mL), time to maximum serum concentration was 19.0 hours (12.0 to 24.0 hours), clearance per bioavailability was 0.22 mL/min/kg (0.16 to 0.30 mL/min/kg), and terminal half-life was 15.4 hours (13.2 to 17.7 hours).",Pharmacokinetics of intravenously and orally administered meloxicam in sheep. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23627392/),h,19.0,54525,DB00814,Meloxicam
,23627392,clearance per bioavailability,"Following oral administration (n = 6), maximum serum concentration was 1.72 μg/mL (1.45 to 1.93 μg/mL), time to maximum serum concentration was 19.0 hours (12.0 to 24.0 hours), clearance per bioavailability was 0.22 mL/min/kg (0.16 to 0.30 mL/min/kg), and terminal half-life was 15.4 hours (13.2 to 17.7 hours).",Pharmacokinetics of intravenously and orally administered meloxicam in sheep. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23627392/),[ml] / [kg·min],0.22,54526,DB00814,Meloxicam
,23627392,terminal half-life,"Following oral administration (n = 6), maximum serum concentration was 1.72 μg/mL (1.45 to 1.93 μg/mL), time to maximum serum concentration was 19.0 hours (12.0 to 24.0 hours), clearance per bioavailability was 0.22 mL/min/kg (0.16 to 0.30 mL/min/kg), and terminal half-life was 15.4 hours (13.2 to 17.7 hours).",Pharmacokinetics of intravenously and orally administered meloxicam in sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23627392/),h,15.4,54527,DB00814,Meloxicam
,23627392,Bioavailability,Bioavailability of orally administered meloxicam was calculated as 72% (40% to 125%; n = 5).,Pharmacokinetics of intravenously and orally administered meloxicam in sheep. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23627392/),%,72,54528,DB00814,Meloxicam
,21729105,absorption half-life,The absorption half-life was relatively short (0.19 h) and the elimination half-life was 2.6 h.,Pharmacokinetics and pharmacodynamic effects of meloxicam in piglets subjected to a kaolin inflammation model. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21729105/),h,0.19,58062,DB00814,Meloxicam
,21729105,elimination half-life,The absorption half-life was relatively short (0.19 h) and the elimination half-life was 2.6 h.,Pharmacokinetics and pharmacodynamic effects of meloxicam in piglets subjected to a kaolin inflammation model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21729105/),h,2.6,58063,DB00814,Meloxicam
,33827188,half-life (t1/2),"After SQ administration, the half-life (t1/2) of meloxicam administered at 1 mg/kg in the Kemp's ridleys was 5.51 hr but could not be determined in the greens.","PHARMACOKINETIC BEHAVIOR OF MELOXICAM IN LOGGERHEAD (CARETTA CARETTA), KEMP'S RIDLEY (LEPIDOCHELYS KEMPII), AND GREEN (CHELONIA MYDAS) SEA TURTLES AFTER SUBCUTANEOUS ADMINISTRATION. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33827188/),h,5.51,60517,DB00814,Meloxicam
,33827188,half-life,The half-life of meloxicam administered at 2 mg/kg in the loggerheads was 2.99 hr.,"PHARMACOKINETIC BEHAVIOR OF MELOXICAM IN LOGGERHEAD (CARETTA CARETTA), KEMP'S RIDLEY (LEPIDOCHELYS KEMPII), AND GREEN (CHELONIA MYDAS) SEA TURTLES AFTER SUBCUTANEOUS ADMINISTRATION. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33827188/),h,2.99,60518,DB00814,Meloxicam
,33827188,maximum concentration (Cmax),The maximum concentration (Cmax) for meloxicam after SQ administration at 1 mg/kg in the Kemp's ridleys was 6.76 µg/ml and in the greens was 9.35 µg/ml.,"PHARMACOKINETIC BEHAVIOR OF MELOXICAM IN LOGGERHEAD (CARETTA CARETTA), KEMP'S RIDLEY (LEPIDOCHELYS KEMPII), AND GREEN (CHELONIA MYDAS) SEA TURTLES AFTER SUBCUTANEOUS ADMINISTRATION. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33827188/),[μg] / [ml],6.76,60519,DB00814,Meloxicam
,33827188,maximum concentration (Cmax),The maximum concentration (Cmax) for meloxicam after SQ administration at 1 mg/kg in the Kemp's ridleys was 6.76 µg/ml and in the greens was 9.35 µg/ml.,"PHARMACOKINETIC BEHAVIOR OF MELOXICAM IN LOGGERHEAD (CARETTA CARETTA), KEMP'S RIDLEY (LEPIDOCHELYS KEMPII), AND GREEN (CHELONIA MYDAS) SEA TURTLES AFTER SUBCUTANEOUS ADMINISTRATION. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33827188/),[μg] / [ml],9.35,60520,DB00814,Meloxicam
,33827188,Cmax,The Cmax in loggerheads for meloxicam after SQ administration at 2 mg/kg was 3.63 µg/mL.,"PHARMACOKINETIC BEHAVIOR OF MELOXICAM IN LOGGERHEAD (CARETTA CARETTA), KEMP'S RIDLEY (LEPIDOCHELYS KEMPII), AND GREEN (CHELONIA MYDAS) SEA TURTLES AFTER SUBCUTANEOUS ADMINISTRATION. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33827188/),[μg] / [ml],3.63,60521,DB00814,Meloxicam
,16806752,AUC(0-->96),"The area under the meloxicam plasma concentration-time curve (AUC(0-->96)(h) was not significantly different between the two preparations (p>0.05), although AUC(0-->96)(h) obtained after oral administration of coated pellets (142.5+/-59.6 microg h/ml) was lower than that obtained after administration of uncoated drug-layered cores (180.8+/-61.9 microg h/ml).",In vitro release and in vivo absorption in beagle dogs of meloxicam from Eudragit FS 30 D-coated pellets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16806752/),[h·μg] / [ml],142.5,60745,DB00814,Meloxicam
,16806752,AUC(0-->96),"The area under the meloxicam plasma concentration-time curve (AUC(0-->96)(h) was not significantly different between the two preparations (p>0.05), although AUC(0-->96)(h) obtained after oral administration of coated pellets (142.5+/-59.6 microg h/ml) was lower than that obtained after administration of uncoated drug-layered cores (180.8+/-61.9 microg h/ml).",In vitro release and in vivo absorption in beagle dogs of meloxicam from Eudragit FS 30 D-coated pellets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16806752/),[h·μg] / [ml],180.8,60746,DB00814,Meloxicam
,30681357,trough plasma concentrations at steady state,"RESULTS Mean trough plasma concentrations at steady state were 10.7 and 9.16 μg/mL after meloxicam administration at 1 mg/kg, IM, and 1 mg/kg, PO, respectively.",Pharmacokinetics of meloxicam during multiple oral or intramuscular dose administration to African grey parrots (Psittacus erithacus). ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30681357/),[μg] / [ml],10.7,61276,DB00814,Meloxicam
,30681357,trough plasma concentrations at steady state,"RESULTS Mean trough plasma concentrations at steady state were 10.7 and 9.16 μg/mL after meloxicam administration at 1 mg/kg, IM, and 1 mg/kg, PO, respectively.",Pharmacokinetics of meloxicam during multiple oral or intramuscular dose administration to African grey parrots (Psittacus erithacus). ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30681357/),[μg] / [ml],9.16,61277,DB00814,Meloxicam
,30681357,accumulation ratios,Plasma drug accumulation was evident (accumulation ratios of 2.04 ± 0.30 [IM treatment] and 2.45 ± 0.26 [PO treatment]).,Pharmacokinetics of meloxicam during multiple oral or intramuscular dose administration to African grey parrots (Psittacus erithacus). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30681357/),,2.04,61278,DB00814,Meloxicam
,30681357,accumulation ratios,Plasma drug accumulation was evident (accumulation ratios of 2.04 ± 0.30 [IM treatment] and 2.45 ± 0.26 [PO treatment]).,Pharmacokinetics of meloxicam during multiple oral or intramuscular dose administration to African grey parrots (Psittacus erithacus). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30681357/),,2.45,61279,DB00814,Meloxicam
,12579866,T 1/2,"The main parameters in the two groups obtained were as follows: T 1/2 were 21 +/- 4 and 38 +/- 9 h, AUC0-infinity were 49 +/- 10 and 110 +/- 8 micrograms.h.mL-1, respectively.",[Pharmacokinetics of meloxicam in healthy Chinese volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579866/),h,21,64039,DB00814,Meloxicam
,12579866,T 1/2,"The main parameters in the two groups obtained were as follows: T 1/2 were 21 +/- 4 and 38 +/- 9 h, AUC0-infinity were 49 +/- 10 and 110 +/- 8 micrograms.h.mL-1, respectively.",[Pharmacokinetics of meloxicam in healthy Chinese volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579866/),h,38,64040,DB00814,Meloxicam
,12579866,AUC0-infinity,"The main parameters in the two groups obtained were as follows: T 1/2 were 21 +/- 4 and 38 +/- 9 h, AUC0-infinity were 49 +/- 10 and 110 +/- 8 micrograms.h.mL-1, respectively.",[Pharmacokinetics of meloxicam in healthy Chinese volunteers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579866/),[h·μg] / [ml],49,64041,DB00814,Meloxicam
,12579866,AUC0-infinity,"The main parameters in the two groups obtained were as follows: T 1/2 were 21 +/- 4 and 38 +/- 9 h, AUC0-infinity were 49 +/- 10 and 110 +/- 8 micrograms.h.mL-1, respectively.",[Pharmacokinetics of meloxicam in healthy Chinese volunteers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579866/),[h·μg] / [ml],110,64042,DB00814,Meloxicam
,19566467,clearance,Mean +/- SE iohexol clearance for cats administered meloxicam (3.31 +/- 0.27 mL/min/kg) was not significantly different from mean baseline value for the meloxicam treatment period (3.07 +/- 0.32 mL/min/kg).,Effects of meloxicam on plasma iohexol clearance as a marker of glomerular filtration rate in conscious healthy cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566467/),[ml] / [kg·min],3.31,65898,DB00814,Meloxicam
,19566467,clearance,Mean +/- SE iohexol clearance for cats administered meloxicam (3.31 +/- 0.27 mL/min/kg) was not significantly different from mean baseline value for the meloxicam treatment period (3.07 +/- 0.32 mL/min/kg).,Effects of meloxicam on plasma iohexol clearance as a marker of glomerular filtration rate in conscious healthy cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566467/),[ml] / [kg·min],3.07,65899,DB00814,Meloxicam
,24471756,peak plasma concentrations,"Mean ± SD peak plasma concentrations of meloxicam after administration of doses 1, 8, 15, 22, and 29 were 0.67 ± 0.19 μg/mL, 0.81 ± 0.21 μg/mL, 1.00 ± 0.31 μg/mL, 1.00 ± 0.29 μg/mL, and 1.07 ± 0.19 μg/mL, respectively; these concentrations did not differ significantly among doses 8 through 29.",Pharmacokinetics of meloxicam administered orally to rabbits (Oryctolagus cuniculus) for 29 days. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24471756/),[μg] / [ml],0.67,66294,DB00814,Meloxicam
,24471756,peak plasma concentrations,"Mean ± SD peak plasma concentrations of meloxicam after administration of doses 1, 8, 15, 22, and 29 were 0.67 ± 0.19 μg/mL, 0.81 ± 0.21 μg/mL, 1.00 ± 0.31 μg/mL, 1.00 ± 0.29 μg/mL, and 1.07 ± 0.19 μg/mL, respectively; these concentrations did not differ significantly among doses 8 through 29.",Pharmacokinetics of meloxicam administered orally to rabbits (Oryctolagus cuniculus) for 29 days. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24471756/),[μg] / [ml],0.81,66295,DB00814,Meloxicam
,24471756,peak plasma concentrations,"Mean ± SD peak plasma concentrations of meloxicam after administration of doses 1, 8, 15, 22, and 29 were 0.67 ± 0.19 μg/mL, 0.81 ± 0.21 μg/mL, 1.00 ± 0.31 μg/mL, 1.00 ± 0.29 μg/mL, and 1.07 ± 0.19 μg/mL, respectively; these concentrations did not differ significantly among doses 8 through 29.",Pharmacokinetics of meloxicam administered orally to rabbits (Oryctolagus cuniculus) for 29 days. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24471756/),[μg] / [ml],1.00,66296,DB00814,Meloxicam
,24471756,peak plasma concentrations,"Mean ± SD peak plasma concentrations of meloxicam after administration of doses 1, 8, 15, 22, and 29 were 0.67 ± 0.19 μg/mL, 0.81 ± 0.21 μg/mL, 1.00 ± 0.31 μg/mL, 1.00 ± 0.29 μg/mL, and 1.07 ± 0.19 μg/mL, respectively; these concentrations did not differ significantly among doses 8 through 29.",Pharmacokinetics of meloxicam administered orally to rabbits (Oryctolagus cuniculus) for 29 days. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24471756/),[μg] / [ml],1.00,66297,DB00814,Meloxicam
,24471756,peak plasma concentrations,"Mean ± SD peak plasma concentrations of meloxicam after administration of doses 1, 8, 15, 22, and 29 were 0.67 ± 0.19 μg/mL, 0.81 ± 0.21 μg/mL, 1.00 ± 0.31 μg/mL, 1.00 ± 0.29 μg/mL, and 1.07 ± 0.19 μg/mL, respectively; these concentrations did not differ significantly among doses 8 through 29.",Pharmacokinetics of meloxicam administered orally to rabbits (Oryctolagus cuniculus) for 29 days. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24471756/),[μg] / [ml],1.07,66298,DB00814,Meloxicam
,22860573,Maximum plasma concentration,Maximum plasma concentration following a single oral dose of meloxicam was 915.1 ± 116.9 ng/mL and elimination half-life 10.2 ± 3.0 hours.,Pharmacokinetics and safety of single and multiple oral doses of meloxicam in adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22860573/),[ng] / [ml],915.1,69061,DB00814,Meloxicam
,22860573,elimination half-life,Maximum plasma concentration following a single oral dose of meloxicam was 915.1 ± 116.9 ng/mL and elimination half-life 10.2 ± 3.0 hours.,Pharmacokinetics and safety of single and multiple oral doses of meloxicam in adult horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22860573/),h,10.2,69062,DB00814,Meloxicam
,20550483,oral disintegration time,The rate of absorption of MLX from ODT was significantly faster (p = 0.030) with a significantly higher peak plasma concentration (P = 0.037) when compared to the marketed immediate release MLX tablet with a mean oral disintegration time of 17 ± 3 s.,A pilot human pharmacokinetic study and influence of formulation factors on orodispersible tablet incorporating meloxicam solid dispersion using factorial design. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20550483/),s,17,69456,DB00814,Meloxicam
,25708937,Cmax,"The mean (± SD) Cmax , Cmin , and Caverage plasma meloxicam concentrations were 4.52 ± 0.87 μg/mL, 2.95 ± 0.77 μg/mL, and 3.84 ± 0.81 μg/mL, respectively.",Pharmacokinetics and tissue disposition of meloxicam in beef calves after repeated oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25708937/),[μg] / [ml],4.52,72380,DB00814,Meloxicam
,25708937,Cmin,"The mean (± SD) Cmax , Cmin , and Caverage plasma meloxicam concentrations were 4.52 ± 0.87 μg/mL, 2.95 ± 0.77 μg/mL, and 3.84 ± 0.81 μg/mL, respectively.",Pharmacokinetics and tissue disposition of meloxicam in beef calves after repeated oral administration. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25708937/),[μg] / [ml],2.95,72381,DB00814,Meloxicam
,25708937,Caverage,"The mean (± SD) Cmax , Cmin , and Caverage plasma meloxicam concentrations were 4.52 ± 0.87 μg/mL, 2.95 ± 0.77 μg/mL, and 3.84 ± 0.81 μg/mL, respectively.",Pharmacokinetics and tissue disposition of meloxicam in beef calves after repeated oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25708937/),[μg] / [ml],3.84,72382,DB00814,Meloxicam
,25708937,concentrations,Mean (± SD) tissue meloxicam concentrations were highest in liver (226.67 ± 118.16 ng/g) and kidney samples (52.73 ± 39.01 ng/g) at 5 days after final treatment.,Pharmacokinetics and tissue disposition of meloxicam in beef calves after repeated oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25708937/),[ng] / [g],226.67,72383,DB00814,Meloxicam
,25708937,concentrations,Mean (± SD) tissue meloxicam concentrations were highest in liver (226.67 ± 118.16 ng/g) and kidney samples (52.73 ± 39.01 ng/g) at 5 days after final treatment.,Pharmacokinetics and tissue disposition of meloxicam in beef calves after repeated oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25708937/),[ng] / [g],52.73,72384,DB00814,Meloxicam
,25269447,peak plasma concentration (CMAX ),Mean peak plasma concentration (CMAX ) after p.o. administration was 1070 ng/mL (645-1749 ng/mL).,Pharmacokinetics of meloxicam in mature swine after intravenous and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25269447/),[ng] / [ml],1070,72392,DB00814,Meloxicam
,25269447,TMAX,TMAX was recorded at 2.40 h (0.50-12.00 h) after p.o. administration.,Pharmacokinetics of meloxicam in mature swine after intravenous and oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25269447/),h,2,72393,DB00814,Meloxicam
,25269447,Half-life (T½ λz ),"Half-life (T½ λz ) for i.v. and p.o. administration was 6.15 h (4.39-7.79 h) and 6.83 h (5.18-9.63 h), respectively.",Pharmacokinetics of meloxicam in mature swine after intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25269447/),h,6.15,72394,DB00814,Meloxicam
,25269447,Half-life (T½ λz ),"Half-life (T½ λz ) for i.v. and p.o. administration was 6.15 h (4.39-7.79 h) and 6.83 h (5.18-9.63 h), respectively.",Pharmacokinetics of meloxicam in mature swine after intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25269447/),h,6.83,72395,DB00814,Meloxicam
,25269447,bioavailability (F),The bioavailability (F) for p.o. administration was 87% (39-351%).,Pharmacokinetics of meloxicam in mature swine after intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25269447/),%,87,72396,DB00814,Meloxicam
,29698068,terminal half-life,"The terminal half-life, maximum concentration, and time to maximum concentration were 3.02 ± 1.15 hours, 7.14 ± 1.54 μg/mL, and 1.6 ± 0.52 hours, respectively.",Pharmacokinetics and Egg Residues of Meloxicam After Multiple Day Oral Dosing in Domestic Chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29698068/),h,3.02,76489,DB00814,Meloxicam
,29698068,maximum concentration,"The terminal half-life, maximum concentration, and time to maximum concentration were 3.02 ± 1.15 hours, 7.14 ± 1.54 μg/mL, and 1.6 ± 0.52 hours, respectively.",Pharmacokinetics and Egg Residues of Meloxicam After Multiple Day Oral Dosing in Domestic Chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29698068/),[μg] / [ml],7.14,76490,DB00814,Meloxicam
,29698068,time to maximum concentration,"The terminal half-life, maximum concentration, and time to maximum concentration were 3.02 ± 1.15 hours, 7.14 ± 1.54 μg/mL, and 1.6 ± 0.52 hours, respectively.",Pharmacokinetics and Egg Residues of Meloxicam After Multiple Day Oral Dosing in Domestic Chickens. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29698068/),h,1.6,76491,DB00814,Meloxicam
,19705923,t((1/2)),Coadministration of cholestyramine resulted in a predicted 56% withdrawal of meloxicam from the EHC process causing a reduction in the t((1/2)) from approximately 19 hours to approximately 12 hours.,A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19705923/),h,19,77594,DB00814,Meloxicam
,19705923,t((1/2)),Coadministration of cholestyramine resulted in a predicted 56% withdrawal of meloxicam from the EHC process causing a reduction in the t((1/2)) from approximately 19 hours to approximately 12 hours.,A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19705923/),h,12,77595,DB00814,Meloxicam
,33355409,maximum plasma concentration,The mean maximum plasma concentration was 1.22 µg/mL and was achieved at 24 hours after drug administration.,Pharmacokinetics of a Single Dose of Oral Meloxicam in Rehabilitated Wild Brown Pelicans (Pelecanus occidentalis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33355409/),[μg] / [ml],1.22,79506,DB00814,Meloxicam
,33355409,elimination half-life,"The elimination half-life was 36.3 hours, the longest reported to date for any avian species.",Pharmacokinetics of a Single Dose of Oral Meloxicam in Rehabilitated Wild Brown Pelicans (Pelecanus occidentalis). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33355409/),h,36.3,79507,DB00814,Meloxicam
,33297790,rate of absorption (Tmax),"MX rate of absorption (Tmax) from Soluplus-based pellets attained a value of 45 min, which was 6-times faster than Mobic® (4.5 hr).","Preparation, characterization and in-Vitro/in-Vivo evaluation of meloxicam extruded pellets with enhanced bioavailability and stability. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33297790/),min,45,80377,DB00814,Meloxicam
,33297790,rate of absorption (Tmax),"MX rate of absorption (Tmax) from Soluplus-based pellets attained a value of 45 min, which was 6-times faster than Mobic® (4.5 hr).","Preparation, characterization and in-Vitro/in-Vivo evaluation of meloxicam extruded pellets with enhanced bioavailability and stability. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33297790/),h,4.5,80378,DB00814,Meloxicam
,33297790,Tmax,"A promising oral MX formula prepared by HME was successfully developed with a rapid onset of analgesic action (Tmax of 45 mins; almost 2-times faster than reported intramuscular injection), hence appropriate in the early relief of pain associated with rheumatoid arthritis and osteoarthritis.","Preparation, characterization and in-Vitro/in-Vivo evaluation of meloxicam extruded pellets with enhanced bioavailability and stability. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33297790/),min,45,80379,DB00814,Meloxicam
,33141479,clearance,The typical values (20 kg bird) for clearance and V1 were 0.54 L/kg/h and 0.095 L/kg.,Perioperative pharmacokinetics and pharmacodynamics of meloxicam in emus (Dromaius novaehollandiae) of different age groups using nonlinear mixed effect modelling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33141479/),[l] / [h·kg],0.54,81848,DB00814,Meloxicam
,33141479,V1,The typical values (20 kg bird) for clearance and V1 were 0.54 L/kg/h and 0.095 L/kg.,Perioperative pharmacokinetics and pharmacodynamics of meloxicam in emus (Dromaius novaehollandiae) of different age groups using nonlinear mixed effect modelling. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33141479/),[l] / [kg],0.095,81849,DB00814,Meloxicam
,33141479,IC50,Meloxicam was partially selective in emus (IC50 COX-1:COX-2 = 9.1:1).,Perioperative pharmacokinetics and pharmacodynamics of meloxicam in emus (Dromaius novaehollandiae) of different age groups using nonlinear mixed effect modelling. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33141479/),,9.1,81850,DB00814,Meloxicam
,28947805,T1/2el,"In contrast to celecoxib (T1/2el = 0.88 h) and meloxicam (T1/2el = 0.90 h), mavacoxib has a prolonged elimination half-life (T1/2el = 135 h) following oral administration of a commercial formulation (CF).","Comparative population pharmacokinetics and absolute oral bioavailability of COX-2 selective inhibitors celecoxib, mavacoxib and meloxicam in cockatiels (Nymphicus hollandicus). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28947805/),h,0.88,84290,DB00814,Meloxicam
,28947805,T1/2el,"In contrast to celecoxib (T1/2el = 0.88 h) and meloxicam (T1/2el = 0.90 h), mavacoxib has a prolonged elimination half-life (T1/2el = 135 h) following oral administration of a commercial formulation (CF).","Comparative population pharmacokinetics and absolute oral bioavailability of COX-2 selective inhibitors celecoxib, mavacoxib and meloxicam in cockatiels (Nymphicus hollandicus). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28947805/),h,0.90,84291,DB00814,Meloxicam
,28947805,elimination half-life (T1/2el,"In contrast to celecoxib (T1/2el = 0.88 h) and meloxicam (T1/2el = 0.90 h), mavacoxib has a prolonged elimination half-life (T1/2el = 135 h) following oral administration of a commercial formulation (CF).","Comparative population pharmacokinetics and absolute oral bioavailability of COX-2 selective inhibitors celecoxib, mavacoxib and meloxicam in cockatiels (Nymphicus hollandicus). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28947805/),h,135,84292,DB00814,Meloxicam
,28947805,F%,"High to complete oral absorption was observed following oral administration of celecoxib (F% = 56-110%) and mavacoxib (F% = 111-113%), CF and standard solutions, respectively.","Comparative population pharmacokinetics and absolute oral bioavailability of COX-2 selective inhibitors celecoxib, mavacoxib and meloxicam in cockatiels (Nymphicus hollandicus). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28947805/),%,56-110,84293,DB00814,Meloxicam
,28947805,F%,"High to complete oral absorption was observed following oral administration of celecoxib (F% = 56-110%) and mavacoxib (F% = 111-113%), CF and standard solutions, respectively.","Comparative population pharmacokinetics and absolute oral bioavailability of COX-2 selective inhibitors celecoxib, mavacoxib and meloxicam in cockatiels (Nymphicus hollandicus). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28947805/),%,111-113,84294,DB00814,Meloxicam
,28947805,F%,"In contrast, the F% of meloxicam was low (F% = 11%).","Comparative population pharmacokinetics and absolute oral bioavailability of COX-2 selective inhibitors celecoxib, mavacoxib and meloxicam in cockatiels (Nymphicus hollandicus). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28947805/),%,11,84295,DB00814,Meloxicam
>,18715548,Absolute bioavailability,"Absolute bioavailability of meloxicam, based on 0-48h measurement, was >0.68 regardless of the type of formulation and treatment.",Pharmacokinetics of meloxicam administered as regular and fast dissolving formulations to the rat: influence of gastrointestinal dysfunction on the relative bioavailability of two formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18715548/),,0.68,86774,DB00814,Meloxicam
,18715548,AUC(0-24),"Vagal suppression, however, significantly reduced AUC(0-24) (microg h mL(-1)) for Brand (control, 58.8+/-22.0 vs treated, 22.1+/-9.7) but not for FD (control, 63.5+/-17.9 vs treated, 64.6+/-8.9) indicating a reduced absorption rate for the former.",Pharmacokinetics of meloxicam administered as regular and fast dissolving formulations to the rat: influence of gastrointestinal dysfunction on the relative bioavailability of two formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18715548/),[h·μg] / [ml],58.8,86775,DB00814,Meloxicam
,18715548,AUC(0-24),"Vagal suppression, however, significantly reduced AUC(0-24) (microg h mL(-1)) for Brand (control, 58.8+/-22.0 vs treated, 22.1+/-9.7) but not for FD (control, 63.5+/-17.9 vs treated, 64.6+/-8.9) indicating a reduced absorption rate for the former.",Pharmacokinetics of meloxicam administered as regular and fast dissolving formulations to the rat: influence of gastrointestinal dysfunction on the relative bioavailability of two formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18715548/),[h·μg] / [ml],22.1,86776,DB00814,Meloxicam
,18715548,AUC(0-24),"Vagal suppression, however, significantly reduced AUC(0-24) (microg h mL(-1)) for Brand (control, 58.8+/-22.0 vs treated, 22.1+/-9.7) but not for FD (control, 63.5+/-17.9 vs treated, 64.6+/-8.9) indicating a reduced absorption rate for the former.",Pharmacokinetics of meloxicam administered as regular and fast dissolving formulations to the rat: influence of gastrointestinal dysfunction on the relative bioavailability of two formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18715548/),[h·μg] / [ml],63.5,86777,DB00814,Meloxicam
,18715548,AUC(0-24),"Vagal suppression, however, significantly reduced AUC(0-24) (microg h mL(-1)) for Brand (control, 58.8+/-22.0 vs treated, 22.1+/-9.7) but not for FD (control, 63.5+/-17.9 vs treated, 64.6+/-8.9) indicating a reduced absorption rate for the former.",Pharmacokinetics of meloxicam administered as regular and fast dissolving formulations to the rat: influence of gastrointestinal dysfunction on the relative bioavailability of two formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18715548/),[h·μg] / [ml],64.6,86778,DB00814,Meloxicam
,34301073,Jss,"After optimization, MX-PO-SNEDDS exhibited a PO:MCT ratio of 1.78:1, surfactant mixture HLB value of 14, and MX:oil mix ratio of 1:15, a particle size of 47 ± 3 nm, stability index of 85 ± 4%, ex vivo Jss of 4 ± 0.6 μg/cm2min, and ulcer index of 1 ± 0.25 %.",Lyophilized Composite Loaded with Meloxicam-Peppermint oil Nanoemulsion for Periodontal Pain. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34301073/),[μg] / [cm2min],4,88699,DB00814,Meloxicam
,34301073,wetting time,Results reveal that MX-SNELCs had a wetting time of 4 ± 1 s and disintegration time of 3 ± 1 s with a high in vitro MX release of 91% by the end of 60 min.,Lyophilized Composite Loaded with Meloxicam-Peppermint oil Nanoemulsion for Periodontal Pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34301073/),s,4,88700,DB00814,Meloxicam
,34301073,disintegration time,Results reveal that MX-SNELCs had a wetting time of 4 ± 1 s and disintegration time of 3 ± 1 s with a high in vitro MX release of 91% by the end of 60 min.,Lyophilized Composite Loaded with Meloxicam-Peppermint oil Nanoemulsion for Periodontal Pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34301073/),s,3,88701,DB00814,Meloxicam
,34301073,bioavailability,"The results of pharmacokinetic studies in human volunteers further demonstrated that, compared to a marketed MX tablets, MX-SNELCs provided a higher Cmax, Tmax, and AUC and a relatively greater bioavailability of 152.97 %.",Lyophilized Composite Loaded with Meloxicam-Peppermint oil Nanoemulsion for Periodontal Pain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34301073/),%,152.97,88702,DB00814,Meloxicam
,27901389,maximum value,RESULTS Plasma drug concentrations after IM administration of meloxicam reached a mean ± SD maximum value of 6.01 ± 3.38 μg/mL.,Population pharmacokinetics of a single dose of meloxicam after oral and intramuscular administration to captive lesser flamingos (Phoeniconaias minor). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27901389/),[μg] / [ml],6.01,89636,DB00814,Meloxicam
,27901389,area under the concentration-versus-time curve,"Mean area under the concentration-versus-time curve was 17.78 ± 2.79 μg•h/mL, and mean elimination half-life was 1.93 ± 0.32 hours.",Population pharmacokinetics of a single dose of meloxicam after oral and intramuscular administration to captive lesser flamingos (Phoeniconaias minor). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27901389/),[h·μg] / [ml],17.78,89637,DB00814,Meloxicam
,27901389,elimination half-life,"Mean area under the concentration-versus-time curve was 17.78 ± 2.79 μg•h/mL, and mean elimination half-life was 1.93 ± 0.32 hours.",Population pharmacokinetics of a single dose of meloxicam after oral and intramuscular administration to captive lesser flamingos (Phoeniconaias minor). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27901389/),h,1.93,89638,DB00814,Meloxicam
,27901389,Plasma concentrations,Plasma concentrations after oral administration reached a mean maximum value of 1.79 ± 0.33 μg/mL.,Population pharmacokinetics of a single dose of meloxicam after oral and intramuscular administration to captive lesser flamingos (Phoeniconaias minor). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27901389/),[μg] / [ml],1.79,89639,DB00814,Meloxicam
,27901389,maximum,Plasma concentrations after oral administration reached a mean maximum value of 1.79 ± 0.33 μg/mL.,Population pharmacokinetics of a single dose of meloxicam after oral and intramuscular administration to captive lesser flamingos (Phoeniconaias minor). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27901389/),[μg] / [ml],1.79,89640,DB00814,Meloxicam
,27901389,area under the curve,"Mean area under the curve was 22.16 ± 7.17 μg•h/mL, and mean elimination half-life was 6.05 ± 3.53 hours.",Population pharmacokinetics of a single dose of meloxicam after oral and intramuscular administration to captive lesser flamingos (Phoeniconaias minor). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27901389/),[h·μg] / [ml],22.16,89641,DB00814,Meloxicam
,27901389,elimination half-life,"Mean area under the curve was 22.16 ± 7.17 μg•h/mL, and mean elimination half-life was 6.05 ± 3.53 hours.",Population pharmacokinetics of a single dose of meloxicam after oral and intramuscular administration to captive lesser flamingos (Phoeniconaias minor). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27901389/),h,6.05,89642,DB00814,Meloxicam
,23531074,peak plasma concentration,"The mean peak plasma concentration and area under the plasma concentration-versus-time curve extrapolated to infinity after administration of a single dose of meloxicam were 0.83 μg/mL and 10.37 h•μg/mL, respectively.",Pharmacokinetics of meloxicam in rabbits after oral administration of single and multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23531074/),[μg] / [ml],0.83,90032,DB00814,Meloxicam
,23531074,area under the plasma concentration-versus-time curve,"The mean peak plasma concentration and area under the plasma concentration-versus-time curve extrapolated to infinity after administration of a single dose of meloxicam were 0.83 μg/mL and 10.37 h•μg/mL, respectively.",Pharmacokinetics of meloxicam in rabbits after oral administration of single and multiple doses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23531074/),[h·μg] / [ml],10.37,90033,DB00814,Meloxicam
,23531074,peak plasma concentration,"After administration of meloxicam for 5 days, the mean peak plasma concentration was 1.33 μg/mL, and the area under the plasma concentration-versus-time curve from the time of administration of the last dose to 24 hours after that time was 18.79 h•μg/mL.",Pharmacokinetics of meloxicam in rabbits after oral administration of single and multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23531074/),[μg] / [ml],1.33,90034,DB00814,Meloxicam
,23531074,area under the plasma concentration-versus-time curve from the time of administration of the last dose to 24 hours after that time,"After administration of meloxicam for 5 days, the mean peak plasma concentration was 1.33 μg/mL, and the area under the plasma concentration-versus-time curve from the time of administration of the last dose to 24 hours after that time was 18.79 h•μg/mL.",Pharmacokinetics of meloxicam in rabbits after oral administration of single and multiple doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23531074/),[h·μg] / [ml],18.79,90035,DB00814,Meloxicam
,23531074,time to maximum plasma concentration,"For single- and multiple-dose meloxicam experiments, the mean time to maximum plasma concentration was 6.5 and 5.8 hours and the mean terminal half-life was 6.1 and 6.7 hours, respectively.",Pharmacokinetics of meloxicam in rabbits after oral administration of single and multiple doses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23531074/),h,6.5,90036,DB00814,Meloxicam
,23531074,time to maximum plasma concentration,"For single- and multiple-dose meloxicam experiments, the mean time to maximum plasma concentration was 6.5 and 5.8 hours and the mean terminal half-life was 6.1 and 6.7 hours, respectively.",Pharmacokinetics of meloxicam in rabbits after oral administration of single and multiple doses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23531074/),h,5.8,90037,DB00814,Meloxicam
,23531074,terminal half-life,"For single- and multiple-dose meloxicam experiments, the mean time to maximum plasma concentration was 6.5 and 5.8 hours and the mean terminal half-life was 6.1 and 6.7 hours, respectively.",Pharmacokinetics of meloxicam in rabbits after oral administration of single and multiple doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23531074/),h,6.1,90038,DB00814,Meloxicam
,23531074,terminal half-life,"For single- and multiple-dose meloxicam experiments, the mean time to maximum plasma concentration was 6.5 and 5.8 hours and the mean terminal half-life was 6.1 and 6.7 hours, respectively.",Pharmacokinetics of meloxicam in rabbits after oral administration of single and multiple doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23531074/),h,6.7,90039,DB00814,Meloxicam
,33295645,initial absorption,"From the start until maximum concentration, the initial absorption of the ODF meloxicam formulation was more rapid (2.08 ± 1.56 hr) as compared to the suspension (3.33 ± 1.03 hr).",Preliminary bioequivalence of an oral integrating film formulation containing meloxicam with a suspension formulation in beagle dogs. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33295645/),h,2.08,90098,DB00814,Meloxicam
,33295645,initial absorption,"From the start until maximum concentration, the initial absorption of the ODF meloxicam formulation was more rapid (2.08 ± 1.56 hr) as compared to the suspension (3.33 ± 1.03 hr).",Preliminary bioequivalence of an oral integrating film formulation containing meloxicam with a suspension formulation in beagle dogs. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33295645/),h,3.33,90099,DB00814,Meloxicam
,33295645,elimination half-lives,"Mean elimination half-lives were 28.77 ± 4.01 and 32.85 ± 9.79 hr for the ODF and the suspension, respectively.",Preliminary bioequivalence of an oral integrating film formulation containing meloxicam with a suspension formulation in beagle dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33295645/),h,28.77,90100,DB00814,Meloxicam
,33295645,elimination half-lives,"Mean elimination half-lives were 28.77 ± 4.01 and 32.85 ± 9.79 hr for the ODF and the suspension, respectively.",Preliminary bioequivalence of an oral integrating film formulation containing meloxicam with a suspension formulation in beagle dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33295645/),h,32.85,90101,DB00814,Meloxicam
,7589053,terminal phase elimination half-life,The mean terminal phase elimination half-life was reduced from 19.5 h to 12.7 h due to an increase in clearance of the drug (0.426 vs 0.636 l.h-1).,"The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589053/),h,19.5,96473,DB00814,Meloxicam
,7589053,terminal phase elimination half-life,The mean terminal phase elimination half-life was reduced from 19.5 h to 12.7 h due to an increase in clearance of the drug (0.426 vs 0.636 l.h-1).,"The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589053/),h,12.7,96474,DB00814,Meloxicam
,7589053,clearance,The mean terminal phase elimination half-life was reduced from 19.5 h to 12.7 h due to an increase in clearance of the drug (0.426 vs 0.636 l.h-1).,"The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589053/),[l] / [h],0.426,96475,DB00814,Meloxicam
,7589053,clearance,The mean terminal phase elimination half-life was reduced from 19.5 h to 12.7 h due to an increase in clearance of the drug (0.426 vs 0.636 l.h-1).,"The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589053/),[l] / [h],0.636,96476,DB00814,Meloxicam
,30768821,Volume of distribution,"Volume of distribution and clearance after intravenous administration of meloxicam were 0.36 L/kg and 29.12 mL/h/kg, respectively, with a 12.39 hours of terminal half-life.",Pharmacokinetics of meloxicam after oral administration of a granule formulation to healthy horses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30768821/),[l] / [kg],0.36,102002,DB00814,Meloxicam
,30768821,clearance,"Volume of distribution and clearance after intravenous administration of meloxicam were 0.36 L/kg and 29.12 mL/h/kg, respectively, with a 12.39 hours of terminal half-life.",Pharmacokinetics of meloxicam after oral administration of a granule formulation to healthy horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30768821/),[ml] / [h·kg],29.12,102003,DB00814,Meloxicam
,30768821,terminal half-life,"Volume of distribution and clearance after intravenous administration of meloxicam were 0.36 L/kg and 29.12 mL/h/kg, respectively, with a 12.39 hours of terminal half-life.",Pharmacokinetics of meloxicam after oral administration of a granule formulation to healthy horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30768821/),h,12.39,102004,DB00814,Meloxicam
,30768821,Protein binding,Protein binding was of 97%.,Pharmacokinetics of meloxicam after oral administration of a granule formulation to healthy horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30768821/),%,97,102005,DB00814,Meloxicam
,30768821,Bioavailability,"Bioavailability was high for every oral formulation, ranging 70%-110%, without feed effect.",Pharmacokinetics of meloxicam after oral administration of a granule formulation to healthy horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30768821/),%,70,102006,DB00814,Meloxicam
,30768821,Bioavailability,"Bioavailability was high for every oral formulation, ranging 70%-110%, without feed effect.",Pharmacokinetics of meloxicam after oral administration of a granule formulation to healthy horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30768821/),%,110,102007,DB00814,Meloxicam
,30768821,half-life,"Because of a slower absorption, meloxicam after administration of granules had a longer half-life (24 and 34 hours, fasted and fed, respectively) and mean residence time (31 and 47 hours), than suspension and tablets (ranging 10-13 and 13-15 hours, respectively).",Pharmacokinetics of meloxicam after oral administration of a granule formulation to healthy horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30768821/),h,24,102008,DB00814,Meloxicam
,30768821,half-life,"Because of a slower absorption, meloxicam after administration of granules had a longer half-life (24 and 34 hours, fasted and fed, respectively) and mean residence time (31 and 47 hours), than suspension and tablets (ranging 10-13 and 13-15 hours, respectively).",Pharmacokinetics of meloxicam after oral administration of a granule formulation to healthy horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30768821/),h,34,102009,DB00814,Meloxicam
,30768821,mean residence time,"Because of a slower absorption, meloxicam after administration of granules had a longer half-life (24 and 34 hours, fasted and fed, respectively) and mean residence time (31 and 47 hours), than suspension and tablets (ranging 10-13 and 13-15 hours, respectively).",Pharmacokinetics of meloxicam after oral administration of a granule formulation to healthy horses. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30768821/),h,31,102010,DB00814,Meloxicam
,30768821,mean residence time,"Because of a slower absorption, meloxicam after administration of granules had a longer half-life (24 and 34 hours, fasted and fed, respectively) and mean residence time (31 and 47 hours), than suspension and tablets (ranging 10-13 and 13-15 hours, respectively).",Pharmacokinetics of meloxicam after oral administration of a granule formulation to healthy horses. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30768821/),h,47,102011,DB00814,Meloxicam
,30768821,mean residence time,"Because of a slower absorption, meloxicam after administration of granules had a longer half-life (24 and 34 hours, fasted and fed, respectively) and mean residence time (31 and 47 hours), than suspension and tablets (ranging 10-13 and 13-15 hours, respectively).",Pharmacokinetics of meloxicam after oral administration of a granule formulation to healthy horses. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30768821/),h,10-13,102012,DB00814,Meloxicam
,30768821,mean residence time,"Because of a slower absorption, meloxicam after administration of granules had a longer half-life (24 and 34 hours, fasted and fed, respectively) and mean residence time (31 and 47 hours), than suspension and tablets (ranging 10-13 and 13-15 hours, respectively).",Pharmacokinetics of meloxicam after oral administration of a granule formulation to healthy horses. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30768821/),h,13-15,102013,DB00814,Meloxicam
,22720782,peak plasma concentration (CMAX),A mean peak plasma concentration (CMAX) of 1.314 μg/mL (Range: 0.826 - 1.776 μg/mL) was recorded at 21.4 hours (Range: 12.0 - 24.0 hours) with a half-life (T ½ λz) of 22.7 hours (Range: 18.0 - 30.8 hours) after oral meloxicam administration.,Bioavailability and pharmacokinetics of oral meloxicam in llamas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22720782/),[μg] / [ml],1.314,102327,DB00814,Meloxicam
,22720782,half-life (T ½ λz),A mean peak plasma concentration (CMAX) of 1.314 μg/mL (Range: 0.826 - 1.776 μg/mL) was recorded at 21.4 hours (Range: 12.0 - 24.0 hours) with a half-life (T ½ λz) of 22.7 hours (Range: 18.0 - 30.8 hours) after oral meloxicam administration.,Bioavailability and pharmacokinetics of oral meloxicam in llamas. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22720782/),h,22.7,102328,DB00814,Meloxicam
,22720782,half-life (T ½ λz),"In comparison, a half-life (T ½ λz) of 17.4 hours (Range: 16.2 - 20.7 hours) was demonstrated with IV meloxicam administration.",Bioavailability and pharmacokinetics of oral meloxicam in llamas. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22720782/),h,17.4,102329,DB00814,Meloxicam
,22720782,oral bioavailability (F),The oral bioavailability (F) of meloxicam (dose normalized) was 76% (Range: 48 - 92%).,Bioavailability and pharmacokinetics of oral meloxicam in llamas. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22720782/),%,76,102330,DB00814,Meloxicam
,22720782,bioavailability (F),The mean bioavailability (F) of oral meloxicam was 76% indicating a high degree of gastrointestinal absorption.,Bioavailability and pharmacokinetics of oral meloxicam in llamas. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22720782/),%,76,102331,DB00814,Meloxicam
,31880830,mean residence time,"The difference was statistically significant (p < .05) between MEL oil suspension and MEL conventional formulation in pharmacokinetic parameters of mean residence time (6.16 ± 4.04) hr versus (2.66 ± 0.55) hr, peak plasma concentration (Cmax ) (0.82 ± 0.12) µg/ml versus (1.12 ± 0.22) µg/ml, time needed to reach Cmax (Tmax ) (2.33 ± 0.82) hr versus (0.59 ± 0.18) hr, and terminal elimination half-life (t1/2λz ) (3.74 ± 2.66) hr versus (1.55 ± 0.37) hr.",Pharmacokinetics and relative bioavailability of meloxicam oil suspension in pigs after intramuscular administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31880830/),h,6.16,103557,DB00814,Meloxicam
,31880830,mean residence time,"The difference was statistically significant (p < .05) between MEL oil suspension and MEL conventional formulation in pharmacokinetic parameters of mean residence time (6.16 ± 4.04) hr versus (2.66 ± 0.55) hr, peak plasma concentration (Cmax ) (0.82 ± 0.12) µg/ml versus (1.12 ± 0.22) µg/ml, time needed to reach Cmax (Tmax ) (2.33 ± 0.82) hr versus (0.59 ± 0.18) hr, and terminal elimination half-life (t1/2λz ) (3.74 ± 2.66) hr versus (1.55 ± 0.37) hr.",Pharmacokinetics and relative bioavailability of meloxicam oil suspension in pigs after intramuscular administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31880830/),h,2.66,103558,DB00814,Meloxicam
,31880830,peak plasma concentration (Cmax ),"The difference was statistically significant (p < .05) between MEL oil suspension and MEL conventional formulation in pharmacokinetic parameters of mean residence time (6.16 ± 4.04) hr versus (2.66 ± 0.55) hr, peak plasma concentration (Cmax ) (0.82 ± 0.12) µg/ml versus (1.12 ± 0.22) µg/ml, time needed to reach Cmax (Tmax ) (2.33 ± 0.82) hr versus (0.59 ± 0.18) hr, and terminal elimination half-life (t1/2λz ) (3.74 ± 2.66) hr versus (1.55 ± 0.37) hr.",Pharmacokinetics and relative bioavailability of meloxicam oil suspension in pigs after intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31880830/),[μg] / [ml],0.82,103559,DB00814,Meloxicam
,31880830,peak plasma concentration (Cmax ),"The difference was statistically significant (p < .05) between MEL oil suspension and MEL conventional formulation in pharmacokinetic parameters of mean residence time (6.16 ± 4.04) hr versus (2.66 ± 0.55) hr, peak plasma concentration (Cmax ) (0.82 ± 0.12) µg/ml versus (1.12 ± 0.22) µg/ml, time needed to reach Cmax (Tmax ) (2.33 ± 0.82) hr versus (0.59 ± 0.18) hr, and terminal elimination half-life (t1/2λz ) (3.74 ± 2.66) hr versus (1.55 ± 0.37) hr.",Pharmacokinetics and relative bioavailability of meloxicam oil suspension in pigs after intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31880830/),[μg] / [ml],1.12,103560,DB00814,Meloxicam
,31880830,time needed to reach Cmax (Tmax ),"The difference was statistically significant (p < .05) between MEL oil suspension and MEL conventional formulation in pharmacokinetic parameters of mean residence time (6.16 ± 4.04) hr versus (2.66 ± 0.55) hr, peak plasma concentration (Cmax ) (0.82 ± 0.12) µg/ml versus (1.12 ± 0.22) µg/ml, time needed to reach Cmax (Tmax ) (2.33 ± 0.82) hr versus (0.59 ± 0.18) hr, and terminal elimination half-life (t1/2λz ) (3.74 ± 2.66) hr versus (1.55 ± 0.37) hr.",Pharmacokinetics and relative bioavailability of meloxicam oil suspension in pigs after intramuscular administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31880830/),h,2.33,103561,DB00814,Meloxicam
,31880830,time needed to reach Cmax (Tmax ),"The difference was statistically significant (p < .05) between MEL oil suspension and MEL conventional formulation in pharmacokinetic parameters of mean residence time (6.16 ± 4.04) hr versus (2.66 ± 0.55) hr, peak plasma concentration (Cmax ) (0.82 ± 0.12) µg/ml versus (1.12 ± 0.22) µg/ml, time needed to reach Cmax (Tmax ) (2.33 ± 0.82) hr versus (0.59 ± 0.18) hr, and terminal elimination half-life (t1/2λz ) (3.74 ± 2.66) hr versus (1.55 ± 0.37) hr.",Pharmacokinetics and relative bioavailability of meloxicam oil suspension in pigs after intramuscular administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31880830/),h,0.59,103562,DB00814,Meloxicam
,31880830,terminal elimination half-life (t1/2λz ),"The difference was statistically significant (p < .05) between MEL oil suspension and MEL conventional formulation in pharmacokinetic parameters of mean residence time (6.16 ± 4.04) hr versus (2.66 ± 0.55) hr, peak plasma concentration (Cmax ) (0.82 ± 0.12) µg/ml versus (1.12 ± 0.22) µg/ml, time needed to reach Cmax (Tmax ) (2.33 ± 0.82) hr versus (0.59 ± 0.18) hr, and terminal elimination half-life (t1/2λz ) (3.74 ± 2.66) hr versus (1.55 ± 0.37) hr.",Pharmacokinetics and relative bioavailability of meloxicam oil suspension in pigs after intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31880830/),h,3.74,103563,DB00814,Meloxicam
,31880830,terminal elimination half-life (t1/2λz ),"The difference was statistically significant (p < .05) between MEL oil suspension and MEL conventional formulation in pharmacokinetic parameters of mean residence time (6.16 ± 4.04) hr versus (2.66 ± 0.55) hr, peak plasma concentration (Cmax ) (0.82 ± 0.12) µg/ml versus (1.12 ± 0.22) µg/ml, time needed to reach Cmax (Tmax ) (2.33 ± 0.82) hr versus (0.59 ± 0.18) hr, and terminal elimination half-life (t1/2λz ) (3.74 ± 2.66) hr versus (1.55 ± 0.37) hr.",Pharmacokinetics and relative bioavailability of meloxicam oil suspension in pigs after intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31880830/),h,1.55,103564,DB00814,Meloxicam
,31880830,area under the concentration-time curve (AUC0-∝ ),"The mean area under the concentration-time curve (AUC0-∝ ) of MEL oil suspension and MEL conventional formulation was 5.35 and 3.43 hr µg/ml, respectively, with a relative bioavailability of 155.98%.",Pharmacokinetics and relative bioavailability of meloxicam oil suspension in pigs after intramuscular administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31880830/),[h·μg] / [ml],5.35,103565,DB00814,Meloxicam
,31880830,area under the concentration-time curve (AUC0-∝ ),"The mean area under the concentration-time curve (AUC0-∝ ) of MEL oil suspension and MEL conventional formulation was 5.35 and 3.43 hr µg/ml, respectively, with a relative bioavailability of 155.98%.",Pharmacokinetics and relative bioavailability of meloxicam oil suspension in pigs after intramuscular administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31880830/),[h·μg] / [ml],3.43,103566,DB00814,Meloxicam
,31880830,relative bioavailability,"The mean area under the concentration-time curve (AUC0-∝ ) of MEL oil suspension and MEL conventional formulation was 5.35 and 3.43 hr µg/ml, respectively, with a relative bioavailability of 155.98%.",Pharmacokinetics and relative bioavailability of meloxicam oil suspension in pigs after intramuscular administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31880830/),%,155.98,103567,DB00814,Meloxicam
,22306039,d(mean),"The optimized formulation, MS5 (d(mean)=44.47 μm, %EE=98.73, %CDR=97.32 and followed zero order release) was developed into colon-targeted matrix tablet using calcium pectinate as the matrix.",Colonic luminal surface retention of meloxicam microsponges delivered by erosion based colon-targeted matrix tablet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22306039/),μm,44.47,104960,DB00814,Meloxicam
,22306039,lag time,"The pharmacokinetic evaluation of MS5T2 in rabbits, revealed appearance of drug appeared in plasma after a lag time of 7h; a t(max) of 30 h with Fr=61.047%, thus presenting a formulation suitable for targeted colonic delivery.",Colonic luminal surface retention of meloxicam microsponges delivered by erosion based colon-targeted matrix tablet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22306039/),h,7,104961,DB00814,Meloxicam
,22306039,t(max),"The pharmacokinetic evaluation of MS5T2 in rabbits, revealed appearance of drug appeared in plasma after a lag time of 7h; a t(max) of 30 h with Fr=61.047%, thus presenting a formulation suitable for targeted colonic delivery.",Colonic luminal surface retention of meloxicam microsponges delivered by erosion based colon-targeted matrix tablet. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22306039/),h,30,104962,DB00814,Meloxicam
,22306039,Fr,"The pharmacokinetic evaluation of MS5T2 in rabbits, revealed appearance of drug appeared in plasma after a lag time of 7h; a t(max) of 30 h with Fr=61.047%, thus presenting a formulation suitable for targeted colonic delivery.",Colonic luminal surface retention of meloxicam microsponges delivered by erosion based colon-targeted matrix tablet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22306039/),%,61.047,104963,DB00814,Meloxicam
,24788875,recovery,"This method is simple, rapid and consistent with a high recovery of meloxicam in human plasma ranging from 93.29 to 111.09%.",Improved protein deproteinization method for the determination of meloxicam in human plasma and application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24788875/),%,93.29 to 111.09,107114,DB00814,Meloxicam
,24788875,Area under the concentration-time curve,"Area under the concentration-time curve, peak concentration (C(max)) and time to reach C(max) were 72,868.61 ng h/mL, 2133.93 ng/mL and 4.06 h for Mobic, and 78,352.52 ng h/mL, 2525.18 ng/mL and 3.61 h for Melocam.",Improved protein deproteinization method for the determination of meloxicam in human plasma and application in pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24788875/),[h·ng] / [ml],"72,868.61",107115,DB00814,Meloxicam
,24788875,peak concentration (C(max)),"Area under the concentration-time curve, peak concentration (C(max)) and time to reach C(max) were 72,868.61 ng h/mL, 2133.93 ng/mL and 4.06 h for Mobic, and 78,352.52 ng h/mL, 2525.18 ng/mL and 3.61 h for Melocam.",Improved protein deproteinization method for the determination of meloxicam in human plasma and application in pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24788875/),[ng] / [ml],2133.93,107116,DB00814,Meloxicam
,24788875,peak concentration (C(max)),"Area under the concentration-time curve, peak concentration (C(max)) and time to reach C(max) were 72,868.61 ng h/mL, 2133.93 ng/mL and 4.06 h for Mobic, and 78,352.52 ng h/mL, 2525.18 ng/mL and 3.61 h for Melocam.",Improved protein deproteinization method for the determination of meloxicam in human plasma and application in pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24788875/),[ng] / [ml],2525.18,107117,DB00814,Meloxicam
,24788875,time to reach C(max),"Area under the concentration-time curve, peak concentration (C(max)) and time to reach C(max) were 72,868.61 ng h/mL, 2133.93 ng/mL and 4.06 h for Mobic, and 78,352.52 ng h/mL, 2525.18 ng/mL and 3.61 h for Melocam.",Improved protein deproteinization method for the determination of meloxicam in human plasma and application in pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24788875/),h,4.06,107118,DB00814,Meloxicam
,24788875,time to reach C(max),"Area under the concentration-time curve, peak concentration (C(max)) and time to reach C(max) were 72,868.61 ng h/mL, 2133.93 ng/mL and 4.06 h for Mobic, and 78,352.52 ng h/mL, 2525.18 ng/mL and 3.61 h for Melocam.",Improved protein deproteinization method for the determination of meloxicam in human plasma and application in pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24788875/),h,3.61,107119,DB00814,Meloxicam
,24344511,elimination half-life,Red-tailed hawks were determined to have the shortest elimination half-life for meloxicam (0.49 +/- 0.5 hours) of any species documented.,Pharmacokinetics of a single dose of intravenous and oral meloxicam in red-tailed hawks (Buteo jamaicensis) and great horned owls (Bubo virginianus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24344511/),h,0.49,110613,DB00814,Meloxicam
,24344511,plasma concentrations,"Great horned owls achieved higher plasma concentrations (368 +/- 87 ng/mL) of meloxicam than RTH (182 +/- 167 ng/mL) after oral administration, although RTH had a markedly higher volume of distribution (832 +/- 711 mL/kg) than GHO (137.6 +/- 62.7 mL/kg).",Pharmacokinetics of a single dose of intravenous and oral meloxicam in red-tailed hawks (Buteo jamaicensis) and great horned owls (Bubo virginianus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24344511/),[ng] / [ml],368,110614,DB00814,Meloxicam
,24344511,plasma concentrations,"Great horned owls achieved higher plasma concentrations (368 +/- 87 ng/mL) of meloxicam than RTH (182 +/- 167 ng/mL) after oral administration, although RTH had a markedly higher volume of distribution (832 +/- 711 mL/kg) than GHO (137.6 +/- 62.7 mL/kg).",Pharmacokinetics of a single dose of intravenous and oral meloxicam in red-tailed hawks (Buteo jamaicensis) and great horned owls (Bubo virginianus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24344511/),[ng] / [ml],182,110615,DB00814,Meloxicam
,24344511,volume of distribution,"Great horned owls achieved higher plasma concentrations (368 +/- 87 ng/mL) of meloxicam than RTH (182 +/- 167 ng/mL) after oral administration, although RTH had a markedly higher volume of distribution (832 +/- 711 mL/kg) than GHO (137.6 +/- 62.7 mL/kg).",Pharmacokinetics of a single dose of intravenous and oral meloxicam in red-tailed hawks (Buteo jamaicensis) and great horned owls (Bubo virginianus). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24344511/),[ml] / [kg],832,110616,DB00814,Meloxicam
,24344511,volume of distribution,"Great horned owls achieved higher plasma concentrations (368 +/- 87 ng/mL) of meloxicam than RTH (182 +/- 167 ng/mL) after oral administration, although RTH had a markedly higher volume of distribution (832 +/- 711 mL/kg) than GHO (137.6 +/- 62.7 mL/kg).",Pharmacokinetics of a single dose of intravenous and oral meloxicam in red-tailed hawks (Buteo jamaicensis) and great horned owls (Bubo virginianus). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24344511/),[ml] / [kg],137.6,110617,DB00814,Meloxicam
,23434065,terminal half-live,"In plasma, the terminal half-live of flunixin, meloxicam and gabapentin were 6.0 h (range, 3.4-11.0 h), 16.7h (range, 13.7-21.3h) and 15.3h (range, 11-32.9h), respectively.","A study to compare circulating flunixin, meloxicam and gabapentin concentrations with prostaglandin E₂ levels in calves undergoing dehorning. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23434065/),h,6.0,114728,DB00814,Meloxicam
,23434065,terminal half-live,"In plasma, the terminal half-live of flunixin, meloxicam and gabapentin were 6.0 h (range, 3.4-11.0 h), 16.7h (range, 13.7-21.3h) and 15.3h (range, 11-32.9h), respectively.","A study to compare circulating flunixin, meloxicam and gabapentin concentrations with prostaglandin E₂ levels in calves undergoing dehorning. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23434065/),h,16.7,114729,DB00814,Meloxicam
,23434065,terminal half-live,"In plasma, the terminal half-live of flunixin, meloxicam and gabapentin were 6.0 h (range, 3.4-11.0 h), 16.7h (range, 13.7-21.3h) and 15.3h (range, 11-32.9h), respectively.","A study to compare circulating flunixin, meloxicam and gabapentin concentrations with prostaglandin E₂ levels in calves undergoing dehorning. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23434065/),h,15.3,114730,DB00814,Meloxicam
,12534638,clearance,"For a typical subject in the population, a clearance of 0.377 l h-1 (95% confidence interval (CI) 0.0304-0.449) in males and 0.347 l h-1 (95% CI 0.274-0.419) in females was obtained.",Population pharmacokinetic analysis of meloxicam in rheumatoid arthritis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534638/),[l] / [h],0.377,115904,DB00814,Meloxicam
,12534638,clearance,"For a typical subject in the population, a clearance of 0.377 l h-1 (95% confidence interval (CI) 0.0304-0.449) in males and 0.347 l h-1 (95% CI 0.274-0.419) in females was obtained.",Population pharmacokinetic analysis of meloxicam in rheumatoid arthritis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534638/),[l] / [h],0.347,115905,DB00814,Meloxicam
,12534638,volume of distribution,The volume of distribution was estimated to be 14.9 l.,Population pharmacokinetic analysis of meloxicam in rheumatoid arthritis patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534638/),l,14.9,115906,DB00814,Meloxicam
,28138901,T lag time,In vivo pharmacokinetic evaluation in rabbits reveal that the onset of drug absorption from the coated tableted microspheres (T lag time = 4.67 ± 0.58 h) was significantly delayed compared to uncoated tableted microspheres.,Formulation and development of di-dependent microparticulate system for colon-specific drug delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28138901/),h,4.67,116387,DB00814,Meloxicam
,12039643,retention time,"The retention time observed for meloxicam and piroxicam (internal standard) were at 6.0 and 4.0 min, respectively.",LC determination and pharmacokinetics of meloxicam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12039643/),min,6.0,117429,DB00814,Meloxicam
,12039643,retention time,"The retention time observed for meloxicam and piroxicam (internal standard) were at 6.0 and 4.0 min, respectively.",LC determination and pharmacokinetics of meloxicam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12039643/),min,4.0,117430,DB00814,Meloxicam
,31986203,signal-to-noise ratio (S/N),"Limits of detection (LOD; signal-to-noise ratio (S/N) = 3) and quantification (LOQ, S/N = 10) were 1 and 5 ng mL-1, respectively.",Quantification of Meloxicam in Human Plasma Using Ionic Liquid-Based Ultrasound-Assisted In Situ Solvent Formation Microextraction Followed by High-Performance Liquid Chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31986203/),,3,118828,DB00814,Meloxicam
,31986203,S/N,"Limits of detection (LOD; signal-to-noise ratio (S/N) = 3) and quantification (LOQ, S/N = 10) were 1 and 5 ng mL-1, respectively.",Quantification of Meloxicam in Human Plasma Using Ionic Liquid-Based Ultrasound-Assisted In Situ Solvent Formation Microextraction Followed by High-Performance Liquid Chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31986203/),[ng] / [ml],10,118829,DB00814,Meloxicam
,31986203,S/N,"Limits of detection (LOD; signal-to-noise ratio (S/N) = 3) and quantification (LOQ, S/N = 10) were 1 and 5 ng mL-1, respectively.",Quantification of Meloxicam in Human Plasma Using Ionic Liquid-Based Ultrasound-Assisted In Situ Solvent Formation Microextraction Followed by High-Performance Liquid Chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31986203/),[ng] / [ml],1,118830,DB00814,Meloxicam
,31986203,S/N,"Limits of detection (LOD; signal-to-noise ratio (S/N) = 3) and quantification (LOQ, S/N = 10) were 1 and 5 ng mL-1, respectively.",Quantification of Meloxicam in Human Plasma Using Ionic Liquid-Based Ultrasound-Assisted In Situ Solvent Formation Microextraction Followed by High-Performance Liquid Chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31986203/),[ng] / [ml],5,118831,DB00814,Meloxicam
,30592922,maximum,Plasma concentrations reached a mean maximum (±standard deviation) of 7.65 (±2.39) μg/ml at 0.56 (±0.18) hr with a terminal half-life of 1.76 (±1.41) hr.,PHARMACOKINETICS OF A SUSTAINED-RELEASE FORMULATION OF MELOXICAM AFTER SUBCUTANEOUS ADMINISTRATION TO AMERICAN FLAMINGOS ( PHOENICOPTERUS RUBER). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30592922/),[μg] / [ml],7.65,123644,DB00814,Meloxicam
,30592922,terminal half-life,Plasma concentrations reached a mean maximum (±standard deviation) of 7.65 (±2.39) μg/ml at 0.56 (±0.18) hr with a terminal half-life of 1.76 (±1.41) hr.,PHARMACOKINETICS OF A SUSTAINED-RELEASE FORMULATION OF MELOXICAM AFTER SUBCUTANEOUS ADMINISTRATION TO AMERICAN FLAMINGOS ( PHOENICOPTERUS RUBER). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30592922/),h,1.76,123645,DB00814,Meloxicam
,9056050,AUCSS,Subjects with no or mild renal impairment showed similar pharmacokinetic profiles (geometric mean AUCSS (%gCV) 55 (33%) vs 55 (38%) micrograms ml-1 h).,Meloxicam pharmacokinetics in renal impairment. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056050/),[h·μg] / [ml],55,125083,DB00814,Meloxicam
,9056050,AUCSS,Subjects with no or mild renal impairment showed similar pharmacokinetic profiles (geometric mean AUCSS (%gCV) 55 (33%) vs 55 (38%) micrograms ml-1 h).,Meloxicam pharmacokinetics in renal impairment. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056050/),[h·μg] / [ml],55,125084,DB00814,Meloxicam
,9056050,total plasma meloxicam concentrations (AUCSS,"Subjects with moderate renal impairment demonstrated lower total plasma meloxicam concentrations (AUCSS 35 (50%) micrograms ml-1 h, with corresponding higher plasma clearance (P = 0.013) compared with subjects with no renal impairment.",Meloxicam pharmacokinetics in renal impairment. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056050/),[h·μg] / [ml],35,125085,DB00814,Meloxicam
,19543299,AUC(0-t),The pharmacokinetic results showed that AUC(0-t) (23.9+/-8.26 microg.h.mL(-1)) in plasma after oral administration was significantly higher than after transdermal delivery (1.00+/-0.43 microg.h.mL(-1)).,Pharmacokinetic studies of meloxicam following oral and transdermal administration in Beagle dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19543299/),[h·μg] / [ml],23.9,125983,DB00814,Meloxicam
,19543299,AUC(0-t),The pharmacokinetic results showed that AUC(0-t) (23.9+/-8.26 microg.h.mL(-1)) in plasma after oral administration was significantly higher than after transdermal delivery (1.00+/-0.43 microg.h.mL(-1)).,Pharmacokinetic studies of meloxicam following oral and transdermal administration in Beagle dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19543299/),[h·μg] / [ml],1.00,125984,DB00814,Meloxicam
,22372845,plasma C(max),The mean (±SD) plasma C(max) and T(max) for meloxicam (2.89±0.48 μg/mL and 11.33±4.12 h) were not much different from gabapentin at 10 mg/kg (2.87±0.2 μg/mL and 8±0 h).,Pharmacokinetics and milk secretion of gabapentin and meloxicam co-administered orally in Holstein-Friesian cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22372845/),[μg] / [ml],2.89,126252,DB00814,Meloxicam
,22372845,plasma C(max),The mean (±SD) plasma C(max) and T(max) for meloxicam (2.89±0.48 μg/mL and 11.33±4.12 h) were not much different from gabapentin at 10 mg/kg (2.87±0.2 μg/mL and 8±0 h).,Pharmacokinetics and milk secretion of gabapentin and meloxicam co-administered orally in Holstein-Friesian cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22372845/),[μg] / [ml],2.87,126253,DB00814,Meloxicam
,22372845,T(max),The mean (±SD) plasma C(max) and T(max) for meloxicam (2.89±0.48 μg/mL and 11.33±4.12 h) were not much different from gabapentin at 10 mg/kg (2.87±0.2 μg/mL and 8±0 h).,Pharmacokinetics and milk secretion of gabapentin and meloxicam co-administered orally in Holstein-Friesian cows. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22372845/),h,11.33,126254,DB00814,Meloxicam
,22372845,T(max),The mean (±SD) plasma C(max) and T(max) for meloxicam (2.89±0.48 μg/mL and 11.33±4.12 h) were not much different from gabapentin at 10 mg/kg (2.87±0.2 μg/mL and 8±0 h).,Pharmacokinetics and milk secretion of gabapentin and meloxicam co-administered orally in Holstein-Friesian cows. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22372845/),h,8,126255,DB00814,Meloxicam
,22372845,milk C(max),The mean (±SD) milk C(max) for meloxicam (0.41±80.16 μg/mL) was comparable to gabapentin at 10 mg/kg (0.63±0.13 μg/mL and 12±6.69 h).,Pharmacokinetics and milk secretion of gabapentin and meloxicam co-administered orally in Holstein-Friesian cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22372845/),[μg] / [ml],0.41,126256,DB00814,Meloxicam
,22372845,milk C(max),The mean (±SD) milk C(max) for meloxicam (0.41±80.16 μg/mL) was comparable to gabapentin at 10 mg/kg (0.63±0.13 μg/mL and 12±6.69 h).,Pharmacokinetics and milk secretion of gabapentin and meloxicam co-administered orally in Holstein-Friesian cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22372845/),[μg] / [ml],0.63,126257,DB00814,Meloxicam
,22372845,milk C(max),The mean (±SD) milk C(max) for meloxicam (0.41±80.16 μg/mL) was comparable to gabapentin at 10 mg/kg (0.63±0.13 μg/mL and 12±6.69 h).,Pharmacokinetics and milk secretion of gabapentin and meloxicam co-administered orally in Holstein-Friesian cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22372845/),h,12,126258,DB00814,Meloxicam
,22372845,milk to plasma ratio,The mean (±SD) milk to plasma ratio for meloxicam (0.14±0.04) was lower than for gabapentin (0.23±0.06).,Pharmacokinetics and milk secretion of gabapentin and meloxicam co-administered orally in Holstein-Friesian cows. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22372845/),,0.14,126259,DB00814,Meloxicam
,22372845,milk to plasma ratio,The mean (±SD) milk to plasma ratio for meloxicam (0.14±0.04) was lower than for gabapentin (0.23±0.06).,Pharmacokinetics and milk secretion of gabapentin and meloxicam co-administered orally in Holstein-Friesian cows. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22372845/),,0.23,126260,DB00814,Meloxicam
,20869892,C(max),"The mean (± standard deviation, SD) C(max), T(max) and elimination half-life (t(½)λz) for gabapentin (10mg/kg) alone was 2.97 ± 0.40μg/mL, 9.33 ± 2.73h and 11.02 ± 3.68h, respectively.",Pharmacokinetics of oral gabapentin alone or co-administered with meloxicam in ruminant beef calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20869892/),[μg] / [ml],2.97,132618,DB00814,Meloxicam
,20869892,T(max),"The mean (± standard deviation, SD) C(max), T(max) and elimination half-life (t(½)λz) for gabapentin (10mg/kg) alone was 2.97 ± 0.40μg/mL, 9.33 ± 2.73h and 11.02 ± 3.68h, respectively.",Pharmacokinetics of oral gabapentin alone or co-administered with meloxicam in ruminant beef calves. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20869892/),h,9.33,132619,DB00814,Meloxicam
,20869892,elimination half-life (t(½)λz),"The mean (± standard deviation, SD) C(max), T(max) and elimination half-life (t(½)λz) for gabapentin (10mg/kg) alone was 2.97 ± 0.40μg/mL, 9.33 ± 2.73h and 11.02 ± 3.68h, respectively.",Pharmacokinetics of oral gabapentin alone or co-administered with meloxicam in ruminant beef calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20869892/),h,11.02,132620,DB00814,Meloxicam
,20869892,C(max),"The mean (± SD) C(max), T(max) and t(½)λz for gabapentin (15mg/kg) co-administered with meloxicam was 3.57±1.04μg/mL, 7.33 ± 1.63h and 8.12±2.11h, respectively.",Pharmacokinetics of oral gabapentin alone or co-administered with meloxicam in ruminant beef calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20869892/),[μg] / [ml],3.57,132621,DB00814,Meloxicam
,20869892,T(max),"The mean (± SD) C(max), T(max) and t(½)λz for gabapentin (15mg/kg) co-administered with meloxicam was 3.57±1.04μg/mL, 7.33 ± 1.63h and 8.12±2.11h, respectively.",Pharmacokinetics of oral gabapentin alone or co-administered with meloxicam in ruminant beef calves. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20869892/),h,7.33,132622,DB00814,Meloxicam
,20869892,t(½)λz,"The mean (± SD) C(max), T(max) and t(½)λz for gabapentin (15mg/kg) co-administered with meloxicam was 3.57±1.04μg/mL, 7.33 ± 1.63h and 8.12±2.11h, respectively.",Pharmacokinetics of oral gabapentin alone or co-administered with meloxicam in ruminant beef calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20869892/),h,8.12,132623,DB00814,Meloxicam
,20869892,C(max),"The mean (±SD) C(max), T(max) and t(½)λz for meloxicam was 2.11± 0.19μg/mL, 11.67 ± 3.44h and 20.47 ± 9.22h, respectively.",Pharmacokinetics of oral gabapentin alone or co-administered with meloxicam in ruminant beef calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20869892/),[μg] / [ml],2.11,132624,DB00814,Meloxicam
,20869892,T(max),"The mean (±SD) C(max), T(max) and t(½)λz for meloxicam was 2.11± 0.19μg/mL, 11.67 ± 3.44h and 20.47 ± 9.22h, respectively.",Pharmacokinetics of oral gabapentin alone or co-administered with meloxicam in ruminant beef calves. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20869892/),h,11.67,132625,DB00814,Meloxicam
,20869892,t(½)λz,"The mean (±SD) C(max), T(max) and t(½)λz for meloxicam was 2.11± 0.19μg/mL, 11.67 ± 3.44h and 20.47 ± 9.22h, respectively.",Pharmacokinetics of oral gabapentin alone or co-administered with meloxicam in ruminant beef calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20869892/),h,20.47,132626,DB00814,Meloxicam
,20557445,total apparent body clearance (CL/F),"Pharmacokinetic parameters were estimated to be 0.00656 L/h/kg for the total apparent body clearance (CL/F), 0.245 L/kg for the apparent volume of distribution (V/F), 1.26 1/h for the absorption constant (K(A)) and 25.7 h for the mean plasma terminal half-life.",Population pharmacokinetic modelling and simulation of single and multiple dose administration of meloxicam in cats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20557445/),[l] / [h·kg],0.00656,135397,DB00814,Meloxicam
,20557445,apparent volume of distribution (V/F),"Pharmacokinetic parameters were estimated to be 0.00656 L/h/kg for the total apparent body clearance (CL/F), 0.245 L/kg for the apparent volume of distribution (V/F), 1.26 1/h for the absorption constant (K(A)) and 25.7 h for the mean plasma terminal half-life.",Population pharmacokinetic modelling and simulation of single and multiple dose administration of meloxicam in cats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20557445/),[l] / [kg],0.245,135398,DB00814,Meloxicam
,20557445,absorption constant (K(A)),"Pharmacokinetic parameters were estimated to be 0.00656 L/h/kg for the total apparent body clearance (CL/F), 0.245 L/kg for the apparent volume of distribution (V/F), 1.26 1/h for the absorption constant (K(A)) and 25.7 h for the mean plasma terminal half-life.",Population pharmacokinetic modelling and simulation of single and multiple dose administration of meloxicam in cats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20557445/),[1] / [h],1.26,135399,DB00814,Meloxicam
,20557445,plasma terminal half-life,"Pharmacokinetic parameters were estimated to be 0.00656 L/h/kg for the total apparent body clearance (CL/F), 0.245 L/kg for the apparent volume of distribution (V/F), 1.26 1/h for the absorption constant (K(A)) and 25.7 h for the mean plasma terminal half-life.",Population pharmacokinetic modelling and simulation of single and multiple dose administration of meloxicam in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20557445/),h,25.7,135400,DB00814,Meloxicam
,20557445,trough steady-state concentrations,"Simulations showed that the median trough steady-state concentrations of 228 ng/mL were reached after five, one or 6 days following a single initial dose of 0.05, 0.1 and 0.2 mg/kg each followed by 0.05 mg/kg/day.",Population pharmacokinetic modelling and simulation of single and multiple dose administration of meloxicam in cats. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20557445/),[ng] / [ml],228,135401,DB00814,Meloxicam
,26638161,maximum plasma concentrations,"Under fasting conditions, SoluMatrix meloxicam 10 mg [1252.8 (254.22) ng/mL] produced similar meloxicam mean (standard deviation (SD)) maximum plasma concentrations vs meloxicam 15-mg tablets [1288.8 (424.40) ng/mL].",Pharmacokinetic properties of low-dose SoluMatrix meloxicam in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26638161/),[ng] / [ml],1288.8,136279,DB00814,Meloxicam
,26638161,exposure,"The overall mean (SD) systemic meloxicam exposure was 33 % lower for SoluMatrix meloxicam 10 mg [29,173.01 (11,042.09) ng*h/mL] vs meloxicam 15-mg tablets [40,875.6 (11,733.47) ng*h/mL].",Pharmacokinetic properties of low-dose SoluMatrix meloxicam in healthy adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26638161/),[h·ng] / [ml],29,136280,DB00814,Meloxicam
,26638161,exposure,"The overall mean (SD) systemic meloxicam exposure was 33 % lower for SoluMatrix meloxicam 10 mg [29,173.01 (11,042.09) ng*h/mL] vs meloxicam 15-mg tablets [40,875.6 (11,733.47) ng*h/mL].",Pharmacokinetic properties of low-dose SoluMatrix meloxicam in healthy adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26638161/),[h·ng] / [ml],"40,875.6",136281,DB00814,Meloxicam
,26638161,time to maximum plasma me,The median time to maximum plasma meloxicam levels occurred earlier following SoluMatrix meloxicam 5 mg (2.0 h) and 10 mg (2.0 h) administration vs meloxicam 15-mg tablets (4.0 h).,Pharmacokinetic properties of low-dose SoluMatrix meloxicam in healthy adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26638161/),h,2.0,136282,DB00814,Meloxicam
,26638161,time to maximum plasma me,The median time to maximum plasma meloxicam levels occurred earlier following SoluMatrix meloxicam 5 mg (2.0 h) and 10 mg (2.0 h) administration vs meloxicam 15-mg tablets (4.0 h).,Pharmacokinetic properties of low-dose SoluMatrix meloxicam in healthy adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26638161/),h,4.0,136283,DB00814,Meloxicam
,18471146,plasma clearance,"The plasma clearance was low (0.061 L/kg/h), the volume of distribution was low (0.19 L/kg) and the elimination half-life was short (2.7 h).",Pharmacokinetics and pharmacodynamics of meloxicam in piglets. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471146/),[l] / [h·kg],0.061,138897,DB00814,Meloxicam
,18471146,volume of distribution,"The plasma clearance was low (0.061 L/kg/h), the volume of distribution was low (0.19 L/kg) and the elimination half-life was short (2.7 h).",Pharmacokinetics and pharmacodynamics of meloxicam in piglets. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471146/),[l] / [kg],0.19,138898,DB00814,Meloxicam
,18471146,elimination half-life,"The plasma clearance was low (0.061 L/kg/h), the volume of distribution was low (0.19 L/kg) and the elimination half-life was short (2.7 h).",Pharmacokinetics and pharmacodynamics of meloxicam in piglets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471146/),h,2.7,138899,DB00814,Meloxicam
,22937949,T(1/2α),Plasma meloxicam concentrations were detectable for 50 h post-administration and fit a 2-compartment model with a rapid distribution phase (mean T(1/2α) = 0.22 ± 0.087 h) and a slower elimination phase (mean T(1/2β) = 21.86 ± 3.03 h).,Pharmacokinetics and effect of intravenous meloxicam in weaned Holstein calves following scoop dehorning without local anesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22937949/),h,0.22,140198,DB00814,Meloxicam
,22937949,T(1/2β),Plasma meloxicam concentrations were detectable for 50 h post-administration and fit a 2-compartment model with a rapid distribution phase (mean T(1/2α) = 0.22 ± 0.087 h) and a slower elimination phase (mean T(1/2β) = 21.86 ± 3.03 h).,Pharmacokinetics and effect of intravenous meloxicam in weaned Holstein calves following scoop dehorning without local anesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22937949/),h,21.86,140199,DB00814,Meloxicam
,22937949,plasma SP concentrations,Mean plasma SP concentrations were lower in meloxicam treated calves (71.36 ± 20.84 pg/mL) compared with control calves (114.70 ± 20.84 pg/mL) (P = 0.038).,Pharmacokinetics and effect of intravenous meloxicam in weaned Holstein calves following scoop dehorning without local anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22937949/),[pg] / [ml],71.36,140200,DB00814,Meloxicam
,22937949,plasma SP concentrations,Mean plasma SP concentrations were lower in meloxicam treated calves (71.36 ± 20.84 pg/mL) compared with control calves (114.70 ± 20.84 pg/mL) (P = 0.038).,Pharmacokinetics and effect of intravenous meloxicam in weaned Holstein calves following scoop dehorning without local anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22937949/),[pg] / [ml],114.70,140201,DB00814,Meloxicam
,23406022,clearance (CL),"Following i.v. administration, meloxicam exhibited a rapid clearance (CL) of 0.44 ± 0.20 (SD) L/h/kg, a volume of distribution at terminal phase (Vz ) of 0.72 ± 0.22 L/kg and a volume of distribution at steady state (Vss ) of 0.22 ± 0.12 L/kg.","Pharmacokinetics of meloxicam in koalas (Phascolarctos cinereus) after intravenous, subcutaneous and oral administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23406022/),[l] / [h·kg],0.44,140689,DB00814,Meloxicam
,23406022,volume of distribution at terminal phase (Vz ),"Following i.v. administration, meloxicam exhibited a rapid clearance (CL) of 0.44 ± 0.20 (SD) L/h/kg, a volume of distribution at terminal phase (Vz ) of 0.72 ± 0.22 L/kg and a volume of distribution at steady state (Vss ) of 0.22 ± 0.12 L/kg.","Pharmacokinetics of meloxicam in koalas (Phascolarctos cinereus) after intravenous, subcutaneous and oral administration. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23406022/),[l] / [kg],0.72,140690,DB00814,Meloxicam
,23406022,volume of distribution at steady state (Vss ),"Following i.v. administration, meloxicam exhibited a rapid clearance (CL) of 0.44 ± 0.20 (SD) L/h/kg, a volume of distribution at terminal phase (Vz ) of 0.72 ± 0.22 L/kg and a volume of distribution at steady state (Vss ) of 0.22 ± 0.12 L/kg.","Pharmacokinetics of meloxicam in koalas (Phascolarctos cinereus) after intravenous, subcutaneous and oral administration. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23406022/),[l] / [kg],0.22,140691,DB00814,Meloxicam
,23406022,plasma terminal half-life (t(1/2)),Median plasma terminal half-life (t(1/2)) was 1.19 h (range 0.71-1.62 h).,"Pharmacokinetics of meloxicam in koalas (Phascolarctos cinereus) after intravenous, subcutaneous and oral administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23406022/),h,1.19,140692,DB00814,Meloxicam
,23406022,maximum peak plasma concentration (C(max),"Following oral administration either from single or repeated doses, only maximum peak plasma concentration (C(max) 0.013 ± 0.001 and 0.014 ± 0.001 μg/mL, respectively) was measurable [limit of quantitation (LOQ) >0.01 μg/mL] between 4-8 h.","Pharmacokinetics of meloxicam in koalas (Phascolarctos cinereus) after intravenous, subcutaneous and oral administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23406022/),[μg] / [ml],0.013,140693,DB00814,Meloxicam
,23406022,maximum peak plasma concentration (C(max),"Following oral administration either from single or repeated doses, only maximum peak plasma concentration (C(max) 0.013 ± 0.001 and 0.014 ± 0.001 μg/mL, respectively) was measurable [limit of quantitation (LOQ) >0.01 μg/mL] between 4-8 h.","Pharmacokinetics of meloxicam in koalas (Phascolarctos cinereus) after intravenous, subcutaneous and oral administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23406022/),[μg] / [ml],0.014,140694,DB00814,Meloxicam
,23406022,Plasma protein binding,Plasma protein binding of meloxicam was ~98%.,"Pharmacokinetics of meloxicam in koalas (Phascolarctos cinereus) after intravenous, subcutaneous and oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23406022/),%,98,140695,DB00814,Meloxicam
,24483951,Maximum plasma concentration,"Maximum plasma concentration, volume of distribution per absorption, and elimination half-life were 0.663 μg/mL, 0.21 L, and 11.4 h, respectively, for females and 0.920 μg/mL, 0.35 L, and 17.8 h, respectively, for males.",Meloxicam pharmacokinetics using nonlinear mixed-effects modeling in ferrets after single subcutaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24483951/),[μg] / [ml],0.663,142514,DB00814,Meloxicam
,24483951,volume of distribution per absorption,"Maximum plasma concentration, volume of distribution per absorption, and elimination half-life were 0.663 μg/mL, 0.21 L, and 11.4 h, respectively, for females and 0.920 μg/mL, 0.35 L, and 17.8 h, respectively, for males.",Meloxicam pharmacokinetics using nonlinear mixed-effects modeling in ferrets after single subcutaneous administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24483951/),l,0.21,142515,DB00814,Meloxicam
,24483951,volume of distribution per absorption,"Maximum plasma concentration, volume of distribution per absorption, and elimination half-life were 0.663 μg/mL, 0.21 L, and 11.4 h, respectively, for females and 0.920 μg/mL, 0.35 L, and 17.8 h, respectively, for males.",Meloxicam pharmacokinetics using nonlinear mixed-effects modeling in ferrets after single subcutaneous administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24483951/),[μg] / [ml],0.920,142516,DB00814,Meloxicam
,24483951,volume of distribution per absorption,"Maximum plasma concentration, volume of distribution per absorption, and elimination half-life were 0.663 μg/mL, 0.21 L, and 11.4 h, respectively, for females and 0.920 μg/mL, 0.35 L, and 17.8 h, respectively, for males.",Meloxicam pharmacokinetics using nonlinear mixed-effects modeling in ferrets after single subcutaneous administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24483951/),l,0.35,142517,DB00814,Meloxicam
,24483951,elimination half-life,"Maximum plasma concentration, volume of distribution per absorption, and elimination half-life were 0.663 μg/mL, 0.21 L, and 11.4 h, respectively, for females and 0.920 μg/mL, 0.35 L, and 17.8 h, respectively, for males.",Meloxicam pharmacokinetics using nonlinear mixed-effects modeling in ferrets after single subcutaneous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24483951/),h,11.4,142518,DB00814,Meloxicam
,24483951,elimination half-life,"Maximum plasma concentration, volume of distribution per absorption, and elimination half-life were 0.663 μg/mL, 0.21 L, and 11.4 h, respectively, for females and 0.920 μg/mL, 0.35 L, and 17.8 h, respectively, for males.",Meloxicam pharmacokinetics using nonlinear mixed-effects modeling in ferrets after single subcutaneous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24483951/),h,17.8,142519,DB00814,Meloxicam
,24483951,Systemic clearance per absorption,Systemic clearance per absorption was not affected by gender and was 13.4 mL/h.,Meloxicam pharmacokinetics using nonlinear mixed-effects modeling in ferrets after single subcutaneous administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24483951/),[ml] / [h],13.4,142520,DB00814,Meloxicam
,26789011,plasma peak,"After intramuscular treatment, a plasma peak of meloxicam equal to 1590.03 ± 1845.32 ng/mL (mean ± SD) and a Tmax of 1.17 ± 0.45 h were reached, indicating a quick absorption of the drug.","Pharmacokinetic profiles of meloxicam in turtles (Trachemys scripta scripta) after single oral, intracoelomic and intramuscular administrations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26789011/),[ng] / [ml],1590.03,143766,DB00814,Meloxicam
,26789011,Tmax,"After intramuscular treatment, a plasma peak of meloxicam equal to 1590.03 ± 1845.32 ng/mL (mean ± SD) and a Tmax of 1.17 ± 0.45 h were reached, indicating a quick absorption of the drug.","Pharmacokinetic profiles of meloxicam in turtles (Trachemys scripta scripta) after single oral, intracoelomic and intramuscular administrations. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26789011/),h,1.17,143767,DB00814,Meloxicam
,26789011,AUC,"The intracoelomic administration brought to the largest AUC (12621.04 ± 6203.79 h*ng/mL) and to a Cmax and a Tmax equal to 1154.52 ± 662.78 ng/mL and 2.82 ± 1.39 h, respectively.","Pharmacokinetic profiles of meloxicam in turtles (Trachemys scripta scripta) after single oral, intracoelomic and intramuscular administrations. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26789011/),[h·ng] / [ml],12621.04,143768,DB00814,Meloxicam
,26789011,Cmax,"The intracoelomic administration brought to the largest AUC (12621.04 ± 6203.79 h*ng/mL) and to a Cmax and a Tmax equal to 1154.52 ± 662.78 ng/mL and 2.82 ± 1.39 h, respectively.","Pharmacokinetic profiles of meloxicam in turtles (Trachemys scripta scripta) after single oral, intracoelomic and intramuscular administrations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26789011/),[ng] / [ml],1154.52,143769,DB00814,Meloxicam
,26789011,Tmax,"The intracoelomic administration brought to the largest AUC (12621.04 ± 6203.79 h*ng/mL) and to a Cmax and a Tmax equal to 1154.52 ± 662.78 ng/mL and 2.82 ± 1.39 h, respectively.","Pharmacokinetic profiles of meloxicam in turtles (Trachemys scripta scripta) after single oral, intracoelomic and intramuscular administrations. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26789011/),h,2.82,143770,DB00814,Meloxicam
,32878683,Plasma concentrations,"Plasma concentrations (mean ± 1 SD) of Melox-SR peaked at the 1-h time point (2180 ± 359 ng/ mL), whereas those of Melox-PO (295 ± 55 ng/mL) and Melox-SC (551 ± 112 ng/mL) peaked at the 4-h time point.","Pharmacokinetics of Sustained-release, Oral, and Subcutaneous Meloxicam over 72 Hours in Male Beagle Dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32878683/),[ng] / [ml],2180,145994,DB00814,Meloxicam
,32878683,Plasma concentrations,"Plasma concentrations (mean ± 1 SD) of Melox-SR peaked at the 1-h time point (2180 ± 359 ng/ mL), whereas those of Melox-PO (295 ± 55 ng/mL) and Melox-SC (551 ± 112 ng/mL) peaked at the 4-h time point.","Pharmacokinetics of Sustained-release, Oral, and Subcutaneous Meloxicam over 72 Hours in Male Beagle Dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32878683/),[ng] / [ml],295,145995,DB00814,Meloxicam
,32878683,Plasma concentrations,"Plasma concentrations (mean ± 1 SD) of Melox-SR peaked at the 1-h time point (2180 ± 359 ng/ mL), whereas those of Melox-PO (295 ± 55 ng/mL) and Melox-SC (551 ± 112 ng/mL) peaked at the 4-h time point.","Pharmacokinetics of Sustained-release, Oral, and Subcutaneous Meloxicam over 72 Hours in Male Beagle Dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32878683/),[ng] / [ml],551,145996,DB00814,Meloxicam
,15286090,C(max),"Geometric mean (percent coefficient of variation for geometric mean [gCV]) C(max), AUC(0- infinity ), apparent clearance, apparent volume of distribution, and elimination half-life values were 1.24 microg/mL (47% gCV), 25.6 microg x h/mL (81% gCV), 0.17 mL/min/kg (83% gCV), 0.19 L/kg (63% gCV), and 13.4 hours (54% gCV) in the younger group and 1.89 microg/mL (25% gCV), 35.8 microg x h/mL (21% gCV), 0.12 mL/min/kg (23% gCV), 0.13 L/kg (22% gCV), and 12.7 hours (21% gCV) for the older group, respectively.",Pharmacokinetics of meloxicam in patients with juvenile rheumatoid arthritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286090/),[μg] / [ml],1.24,146395,DB00814,Meloxicam
,15286090,elimination half-life,"Geometric mean (percent coefficient of variation for geometric mean [gCV]) C(max), AUC(0- infinity ), apparent clearance, apparent volume of distribution, and elimination half-life values were 1.24 microg/mL (47% gCV), 25.6 microg x h/mL (81% gCV), 0.17 mL/min/kg (83% gCV), 0.19 L/kg (63% gCV), and 13.4 hours (54% gCV) in the younger group and 1.89 microg/mL (25% gCV), 35.8 microg x h/mL (21% gCV), 0.12 mL/min/kg (23% gCV), 0.13 L/kg (22% gCV), and 12.7 hours (21% gCV) for the older group, respectively.",Pharmacokinetics of meloxicam in patients with juvenile rheumatoid arthritis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286090/),h,13.4,146396,DB00814,Meloxicam
,8591720,terminal,"Its terminal and dominant half-life of elimination from plasma, as determined from plasma and urinary data in this study, ranged from 12 to 17 hr in the volunteers.",Pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8591720/),h,12 to 17,147298,DB00814,Meloxicam
,8591720,dominant half-life of elimination,"Its terminal and dominant half-life of elimination from plasma, as determined from plasma and urinary data in this study, ranged from 12 to 17 hr in the volunteers.",Pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8591720/),h,12 to 17,147299,DB00814,Meloxicam
,8591720,serum protein binding,The serum protein binding of the radioactivity from in vivo samples was very high (99.1-99.7%).,Pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8591720/),%,99.1-99.7,147300,DB00814,Meloxicam
,20063804,area under the curve,"After oral administration, mean +/- standard deviation values for area under the curve were 1.8 +/- 0.50 and 2.1 +/- 0.55 microg x h/ml, and maximum plasma concentrations were 0.17 +/- 0.06 and 0.24 +/- 0.07 microg/ml for Day 1 and Day 10, respectively.",Single and multiple-dose pharmacokinetics of meloxicam after oral administration to the rabbit (Oryctolagus cuniculus). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20063804/),[h·μg] / [ml],1.8,147454,DB00814,Meloxicam
,20063804,area under the curve,"After oral administration, mean +/- standard deviation values for area under the curve were 1.8 +/- 0.50 and 2.1 +/- 0.55 microg x h/ml, and maximum plasma concentrations were 0.17 +/- 0.06 and 0.24 +/- 0.07 microg/ml for Day 1 and Day 10, respectively.",Single and multiple-dose pharmacokinetics of meloxicam after oral administration to the rabbit (Oryctolagus cuniculus). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20063804/),[h·μg] / [ml],2.1,147455,DB00814,Meloxicam
,20063804,maximum plasma concentrations,"After oral administration, mean +/- standard deviation values for area under the curve were 1.8 +/- 0.50 and 2.1 +/- 0.55 microg x h/ml, and maximum plasma concentrations were 0.17 +/- 0.06 and 0.24 +/- 0.07 microg/ml for Day 1 and Day 10, respectively.",Single and multiple-dose pharmacokinetics of meloxicam after oral administration to the rabbit (Oryctolagus cuniculus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20063804/),[μg] / [ml],0.17,147456,DB00814,Meloxicam
,20063804,maximum plasma concentrations,"After oral administration, mean +/- standard deviation values for area under the curve were 1.8 +/- 0.50 and 2.1 +/- 0.55 microg x h/ml, and maximum plasma concentrations were 0.17 +/- 0.06 and 0.24 +/- 0.07 microg/ml for Day 1 and Day 10, respectively.",Single and multiple-dose pharmacokinetics of meloxicam after oral administration to the rabbit (Oryctolagus cuniculus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20063804/),[μg] / [ml],0.24,147457,DB00814,Meloxicam
,20063804,half-life,The half-life was approximately 8 hr.,Single and multiple-dose pharmacokinetics of meloxicam after oral administration to the rabbit (Oryctolagus cuniculus). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20063804/),h,8,147458,DB00814,Meloxicam
,27111010,distribution half-life,"RESULTS For IV administration, mean ± SD values of major pharmacokinetic variables were 1.02 ± 0.41 hours for distribution half-life, 9.78 ± 2.23 hours for elimination half-life, 215 ± 32 mL/kg for volume of distribution at steady state, 11.27 ± 1.44 μg•h/mL for area under the plasma concentration versus time curve, and 18.00 ± 2.32 mL/h/kg for total body clearance.",Pharmacokinetics of meloxicam in red-eared slider turtles (Trachemys scripta elegans) after single intravenous and intramuscular injections. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27111010/),h,1.02,147506,DB00814,Meloxicam
,27111010,elimination half-life,"RESULTS For IV administration, mean ± SD values of major pharmacokinetic variables were 1.02 ± 0.41 hours for distribution half-life, 9.78 ± 2.23 hours for elimination half-life, 215 ± 32 mL/kg for volume of distribution at steady state, 11.27 ± 1.44 μg•h/mL for area under the plasma concentration versus time curve, and 18.00 ± 2.32 mL/h/kg for total body clearance.",Pharmacokinetics of meloxicam in red-eared slider turtles (Trachemys scripta elegans) after single intravenous and intramuscular injections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27111010/),h,9.78,147507,DB00814,Meloxicam
,27111010,volume of distribution at steady state,"RESULTS For IV administration, mean ± SD values of major pharmacokinetic variables were 1.02 ± 0.41 hours for distribution half-life, 9.78 ± 2.23 hours for elimination half-life, 215 ± 32 mL/kg for volume of distribution at steady state, 11.27 ± 1.44 μg•h/mL for area under the plasma concentration versus time curve, and 18.00 ± 2.32 mL/h/kg for total body clearance.",Pharmacokinetics of meloxicam in red-eared slider turtles (Trachemys scripta elegans) after single intravenous and intramuscular injections. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27111010/),[ml] / [kg],215,147508,DB00814,Meloxicam
,27111010,area under the plasma concentration versus time curve,"RESULTS For IV administration, mean ± SD values of major pharmacokinetic variables were 1.02 ± 0.41 hours for distribution half-life, 9.78 ± 2.23 hours for elimination half-life, 215 ± 32 mL/kg for volume of distribution at steady state, 11.27 ± 1.44 μg•h/mL for area under the plasma concentration versus time curve, and 18.00 ± 2.32 mL/h/kg for total body clearance.",Pharmacokinetics of meloxicam in red-eared slider turtles (Trachemys scripta elegans) after single intravenous and intramuscular injections. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27111010/),[h·μg] / [ml],11.27,147509,DB00814,Meloxicam
,27111010,total body clearance,"RESULTS For IV administration, mean ± SD values of major pharmacokinetic variables were 1.02 ± 0.41 hours for distribution half-life, 9.78 ± 2.23 hours for elimination half-life, 215 ± 32 mL/kg for volume of distribution at steady state, 11.27 ± 1.44 μg•h/mL for area under the plasma concentration versus time curve, and 18.00 ± 2.32 mL/h/kg for total body clearance.",Pharmacokinetics of meloxicam in red-eared slider turtles (Trachemys scripta elegans) after single intravenous and intramuscular injections. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27111010/),[ml] / [h·kg],18.00,147510,DB00814,Meloxicam
,27111010,absorption half-life,"For IM administration, mean values were 0.35 ± 0.06 hours for absorption half-life, 0.72 ± 0.06 μg/mL for peak plasma concentration, 1.5 ± 0.0 hours for time to peak concentration, 3.73 ± 2.41 hours for distribution half-life, 13.53 ± 1.95 hours for elimination half-life, 11.33 ± 0.92 μg•h/mL for area under the plasma concentration versus time curve, and 101 ± 6% for bioavailability.",Pharmacokinetics of meloxicam in red-eared slider turtles (Trachemys scripta elegans) after single intravenous and intramuscular injections. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27111010/),h,0.35,147511,DB00814,Meloxicam
,27111010,peak plasma concentration,"For IM administration, mean values were 0.35 ± 0.06 hours for absorption half-life, 0.72 ± 0.06 μg/mL for peak plasma concentration, 1.5 ± 0.0 hours for time to peak concentration, 3.73 ± 2.41 hours for distribution half-life, 13.53 ± 1.95 hours for elimination half-life, 11.33 ± 0.92 μg•h/mL for area under the plasma concentration versus time curve, and 101 ± 6% for bioavailability.",Pharmacokinetics of meloxicam in red-eared slider turtles (Trachemys scripta elegans) after single intravenous and intramuscular injections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27111010/),[μg] / [ml],0.72,147512,DB00814,Meloxicam
,27111010,time to peak concentration,"For IM administration, mean values were 0.35 ± 0.06 hours for absorption half-life, 0.72 ± 0.06 μg/mL for peak plasma concentration, 1.5 ± 0.0 hours for time to peak concentration, 3.73 ± 2.41 hours for distribution half-life, 13.53 ± 1.95 hours for elimination half-life, 11.33 ± 0.92 μg•h/mL for area under the plasma concentration versus time curve, and 101 ± 6% for bioavailability.",Pharmacokinetics of meloxicam in red-eared slider turtles (Trachemys scripta elegans) after single intravenous and intramuscular injections. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27111010/),h,1.5,147513,DB00814,Meloxicam
,27111010,distribution half-life,"For IM administration, mean values were 0.35 ± 0.06 hours for absorption half-life, 0.72 ± 0.06 μg/mL for peak plasma concentration, 1.5 ± 0.0 hours for time to peak concentration, 3.73 ± 2.41 hours for distribution half-life, 13.53 ± 1.95 hours for elimination half-life, 11.33 ± 0.92 μg•h/mL for area under the plasma concentration versus time curve, and 101 ± 6% for bioavailability.",Pharmacokinetics of meloxicam in red-eared slider turtles (Trachemys scripta elegans) after single intravenous and intramuscular injections. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27111010/),h,3.73,147514,DB00814,Meloxicam
,27111010,elimination half-life,"For IM administration, mean values were 0.35 ± 0.06 hours for absorption half-life, 0.72 ± 0.06 μg/mL for peak plasma concentration, 1.5 ± 0.0 hours for time to peak concentration, 3.73 ± 2.41 hours for distribution half-life, 13.53 ± 1.95 hours for elimination half-life, 11.33 ± 0.92 μg•h/mL for area under the plasma concentration versus time curve, and 101 ± 6% for bioavailability.",Pharmacokinetics of meloxicam in red-eared slider turtles (Trachemys scripta elegans) after single intravenous and intramuscular injections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27111010/),h,13.53,147515,DB00814,Meloxicam
,27111010,area under the plasma concentration versus time curve,"For IM administration, mean values were 0.35 ± 0.06 hours for absorption half-life, 0.72 ± 0.06 μg/mL for peak plasma concentration, 1.5 ± 0.0 hours for time to peak concentration, 3.73 ± 2.41 hours for distribution half-life, 13.53 ± 1.95 hours for elimination half-life, 11.33 ± 0.92 μg•h/mL for area under the plasma concentration versus time curve, and 101 ± 6% for bioavailability.",Pharmacokinetics of meloxicam in red-eared slider turtles (Trachemys scripta elegans) after single intravenous and intramuscular injections. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27111010/),[h·μg] / [ml],11.33,147516,DB00814,Meloxicam
,27111010,bioavailability,"For IM administration, mean values were 0.35 ± 0.06 hours for absorption half-life, 0.72 ± 0.06 μg/mL for peak plasma concentration, 1.5 ± 0.0 hours for time to peak concentration, 3.73 ± 2.41 hours for distribution half-life, 13.53 ± 1.95 hours for elimination half-life, 11.33 ± 0.92 μg•h/mL for area under the plasma concentration versus time curve, and 101 ± 6% for bioavailability.",Pharmacokinetics of meloxicam in red-eared slider turtles (Trachemys scripta elegans) after single intravenous and intramuscular injections. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27111010/),%,101,147517,DB00814,Meloxicam
,33846990,Vdarea /F,"The Vdarea /F of MLX, CRP, and TA after IM administration was 0.28, 2.05, and 0.20 L/kg.","Pharmacokinetics of meloxicam, carprofen, and tolfenamic acid after intramuscular and oral administration in Japanese quails (Coturnix coturnix japonica). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33846990/),[l] / [kg],0.28,150315,DB00814,Meloxicam
,33846990,Vdarea /F,"The Vdarea /F of MLX, CRP, and TA after IM administration was 0.28, 2.05, and 0.20 L/kg.","Pharmacokinetics of meloxicam, carprofen, and tolfenamic acid after intramuscular and oral administration in Japanese quails (Coturnix coturnix japonica). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33846990/),[l] / [kg],2.05,150316,DB00814,Meloxicam
,33846990,Vdarea /F,"The Vdarea /F of MLX, CRP, and TA after IM administration was 0.28, 2.05, and 0.20 L/kg.","Pharmacokinetics of meloxicam, carprofen, and tolfenamic acid after intramuscular and oral administration in Japanese quails (Coturnix coturnix japonica). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33846990/),[l] / [kg],0.20,150317,DB00814,Meloxicam
,33846990,Cl/F,"The Cl/F of MLX, CRP, and TA after IM administration was 0.12, 0.19, and 0.09 L/h/kg.","Pharmacokinetics of meloxicam, carprofen, and tolfenamic acid after intramuscular and oral administration in Japanese quails (Coturnix coturnix japonica). ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33846990/),[l] / [h·kg],0.12,150318,DB00814,Meloxicam
,33846990,Cl/F,"The Cl/F of MLX, CRP, and TA after IM administration was 0.12, 0.19, and 0.09 L/h/kg.","Pharmacokinetics of meloxicam, carprofen, and tolfenamic acid after intramuscular and oral administration in Japanese quails (Coturnix coturnix japonica). ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33846990/),[l] / [h·kg],0.19,150319,DB00814,Meloxicam
,33846990,Cl/F,"The Cl/F of MLX, CRP, and TA after IM administration was 0.12, 0.19, and 0.09 L/h/kg.","Pharmacokinetics of meloxicam, carprofen, and tolfenamic acid after intramuscular and oral administration in Japanese quails (Coturnix coturnix japonica). ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33846990/),[l] / [h·kg],0.09,150320,DB00814,Meloxicam
,33846990,relative bioavailability,"The relative bioavailability of MLX, CRP, and TA following oral administration in quails was 76.13%, 61.46%, and 57.32%, respectively.","Pharmacokinetics of meloxicam, carprofen, and tolfenamic acid after intramuscular and oral administration in Japanese quails (Coturnix coturnix japonica). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33846990/),%,76.13,150321,DB00814,Meloxicam
,33846990,relative bioavailability,"The relative bioavailability of MLX, CRP, and TA following oral administration in quails was 76.13%, 61.46%, and 57.32%, respectively.","Pharmacokinetics of meloxicam, carprofen, and tolfenamic acid after intramuscular and oral administration in Japanese quails (Coturnix coturnix japonica). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33846990/),%,61.46,150322,DB00814,Meloxicam
,33846990,relative bioavailability,"The relative bioavailability of MLX, CRP, and TA following oral administration in quails was 76.13%, 61.46%, and 57.32%, respectively.","Pharmacokinetics of meloxicam, carprofen, and tolfenamic acid after intramuscular and oral administration in Japanese quails (Coturnix coturnix japonica). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33846990/),%,57.32,150323,DB00814,Meloxicam
,29256371,Cmax,"Pediatric rats received 1.34 mg/kg SC meloxicam, and in all age groups, Cmax met or exceeded that in adults (11.5 ±2.7 μg/mL).",Plasma Concentration of Meloxicam in Pediatric Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29256371/),[μg] / [ml],11.5,152744,DB00814,Meloxicam
,17921074,flow rate of mobile phase,"The flow rate of mobile phase was 1.2 ml/min and the retention time of meloxicam and internal standard, piroxicam, was found to be 11.6 and 6.3 min, respectively.",Determination of meloxicam in human plasma using a HPLC method with UV detection and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17921074/),[ml] / [min],1.2,153005,DB00814,Meloxicam
,17921074,retention time,"The flow rate of mobile phase was 1.2 ml/min and the retention time of meloxicam and internal standard, piroxicam, was found to be 11.6 and 6.3 min, respectively.",Determination of meloxicam in human plasma using a HPLC method with UV detection and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17921074/),min,11.6,153006,DB00814,Meloxicam
,17921074,retention time,"The flow rate of mobile phase was 1.2 ml/min and the retention time of meloxicam and internal standard, piroxicam, was found to be 11.6 and 6.3 min, respectively.",Determination of meloxicam in human plasma using a HPLC method with UV detection and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17921074/),min,6.3,153007,DB00814,Meloxicam
,17921074,AUCinf,"The AUCinf, Cmax, tmax and t1/2 were 42.4+/-13.2 microg h/ml, 1445.7+/-305.5 ng/ml, 4.1+/-0.3h and 22.0+/-4.9h, respectively.",Determination of meloxicam in human plasma using a HPLC method with UV detection and its application to a pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17921074/),[h·μg] / [ml],42.4,153008,DB00814,Meloxicam
,17921074,Cmax,"The AUCinf, Cmax, tmax and t1/2 were 42.4+/-13.2 microg h/ml, 1445.7+/-305.5 ng/ml, 4.1+/-0.3h and 22.0+/-4.9h, respectively.",Determination of meloxicam in human plasma using a HPLC method with UV detection and its application to a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17921074/),[ng] / [ml],1445.7,153009,DB00814,Meloxicam
,17921074,Cmax,"The AUCinf, Cmax, tmax and t1/2 were 42.4+/-13.2 microg h/ml, 1445.7+/-305.5 ng/ml, 4.1+/-0.3h and 22.0+/-4.9h, respectively.",Determination of meloxicam in human plasma using a HPLC method with UV detection and its application to a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17921074/),h,4.1,153010,DB00814,Meloxicam
,17921074,tmax,"The AUCinf, Cmax, tmax and t1/2 were 42.4+/-13.2 microg h/ml, 1445.7+/-305.5 ng/ml, 4.1+/-0.3h and 22.0+/-4.9h, respectively.",Determination of meloxicam in human plasma using a HPLC method with UV detection and its application to a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17921074/),[ng] / [ml],1445.7,153011,DB00814,Meloxicam
,17921074,tmax,"The AUCinf, Cmax, tmax and t1/2 were 42.4+/-13.2 microg h/ml, 1445.7+/-305.5 ng/ml, 4.1+/-0.3h and 22.0+/-4.9h, respectively.",Determination of meloxicam in human plasma using a HPLC method with UV detection and its application to a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17921074/),h,4.1,153012,DB00814,Meloxicam
,17921074,t1/2,"The AUCinf, Cmax, tmax and t1/2 were 42.4+/-13.2 microg h/ml, 1445.7+/-305.5 ng/ml, 4.1+/-0.3h and 22.0+/-4.9h, respectively.",Determination of meloxicam in human plasma using a HPLC method with UV detection and its application to a pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17921074/),h,22.0,153013,DB00814,Meloxicam
,20004922,IC(50,"The rank order of selectivity for inhibition of COX-2 versus COX-1 (IC(50) COX-1:IC(50) COX-2) for veterinary drugs was highest with robenacoxib (128.8) compared to deracoxib (48.5), nimesulide (29.2), S+ carprofen (17.6), meloxicam (7.3), etodolac (6.6), R- carprofen (5.8) and ketoprofen (0.88).",In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004922/),,128.8,153272,DB00814,Meloxicam
,20004922,IC(50,"The rank order of selectivity for inhibition of COX-2 versus COX-1 (IC(50) COX-1:IC(50) COX-2) for veterinary drugs was highest with robenacoxib (128.8) compared to deracoxib (48.5), nimesulide (29.2), S+ carprofen (17.6), meloxicam (7.3), etodolac (6.6), R- carprofen (5.8) and ketoprofen (0.88).",In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004922/),,48.5,153273,DB00814,Meloxicam
,20004922,IC(50,"The rank order of selectivity for inhibition of COX-2 versus COX-1 (IC(50) COX-1:IC(50) COX-2) for veterinary drugs was highest with robenacoxib (128.8) compared to deracoxib (48.5), nimesulide (29.2), S+ carprofen (17.6), meloxicam (7.3), etodolac (6.6), R- carprofen (5.8) and ketoprofen (0.88).",In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004922/),,29.2,153274,DB00814,Meloxicam
,20004922,IC(50,"The rank order of selectivity for inhibition of COX-2 versus COX-1 (IC(50) COX-1:IC(50) COX-2) for veterinary drugs was highest with robenacoxib (128.8) compared to deracoxib (48.5), nimesulide (29.2), S+ carprofen (17.6), meloxicam (7.3), etodolac (6.6), R- carprofen (5.8) and ketoprofen (0.88).",In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004922/),,17.,153275,DB00814,Meloxicam
,20004922,IC(50,"The rank order of selectivity for inhibition of COX-2 versus COX-1 (IC(50) COX-1:IC(50) COX-2) for veterinary drugs was highest with robenacoxib (128.8) compared to deracoxib (48.5), nimesulide (29.2), S+ carprofen (17.6), meloxicam (7.3), etodolac (6.6), R- carprofen (5.8) and ketoprofen (0.88).",In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004922/),,7,153276,DB00814,Meloxicam
,29077759,distribution half-life,"The pharmacokinetic profile was best fitted by a two-compartmental model and characterized by a fast distribution half-life and slow elimination half-life (0.09 ± 0.06 h and 21.51 ± 6.4 h, respectively) and meloxicam mean concentrations at 96 h was of 0.18 ± 0.14 μg/mL.",Clinical efficacy and pharmacokinetics of meloxicam in Mediterranean buffalo calves (Bubalus bubalis). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29077759/),h,0.09,158840,DB00814,Meloxicam
,29077759,elimination half-life,"The pharmacokinetic profile was best fitted by a two-compartmental model and characterized by a fast distribution half-life and slow elimination half-life (0.09 ± 0.06 h and 21.51 ± 6.4 h, respectively) and meloxicam mean concentrations at 96 h was of 0.18 ± 0.14 μg/mL.",Clinical efficacy and pharmacokinetics of meloxicam in Mediterranean buffalo calves (Bubalus bubalis). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29077759/),h,21.51,158841,DB00814,Meloxicam
,29077759,mean concentrations,"The pharmacokinetic profile was best fitted by a two-compartmental model and characterized by a fast distribution half-life and slow elimination half-life (0.09 ± 0.06 h and 21.51 ± 6.4 h, respectively) and meloxicam mean concentrations at 96 h was of 0.18 ± 0.14 μg/mL.",Clinical efficacy and pharmacokinetics of meloxicam in Mediterranean buffalo calves (Bubalus bubalis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29077759/),[μg] / [ml],0.18,158842,DB00814,Meloxicam
,29077759,Vdss,"The volume of distribution and clearance values were quite low, but reasonably homogenous among individuals (Vdss 142.31 ± 55.08 mL/kg and ClB 4.38 ± 0.95 mL/kg/h, respectively).",Clinical efficacy and pharmacokinetics of meloxicam in Mediterranean buffalo calves (Bubalus bubalis). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29077759/),[ml] / [kg],142.31,158843,DB00814,Meloxicam
,29077759,ClB,"The volume of distribution and clearance values were quite low, but reasonably homogenous among individuals (Vdss 142.31 ± 55.08 mL/kg and ClB 4.38 ± 0.95 mL/kg/h, respectively).",Clinical efficacy and pharmacokinetics of meloxicam in Mediterranean buffalo calves (Bubalus bubalis). ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29077759/),[ml] / [h·kg],4.38,158844,DB00814,Meloxicam
,22533512,elimination half-lives,Mean elimination half-lives were 29.6 h (test article) and 30.0 h (reference article).,Bioequivalence in dogs of a meloxicam formulation administered as a transmucosal oral mist with an orally administered pioneer suspension product. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22533512/),h,29.6,163079,DB00814,Meloxicam
,22533512,elimination half-lives,Mean elimination half-lives were 29.6 h (test article) and 30.0 h (reference article).,Bioequivalence in dogs of a meloxicam formulation administered as a transmucosal oral mist with an orally administered pioneer suspension product. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22533512/),h,30.0,163080,DB00814,Meloxicam
,30154656,polydispersity index,"The results obtained showed that the prepared nanosuspensions had a narrow size distribution with a mean particle size of 78.67±0.22 nm, a polydispersity index of 0.133±0.01, and a zeta potential of -11.87±0.91 mV.",A novel albumin wrapped nanosuspension of meloxicam to improve inflammation-targeting effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30154656/),,0.133,165416,DB00814,Meloxicam
,30154656,zeta potential,"The results obtained showed that the prepared nanosuspensions had a narrow size distribution with a mean particle size of 78.67±0.22 nm, a polydispersity index of 0.133±0.01, and a zeta potential of -11.87±0.91 mV.",A novel albumin wrapped nanosuspension of meloxicam to improve inflammation-targeting effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30154656/),mv,-,165417,DB00814,Meloxicam
,30154656,zeta potential,"The results obtained showed that the prepared nanosuspensions had a narrow size distribution with a mean particle size of 78.67±0.22 nm, a polydispersity index of 0.133±0.01, and a zeta potential of -11.87±0.91 mV.",A novel albumin wrapped nanosuspension of meloxicam to improve inflammation-targeting effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30154656/),mv,11.87,165418,DB00814,Meloxicam
,9049585,Pro,"Prothrombin times, expressed as mean INR values, were not significantly altered by concomitant meloxicam treatment, being 1.20 for warfarin alone and 1.27 for warfarin with meloxicam cotreatment.",Lack of interaction between meloxicam and warfarin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049585/),,1.20,168081,DB00814,Meloxicam
,9049585,Pro,"Prothrombin times, expressed as mean INR values, were not significantly altered by concomitant meloxicam treatment, being 1.20 for warfarin alone and 1.27 for warfarin with meloxicam cotreatment.",Lack of interaction between meloxicam and warfarin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049585/),,1.27,168082,DB00814,Meloxicam
,9049585,AUCss,Geometric mean (% gCV) AUCss values for the more potent S-enantiomer were 5.07 mg.h.l-1 (27.5%) for warfarin alone and 5.64 mg.h.l-1 (28.1%) during the interaction phase.,Lack of interaction between meloxicam and warfarin in healthy volunteers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049585/),[h·mg] / [l],5.07,168083,DB00814,Meloxicam
,9049585,AUCss,Geometric mean (% gCV) AUCss values for the more potent S-enantiomer were 5.07 mg.h.l-1 (27.5%) for warfarin alone and 5.64 mg.h.l-1 (28.1%) during the interaction phase.,Lack of interaction between meloxicam and warfarin in healthy volunteers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049585/),[h·mg] / [l],5.64,168084,DB00814,Meloxicam
,9049585,AUCss,Respective AUCss values for R-warfarin were 7.31 mg.h.l-1 (43.8%) and 7.58 mg.h.l-1 (39.1%).,Lack of interaction between meloxicam and warfarin in healthy volunteers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049585/),[h·mg] / [l],7.31,168085,DB00814,Meloxicam
,9049585,AUCss,Respective AUCss values for R-warfarin were 7.31 mg.h.l-1 (43.8%) and 7.58 mg.h.l-1 (39.1%).,Lack of interaction between meloxicam and warfarin in healthy volunteers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049585/),[h·mg] / [l],7.58,168086,DB00814,Meloxicam
,18193109,half-life,"Then, concentrations decayed with a half-life of 9 h.",Oral pharmacokinetics of meloxicam in the rat using a high-performance liquid chromatography method in micro-whole-blood samples. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193109/),h,9,170739,DB00814,Meloxicam
,23425143,elimination half-life,"However, drug clearance was much more rapid in foals (elimination half-life 2.48 ± 0.25 hours).",Pharmacokinetics and safety of oral administration of meloxicam to foals. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23425143/),h,2.48,175324,DB00814,Meloxicam
,32217099,area under the plasma concentration-time curve,"After oral administration of meloxicam, the area under the plasma concentration-time curve in Abcg2-/- mice was 2-fold higher than in wild type mice (146.06 ± 10.57 µg·h/ml versus 73.80 ± 10.00 µg·h/ml).","Abcg2 transporter affects plasma, milk and tissue levels of meloxicam. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32217099/),[h·μg] / [ml],146.06,177856,DB00814,Meloxicam
,32217099,area under the plasma concentration-time curve,"After oral administration of meloxicam, the area under the plasma concentration-time curve in Abcg2-/- mice was 2-fold higher than in wild type mice (146.06 ± 10.57 µg·h/ml versus 73.80 ± 10.00 µg·h/ml).","Abcg2 transporter affects plasma, milk and tissue levels of meloxicam. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32217099/),[h·μg] / [ml],73.80,177857,DB00814,Meloxicam
,28385631,transdermal flux,The formulation showed a significant drug deposition within skin (63.37%) and an improved transdermal flux (1.60μg/cm2/h) with a 2.58 fold enhancement in permeation as compared to plain drug solution.,Statistically optimized fast dissolving microneedle transdermal patch of meloxicam: A patient friendly approach to manage arthritis. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28385631/),[μg] / [cm2·h],1.60,178067,DB00814,Meloxicam
,9010704,AUC0-infinity,Total plasma meloxicam concentrations were lower in patients with end-stage renal failure (AUC0-infinity 12.6 micrograms.h.ml-1) in comparison with healthy volunteers (AUC0-infinity 39.3 micrograms.h.ml-1).,Pharmacokinetics of meloxicam in patients with end-stage renal failure on haemodialysis: a comparison with healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010704/),[h·μg] / [ml],12.6,178178,DB00814,Meloxicam
,9010704,AUC0-infinity,Total plasma meloxicam concentrations were lower in patients with end-stage renal failure (AUC0-infinity 12.6 micrograms.h.ml-1) in comparison with healthy volunteers (AUC0-infinity 39.3 micrograms.h.ml-1).,Pharmacokinetics of meloxicam in patients with end-stage renal failure on haemodialysis: a comparison with healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010704/),[h·μg] / [ml],39.3,178179,DB00814,Meloxicam
,9010704,fraction (unbound drug),"However, there was an enhanced free meloxicam fraction (unbound drug) in the end-stage renal failure patients (0.9% vs. 0.3% in healthy volunteers).",Pharmacokinetics of meloxicam in patients with end-stage renal failure on haemodialysis: a comparison with healthy volunteers. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010704/),,0,178180,DB00814,Meloxicam
,9010704,fraction (unbound drug),"However, there was an enhanced free meloxicam fraction (unbound drug) in the end-stage renal failure patients (0.9% vs. 0.3% in healthy volunteers).",Pharmacokinetics of meloxicam in patients with end-stage renal failure on haemodialysis: a comparison with healthy volunteers. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010704/),%,0.3,178181,DB00814,Meloxicam
,9010704,free Cmax,This was observed in association with raised free Cmax (5.0 vs. 2.6 ng/ml) but similar free AUC0-infinity (0.13 vs. 0.11 microgram.h.ml-1) in both groups.,Pharmacokinetics of meloxicam in patients with end-stage renal failure on haemodialysis: a comparison with healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010704/),[ng] / [ml],5.0,178182,DB00814,Meloxicam
,9010704,free Cmax,This was observed in association with raised free Cmax (5.0 vs. 2.6 ng/ml) but similar free AUC0-infinity (0.13 vs. 0.11 microgram.h.ml-1) in both groups.,Pharmacokinetics of meloxicam in patients with end-stage renal failure on haemodialysis: a comparison with healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010704/),[ng] / [ml],2.6,178183,DB00814,Meloxicam
,9010704,free AUC0-infinity,This was observed in association with raised free Cmax (5.0 vs. 2.6 ng/ml) but similar free AUC0-infinity (0.13 vs. 0.11 microgram.h.ml-1) in both groups.,Pharmacokinetics of meloxicam in patients with end-stage renal failure on haemodialysis: a comparison with healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010704/),[h·μg] / [ml],0.13,178184,DB00814,Meloxicam
,9010704,free AUC0-infinity,This was observed in association with raised free Cmax (5.0 vs. 2.6 ng/ml) but similar free AUC0-infinity (0.13 vs. 0.11 microgram.h.ml-1) in both groups.,Pharmacokinetics of meloxicam in patients with end-stage renal failure on haemodialysis: a comparison with healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010704/),[h·μg] / [ml],0.11,178185,DB00814,Meloxicam
,28315645,mean plasma concentration,The highest mean plasma concentration for buprenorphine SR occurred at the 24-h time point (0.0098 μg/mL) in the low-dose group and at the 8-h time point (0.015 μg/mL) for the high-dose group.,Pharmacokinetic Profiles of Meloxicam and Sustained-release Buprenorphine in Prairie Dogs (Cynomys ludovicianus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28315645/),,0,181415,DB00814,Meloxicam
,32938437,renal clearance,"The renal clearance of flunixin and meloxicam was 4.72 ± 2.98 mL/h/kg and 0.16 ± 0.04 mL/h/kg, respectively.","Plasma, urine and tissue concentrations of Flunixin and Meloxicam in Pigs. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32938437/),[ml] / [h·kg],4.72,182454,DB00814,Meloxicam
,32938437,renal clearance,"The renal clearance of flunixin and meloxicam was 4.72 ± 2.98 mL/h/kg and 0.16 ± 0.04 mL/h/kg, respectively.","Plasma, urine and tissue concentrations of Flunixin and Meloxicam in Pigs. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32938437/),[ml] / [h·kg],0.16,182455,DB00814,Meloxicam
,32938437,apparent elimination half-life,"Mean apparent elimination half-life in plasma was 5.00 ± 1.89 h and 3.22 ± 1.52 h for flunixin and meloxicam, respectively.","Plasma, urine and tissue concentrations of Flunixin and Meloxicam in Pigs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32938437/),h,5.00,182456,DB00814,Meloxicam
,32938437,apparent elimination half-life,"Mean apparent elimination half-life in plasma was 5.00 ± 1.89 h and 3.22 ± 1.52 h for flunixin and meloxicam, respectively.","Plasma, urine and tissue concentrations of Flunixin and Meloxicam in Pigs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32938437/),h,3.22,182457,DB00814,Meloxicam
,12485350,half-life,"After intravenous administration of sodium salicylate (50 mg/kg), FLU (1.1 mg/kg) and MEL (0.5 mg/kg), these drugs were eliminated from plasma with a mean half-life of 04.04, 05.45 and 03.20 h, respectively.","Disposition of sodium salicylate, flunixin and meloxicam after intravenous administration in broiler chickens. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485350/),h,04.04,186503,DB00814,Meloxicam
,12485350,half-life,"After intravenous administration of sodium salicylate (50 mg/kg), FLU (1.1 mg/kg) and MEL (0.5 mg/kg), these drugs were eliminated from plasma with a mean half-life of 04.04, 05.45 and 03.20 h, respectively.","Disposition of sodium salicylate, flunixin and meloxicam after intravenous administration in broiler chickens. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485350/),h,05.45,186504,DB00814,Meloxicam
,12485350,half-life,"After intravenous administration of sodium salicylate (50 mg/kg), FLU (1.1 mg/kg) and MEL (0.5 mg/kg), these drugs were eliminated from plasma with a mean half-life of 04.04, 05.45 and 03.20 h, respectively.","Disposition of sodium salicylate, flunixin and meloxicam after intravenous administration in broiler chickens. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485350/),h,03.20,186505,DB00814,Meloxicam
,12485350,Apparent volumes of distribution,"Apparent volumes of distribution (0.39, 0.08 and 0.12 L/kg, respectively) indicated that tissue distribution was limited for the three drugs.","Disposition of sodium salicylate, flunixin and meloxicam after intravenous administration in broiler chickens. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485350/),[l] / [kg],0.39,186506,DB00814,Meloxicam
,12485350,Apparent volumes of distribution,"Apparent volumes of distribution (0.39, 0.08 and 0.12 L/kg, respectively) indicated that tissue distribution was limited for the three drugs.","Disposition of sodium salicylate, flunixin and meloxicam after intravenous administration in broiler chickens. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485350/),[l] / [kg],0.08,186507,DB00814,Meloxicam
,12485350,Apparent volumes of distribution,"Apparent volumes of distribution (0.39, 0.08 and 0.12 L/kg, respectively) indicated that tissue distribution was limited for the three drugs.","Disposition of sodium salicylate, flunixin and meloxicam after intravenous administration in broiler chickens. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485350/),[l] / [kg],0.12,186508,DB00814,Meloxicam
,12485350,Total body clearance,"Total body clearance was 70 mL/h.kg for sodium salicylate and 10 and 25 mL/kg.h for FLU and MEL, respectively.","Disposition of sodium salicylate, flunixin and meloxicam after intravenous administration in broiler chickens. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485350/),[ml] / [h·kg],70,186509,DB00814,Meloxicam
,12485350,Total body clearance,"Total body clearance was 70 mL/h.kg for sodium salicylate and 10 and 25 mL/kg.h for FLU and MEL, respectively.","Disposition of sodium salicylate, flunixin and meloxicam after intravenous administration in broiler chickens. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485350/),[ml] / [h·kg],10,186510,DB00814,Meloxicam
,12485350,Total body clearance,"Total body clearance was 70 mL/h.kg for sodium salicylate and 10 and 25 mL/kg.h for FLU and MEL, respectively.","Disposition of sodium salicylate, flunixin and meloxicam after intravenous administration in broiler chickens. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485350/),[ml] / [h·kg],25,186511,DB00814,Meloxicam
,27691947,peak plasma concentration,The mean peak plasma concentration after i.m. injection was 1.95 μg/ml.,PHARMACOKINETIC EVALUATION OF MELOXICAM AFTER INTRAVENOUS AND INTRAMUSCULAR ADMINISTRATION IN NILE TILAPIA (OREOCHROMIS NILOTICUS). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27691947/),[μg] / [ml],1.95,194078,DB00814,Meloxicam
,27691947,terminal half-life,"The mean terminal half-life of meloxicam after i.v. and i.m. administration was 1.36 and 1.8 hr, respectively.",PHARMACOKINETIC EVALUATION OF MELOXICAM AFTER INTRAVENOUS AND INTRAMUSCULAR ADMINISTRATION IN NILE TILAPIA (OREOCHROMIS NILOTICUS). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27691947/),h,1.36,194079,DB00814,Meloxicam
,27691947,terminal half-life,"The mean terminal half-life of meloxicam after i.v. and i.m. administration was 1.36 and 1.8 hr, respectively.",PHARMACOKINETIC EVALUATION OF MELOXICAM AFTER INTRAVENOUS AND INTRAMUSCULAR ADMINISTRATION IN NILE TILAPIA (OREOCHROMIS NILOTICUS). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27691947/),h,1.8,194080,DB00814,Meloxicam
,27691947,area under the plasma concentration-versus-time curve,The area under the plasma concentration-versus-time curve extrapolated to infinity was 11.26 hr·μg/ml after i.v. administration and 5.72 hr·μg/ml after i.m. administration.,PHARMACOKINETIC EVALUATION OF MELOXICAM AFTER INTRAVENOUS AND INTRAMUSCULAR ADMINISTRATION IN NILE TILAPIA (OREOCHROMIS NILOTICUS). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27691947/),[h·μg] / [ml],11.26,194081,DB00814,Meloxicam
,27691947,area under the plasma concentration-versus-time curve,The area under the plasma concentration-versus-time curve extrapolated to infinity was 11.26 hr·μg/ml after i.v. administration and 5.72 hr·μg/ml after i.m. administration.,PHARMACOKINETIC EVALUATION OF MELOXICAM AFTER INTRAVENOUS AND INTRAMUSCULAR ADMINISTRATION IN NILE TILAPIA (OREOCHROMIS NILOTICUS). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27691947/),[h·μg] / [ml],5.72,194082,DB00814,Meloxicam
,17532668,maximum concentration (C(max)),"After administration of meloxicam, plasma levels increased to a maximum concentration (C(max)) of 0.702 +/- 0.027 (mean +/- SEM) microg/mL with a time to reach C(max) of 4.77 +/- 0.65h.",Further evidence for interethnic differences in the oral pharmacokinetics of meloxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17532668/),[μg] / [ml],0.702,195377,DB00814,Meloxicam
,17532668,time to reach C(max),"After administration of meloxicam, plasma levels increased to a maximum concentration (C(max)) of 0.702 +/- 0.027 (mean +/- SEM) microg/mL with a time to reach C(max) of 4.77 +/- 0.65h.",Further evidence for interethnic differences in the oral pharmacokinetics of meloxicam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17532668/),h,4.77,195378,DB00814,Meloxicam
,17532668,area under the plasma concentration versus time curve,The area under the plasma concentration versus time curve was 24.82 +/- 1.23 microg .,Further evidence for interethnic differences in the oral pharmacokinetics of meloxicam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17532668/),μg,24.82,195379,DB00814,Meloxicam
,17532668,clearance,The clearance was about 4.8 mL/min and the volume of distribution 9.8 +/- 0.36L.,Further evidence for interethnic differences in the oral pharmacokinetics of meloxicam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17532668/),[ml] / [min],4.8,195380,DB00814,Meloxicam
,17532668,volume of distribution,The clearance was about 4.8 mL/min and the volume of distribution 9.8 +/- 0.36L.,Further evidence for interethnic differences in the oral pharmacokinetics of meloxicam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17532668/),l,9.8,195381,DB00814,Meloxicam
,24628898,maximum plasma detomidine concentration,The maximum plasma detomidine concentration after GEL was 2.1 ± 1.2 ng mL(-1) (mean ±SD) and the time of maximum concentration was 66.0 ± 36.9 minutes.,Sublingual administration of detomidine to calves prior to disbudding: a comparison with the intravenous route. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24628898/),[ng] / [ml],2.1,195779,DB00814,Meloxicam
,24628898,time of maximum concentration,The maximum plasma detomidine concentration after GEL was 2.1 ± 1.2 ng mL(-1) (mean ±SD) and the time of maximum concentration was 66.0 ± 36.9 minutes.,Sublingual administration of detomidine to calves prior to disbudding: a comparison with the intravenous route. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24628898/),min,66.0,195780,DB00814,Meloxicam
,24628898,bioavailability,The bioavailability of detomidine was approximately 34% with GEL.,Sublingual administration of detomidine to calves prior to disbudding: a comparison with the intravenous route. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24628898/),%,34,195781,DB00814,Meloxicam
,20840388,T(max),"In an in vivo pharmacokinetic ex vivo pharmacodynamic study, after both p.o. (1-2 mg/kg) and subcutaneous (2 mg/kg) dosing, robenacoxib achieved peak blood concentrations rapidly (T(max) = 1 h for both administration routes) and was cleared from blood relatively rapidly (mean residence time was 1.70 h after p.o. and 1.79 h after subcutaneous dosing).",In vitro and ex vivo inhibition of COX isoforms by robenacoxib in the cat: a comparative study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840388/),h,1,196332,DB00814,Meloxicam
,20840388,mean residence time,"In an in vivo pharmacokinetic ex vivo pharmacodynamic study, after both p.o. (1-2 mg/kg) and subcutaneous (2 mg/kg) dosing, robenacoxib achieved peak blood concentrations rapidly (T(max) = 1 h for both administration routes) and was cleared from blood relatively rapidly (mean residence time was 1.70 h after p.o. and 1.79 h after subcutaneous dosing).",In vitro and ex vivo inhibition of COX isoforms by robenacoxib in the cat: a comparative study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840388/),h,1.70,196333,DB00814,Meloxicam
,20840388,mean residence time,"In an in vivo pharmacokinetic ex vivo pharmacodynamic study, after both p.o. (1-2 mg/kg) and subcutaneous (2 mg/kg) dosing, robenacoxib achieved peak blood concentrations rapidly (T(max) = 1 h for both administration routes) and was cleared from blood relatively rapidly (mean residence time was 1.70 h after p.o. and 1.79 h after subcutaneous dosing).",In vitro and ex vivo inhibition of COX isoforms by robenacoxib in the cat: a comparative study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840388/),h,1.79,196334,DB00814,Meloxicam
,29566073,AUC 0-t,The pharmacokinetic study exhibited prompt absorption of MLX with better AUC 0-t (6655.64 ng/ml*h vs 6538.99 ng/ml*h) and Cmax (436.98 ng/ml vs 411.33 ng/ml) from oral dispersion.,Development of Tizanidine HCl-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29566073/),[ng] / [h·ml],6655.64,196390,DB00814,Meloxicam
,29566073,AUC 0-t,The pharmacokinetic study exhibited prompt absorption of MLX with better AUC 0-t (6655.64 ng/ml*h vs 6538.99 ng/ml*h) and Cmax (436.98 ng/ml vs 411.33 ng/ml) from oral dispersion.,Development of Tizanidine HCl-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29566073/),[ng] / [h·ml],6538.99,196391,DB00814,Meloxicam
,29566073,Cmax,The pharmacokinetic study exhibited prompt absorption of MLX with better AUC 0-t (6655.64 ng/ml*h vs 6538.99 ng/ml*h) and Cmax (436.98 ng/ml vs 411.33 ng/ml) from oral dispersion.,Development of Tizanidine HCl-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29566073/),[ng] / [ml],436.98,196392,DB00814,Meloxicam
,29566073,Cmax,The pharmacokinetic study exhibited prompt absorption of MLX with better AUC 0-t (6655.64 ng/ml*h vs 6538.99 ng/ml*h) and Cmax (436.98 ng/ml vs 411.33 ng/ml) from oral dispersion.,Development of Tizanidine HCl-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29566073/),[ng] / [ml],411.33,196393,DB00814,Meloxicam
,29566073,half-life,"Similarly buccal films has shown enhanced half-life (9.91hr vs 2.51 hr), AUC 0-t (1043.4 ng/ml*h vs 149.1 ng/ml*h) and Cmax (91.92 ng/ml vs 42.29 ng/ml) from oral solution.",Development of Tizanidine HCl-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29566073/),h,9.91,196394,DB00814,Meloxicam
,29566073,half-life,"Similarly buccal films has shown enhanced half-life (9.91hr vs 2.51 hr), AUC 0-t (1043.4 ng/ml*h vs 149.1 ng/ml*h) and Cmax (91.92 ng/ml vs 42.29 ng/ml) from oral solution.",Development of Tizanidine HCl-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29566073/),h,2.51,196395,DB00814,Meloxicam
,29566073,AUC 0-t,"Similarly buccal films has shown enhanced half-life (9.91hr vs 2.51 hr), AUC 0-t (1043.4 ng/ml*h vs 149.1 ng/ml*h) and Cmax (91.92 ng/ml vs 42.29 ng/ml) from oral solution.",Development of Tizanidine HCl-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29566073/),[ng] / [h·ml],1043.4,196396,DB00814,Meloxicam
,29566073,AUC 0-t,"Similarly buccal films has shown enhanced half-life (9.91hr vs 2.51 hr), AUC 0-t (1043.4 ng/ml*h vs 149.1 ng/ml*h) and Cmax (91.92 ng/ml vs 42.29 ng/ml) from oral solution.",Development of Tizanidine HCl-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29566073/),[ng] / [h·ml],149.1,196397,DB00814,Meloxicam
,29566073,Cmax,"Similarly buccal films has shown enhanced half-life (9.91hr vs 2.51 hr), AUC 0-t (1043.4 ng/ml*h vs 149.1 ng/ml*h) and Cmax (91.92 ng/ml vs 42.29 ng/ml) from oral solution.",Development of Tizanidine HCl-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29566073/),[ng] / [ml],91.92,196398,DB00814,Meloxicam
,29566073,Cmax,"Similarly buccal films has shown enhanced half-life (9.91hr vs 2.51 hr), AUC 0-t (1043.4 ng/ml*h vs 149.1 ng/ml*h) and Cmax (91.92 ng/ml vs 42.29 ng/ml) from oral solution.",Development of Tizanidine HCl-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29566073/),[ng] / [ml],42.29,196399,DB00814,Meloxicam
,12022326,Plasma elimination half-life,Plasma elimination half-life (13 h) was similar in all patients.,High response rate in the phase I/II study of meloxicam in juvenile rheumatoid arthritis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12022326/),h,13,200512,DB00814,Meloxicam
,23746590,peak meloxicam concentrations,"Mean peak meloxicam concentrations were 3.61±0 0.21 and 3.27±0.14 μg/mL with average elimination half-lives of 38.62±5.87 and 35.81±6.26 h for MEL-PRE and MEL-POST, respectively.",The effect of timing of oral meloxicam administration on physiological responses in calves after cautery dehorning with local anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23746590/),[μg] / [ml],3.61,202278,DB00814,Meloxicam
,23746590,peak meloxicam concentrations,"Mean peak meloxicam concentrations were 3.61±0 0.21 and 3.27±0.14 μg/mL with average elimination half-lives of 38.62±5.87 and 35.81±6.26 h for MEL-PRE and MEL-POST, respectively.",The effect of timing of oral meloxicam administration on physiological responses in calves after cautery dehorning with local anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23746590/),[μg] / [ml],3.27,202279,DB00814,Meloxicam
,23746590,elimination half-lives,"Mean peak meloxicam concentrations were 3.61±0 0.21 and 3.27±0.14 μg/mL with average elimination half-lives of 38.62±5.87 and 35.81±6.26 h for MEL-PRE and MEL-POST, respectively.",The effect of timing of oral meloxicam administration on physiological responses in calves after cautery dehorning with local anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23746590/),h,38.62,202280,DB00814,Meloxicam
,23746590,elimination half-lives,"Mean peak meloxicam concentrations were 3.61±0 0.21 and 3.27±0.14 μg/mL with average elimination half-lives of 38.62±5.87 and 35.81±6.26 h for MEL-PRE and MEL-POST, respectively.",The effect of timing of oral meloxicam administration on physiological responses in calves after cautery dehorning with local anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23746590/),h,35.81,202281,DB00814,Meloxicam
,19833177,C(max),PX-patch produced a C(max) at 8 h.,A novel transdermal patch incorporating meloxicam: in vitro and in vivo characterization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19833177/),h,8,203030,DB00814,Meloxicam
>,23072611,Dissolution,Dissolution of meloxicam from the powdered SEDDS was >90% vs. <12% for powdered meloxicam and <80% for the commercial tablets.,Powdered self-emulsified lipid formulations of meloxicam as solid dosage forms for oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23072611/),%,90,205499,DB00814,Meloxicam
<,23072611,Dissolution,Dissolution of meloxicam from the powdered SEDDS was >90% vs. <12% for powdered meloxicam and <80% for the commercial tablets.,Powdered self-emulsified lipid formulations of meloxicam as solid dosage forms for oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23072611/),%,12,205500,DB00814,Meloxicam
<,23072611,Dissolution,Dissolution of meloxicam from the powdered SEDDS was >90% vs. <12% for powdered meloxicam and <80% for the commercial tablets.,Powdered self-emulsified lipid formulations of meloxicam as solid dosage forms for oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23072611/),%,80,205501,DB00814,Meloxicam
,25647596,maximum concentration [C(max)],Plasma concentrations of meloxicam were unexpectedly low both for intravenous (IV; maximum concentration [C(max)] = 0.04±0.02 µg/mL) and intramuscular (IM; C(max) = 0.07±0.09 µg/mL) administration.,Pharmacokinetic behavior of meloxicam in loggerhead sea turtles (Caretta caretta) after intramuscular and intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25647596/),[μg] / [ml],0.04,209834,DB00814,Meloxicam
,25647596,C(max),Plasma concentrations of meloxicam were unexpectedly low both for intravenous (IV; maximum concentration [C(max)] = 0.04±0.02 µg/mL) and intramuscular (IM; C(max) = 0.07±0.09 µg/mL) administration.,Pharmacokinetic behavior of meloxicam in loggerhead sea turtles (Caretta caretta) after intramuscular and intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25647596/),[μg] / [ml],0.07,209835,DB00814,Meloxicam
,25647596,time for second peak concentration T(max2),A double-peak phenomenon occurred after both IV (time for second peak concentration T(max2) = 10.33±10.89 h) and IM (T(max2) = 1.17±0.75 h).,Pharmacokinetic behavior of meloxicam in loggerhead sea turtles (Caretta caretta) after intramuscular and intravenous administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25647596/),h,10.33,209836,DB00814,Meloxicam
,25647596,T(max2),A double-peak phenomenon occurred after both IV (time for second peak concentration T(max2) = 10.33±10.89 h) and IM (T(max2) = 1.17±0.75 h).,Pharmacokinetic behavior of meloxicam in loggerhead sea turtles (Caretta caretta) after intramuscular and intravenous administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25647596/),h,1.17,209837,DB00814,Meloxicam
,25647596,area,"Furthermore, the area under the curve, and therefore systemic bioavailability (F = 31.82±28.24%), after both IV (0.30±0.29) and IM (0.10±0.03) injection appeared particularly limited.",Pharmacokinetic behavior of meloxicam in loggerhead sea turtles (Caretta caretta) after intramuscular and intravenous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25647596/),%,31.82,209838,DB00814,Meloxicam
,25647596,systemic bioavailability (F,"Furthermore, the area under the curve, and therefore systemic bioavailability (F = 31.82±28.24%), after both IV (0.30±0.29) and IM (0.10±0.03) injection appeared particularly limited.",Pharmacokinetic behavior of meloxicam in loggerhead sea turtles (Caretta caretta) after intramuscular and intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25647596/),%,31.82,209839,DB00814,Meloxicam
,28903825,peak plasma concentrations,"The peak plasma concentrations, time to peak plasma concentration, and terminal half-life of meloxicam after subcutaneous administration (median [minimum-maximum]) were 4.30 (3.00-4.89) μg/mL, 2.00 (0.62-4.00) h, and 11.88 (7.35-18.64) h, respectively.",Pharmacokinetics of Single-dose Subcutaneous Meloxicam Injections in Black-tailed Prairie Dogs (Cynomys ludovicianus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28903825/),[μg] / [ml],4.30,210205,DB00814,Meloxicam
,28903825,time to peak plasma concentration,"The peak plasma concentrations, time to peak plasma concentration, and terminal half-life of meloxicam after subcutaneous administration (median [minimum-maximum]) were 4.30 (3.00-4.89) μg/mL, 2.00 (0.62-4.00) h, and 11.88 (7.35-18.64) h, respectively.",Pharmacokinetics of Single-dose Subcutaneous Meloxicam Injections in Black-tailed Prairie Dogs (Cynomys ludovicianus). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28903825/),h,2.00,210206,DB00814,Meloxicam
,28903825,terminal half-life,"The peak plasma concentrations, time to peak plasma concentration, and terminal half-life of meloxicam after subcutaneous administration (median [minimum-maximum]) were 4.30 (3.00-4.89) μg/mL, 2.00 (0.62-4.00) h, and 11.88 (7.35-18.64) h, respectively.",Pharmacokinetics of Single-dose Subcutaneous Meloxicam Injections in Black-tailed Prairie Dogs (Cynomys ludovicianus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28903825/),h,11.88,210207,DB00814,Meloxicam
,21138335,lag time,Optimized tablet formulations demonstrated good potential to deliver the drug to the colon by successfully exhibiting a lag time of 5 h during in vitro drug release study.,Formulation and development of release modulated colon targeted system of meloxicam for potential application in the prophylaxis of colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21138335/),h,5,212169,DB00814,Meloxicam
,21138335,T(lag time),An in vivo evaluation study conducted to ascertain pharmacokinetic parameters in rabbits revealed that the onset of drug absorption from the coated tablets (T(lag time) = 4.67 ± 0.58 h) was significantly delayed compared to that from the uncoated tablets.,Formulation and development of release modulated colon targeted system of meloxicam for potential application in the prophylaxis of colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21138335/),h,4.67,212170,DB00814,Meloxicam
,21485709,C(max),The value of C(max) calculated in present study was 1.051 +/- 3.762 microg/mL for reference formulation and 1.023 +/- 4.102 microg/mL (the mean +/- SEM) for test sample.,Bioequivalence study of two brands of meloxicam tablets in healthy human Pakistani male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21485709/),[μg] / [ml],1.051,214715,DB00814,Meloxicam
,21485709,C(max),The value of C(max) calculated in present study was 1.051 +/- 3.762 microg/mL for reference formulation and 1.023 +/- 4.102 microg/mL (the mean +/- SEM) for test sample.,Bioequivalence study of two brands of meloxicam tablets in healthy human Pakistani male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21485709/),[μg] / [ml],1.023,214716,DB00814,Meloxicam
,21485709,T(max),The value of T(max) was 3.125 +/- 1.004 h for reference standard and 3.750 +/- 1.469 h (the mean +/- SEM) for test sample.,Bioequivalence study of two brands of meloxicam tablets in healthy human Pakistani male subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21485709/),h,3.125,214717,DB00814,Meloxicam
,21485709,T(max),The value of T(max) was 3.125 +/- 1.004 h for reference standard and 3.750 +/- 1.469 h (the mean +/- SEM) for test sample.,Bioequivalence study of two brands of meloxicam tablets in healthy human Pakistani male subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21485709/),h,3.750,214718,DB00814,Meloxicam
,21485709,area under the curve from zero to infinity (AUC(0-72)),The area under the curve from zero to infinity (AUC(0-72)) was 28.667 +/- 0.414 microg x h/mL for reference standard and 28.367 +/- 0.333 microg x h/mL for test sample (the mean +/- SEM).,Bioequivalence study of two brands of meloxicam tablets in healthy human Pakistani male subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21485709/),[h·μg] / [ml],28.667,214719,DB00814,Meloxicam
,21485709,area under the curve from zero to infinity (AUC(0-72)),The area under the curve from zero to infinity (AUC(0-72)) was 28.667 +/- 0.414 microg x h/mL for reference standard and 28.367 +/- 0.333 microg x h/mL for test sample (the mean +/- SEM).,Bioequivalence study of two brands of meloxicam tablets in healthy human Pakistani male subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21485709/),[h·μg] / [ml],28.367,214720,DB00814,Meloxicam
,21485709,t1/2,"The t1/2 values were 13.694 +/- 0.568 h and 13.319 +/- 0.567 h (the mean +/- SEM) for reference formulation and for test sample, respectively.",Bioequivalence study of two brands of meloxicam tablets in healthy human Pakistani male subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21485709/),h,13.694,214721,DB00814,Meloxicam
,21485709,t1/2,"The t1/2 values were 13.694 +/- 0.568 h and 13.319 +/- 0.567 h (the mean +/- SEM) for reference formulation and for test sample, respectively.",Bioequivalence study of two brands of meloxicam tablets in healthy human Pakistani male subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21485709/),h,13.319,214722,DB00814,Meloxicam
,17063980,retention time,"The retention time observed for meloxicam and tenoxicam (internal standard) was 1.8 and 1.4 minutes, respectively.",Meloxicam determination in human plasma by high-performance liquid chromatography coupled with tandem mass spectrometry (LC-MS-MS) in Brazilian bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17063980/),min,1.8,216288,DB00814,Meloxicam
,17063980,retention time,"The retention time observed for meloxicam and tenoxicam (internal standard) was 1.8 and 1.4 minutes, respectively.",Meloxicam determination in human plasma by high-performance liquid chromatography coupled with tandem mass spectrometry (LC-MS-MS) in Brazilian bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17063980/),min,1.4,216289,DB00814,Meloxicam
,17063980,recovery,The mean recovery of meloxicam was 95.9% and the limit ofquantification was 0.02 microg/ml.,Meloxicam determination in human plasma by high-performance liquid chromatography coupled with tandem mass spectrometry (LC-MS-MS) in Brazilian bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17063980/),%,95.9,216290,DB00814,Meloxicam
,10092958,plasma half-life,"Meloxicam has a plasma half-life of approximately 20 hours, making it convenient for once-daily administration.",Clinical pharmacokinetics of meloxicam. A cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10092958/),h,20,216291,DB00814,Meloxicam
,28891702,Cmax,"Plasma concentrations reached a mean Cmax of 23.4 μg/mL (range, 14.7-46.0 μg/mL) at 1.8 hours (range, 0.5-6 hours), with a terminal half-life of 7.4 hours (range, 1.4-40.9 hours).",Pharmacokinetics of a Sustained-release Formulation of Meloxicam After Subcutaneous Administration to Hispaniolan Amazon Parrots (Amazona ventralis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28891702/),[μg] / [ml],23.4,219567,DB00814,Meloxicam
,28891702,terminal half-life,"Plasma concentrations reached a mean Cmax of 23.4 μg/mL (range, 14.7-46.0 μg/mL) at 1.8 hours (range, 0.5-6 hours), with a terminal half-life of 7.4 hours (range, 1.4-40.9 hours).",Pharmacokinetics of a Sustained-release Formulation of Meloxicam After Subcutaneous Administration to Hispaniolan Amazon Parrots (Amazona ventralis). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28891702/),h,7.4,219568,DB00814,Meloxicam
,24041210,peak meloxicam,"Plasma analyzed by HPLC (meloxicam) and tandem mass spectrometry (carprofen) revealed that the peak meloxicam and carprofen concentrations were 16.7 and 20.3 μg/mL and occurred at 4 and 2 h after oral gavage, respectively.",Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041210/),[μg] / [ml],16.7,219752,DB00814,Meloxicam
,24041210,peak meloxicam,"Plasma analyzed by HPLC (meloxicam) and tandem mass spectrometry (carprofen) revealed that the peak meloxicam and carprofen concentrations were 16.7 and 20.3 μg/mL and occurred at 4 and 2 h after oral gavage, respectively.",Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041210/),[μg] / [ml],20.3,219753,DB00814,Meloxicam
,24041210,concentrations,"Plasma analyzed by HPLC (meloxicam) and tandem mass spectrometry (carprofen) revealed that the peak meloxicam and carprofen concentrations were 16.7 and 20.3 μg/mL and occurred at 4 and 2 h after oral gavage, respectively.",Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041210/),[μg] / [ml],16.7,219754,DB00814,Meloxicam
,24041210,concentrations,"Plasma analyzed by HPLC (meloxicam) and tandem mass spectrometry (carprofen) revealed that the peak meloxicam and carprofen concentrations were 16.7 and 20.3 μg/mL and occurred at 4 and 2 h after oral gavage, respectively.",Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041210/),[μg] / [ml],20.3,219755,DB00814,Meloxicam
,24041210,plasma AUC,"Meloxicam plasma AUC, elimination half-life, apparent volume of distribution, and apparent oral clearance were 160.4 mg/L × h, 7.4 h, 0.36 L/kg, and 0.125 mL/h × kg, respectively.",Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041210/),[mg] / [h·l],160.4,219756,DB00814,Meloxicam
,24041210,elimination half-life,"Meloxicam plasma AUC, elimination half-life, apparent volume of distribution, and apparent oral clearance were 160.4 mg/L × h, 7.4 h, 0.36 L/kg, and 0.125 mL/h × kg, respectively.",Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041210/),h,7.4,219757,DB00814,Meloxicam
,24041210,apparent volume of distribution,"Meloxicam plasma AUC, elimination half-life, apparent volume of distribution, and apparent oral clearance were 160.4 mg/L × h, 7.4 h, 0.36 L/kg, and 0.125 mL/h × kg, respectively.",Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041210/),h,7.4,219758,DB00814,Meloxicam
,24041210,apparent volume of distribution,"Meloxicam plasma AUC, elimination half-life, apparent volume of distribution, and apparent oral clearance were 160.4 mg/L × h, 7.4 h, 0.36 L/kg, and 0.125 mL/h × kg, respectively.",Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041210/),[l] / [kg],0.36,219759,DB00814,Meloxicam
,24041210,apparent oral clearance,"Meloxicam plasma AUC, elimination half-life, apparent volume of distribution, and apparent oral clearance were 160.4 mg/L × h, 7.4 h, 0.36 L/kg, and 0.125 mL/h × kg, respectively.",Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041210/),[ml] / [h·kg],0.125,219760,DB00814,Meloxicam
,24041210,plasma AUC,"Carprofen plasma AUC, elimination half-life, apparent volume of distribution, and apparent oral clearance were 160.8 mg/L × h, 7.4 h, 0.42 L/kg, and 0.062 mL/h × kg, respectively.",Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041210/),[mg] / [h·l],160.8,219761,DB00814,Meloxicam
,24041210,elimination half-life,"Carprofen plasma AUC, elimination half-life, apparent volume of distribution, and apparent oral clearance were 160.8 mg/L × h, 7.4 h, 0.42 L/kg, and 0.062 mL/h × kg, respectively.",Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041210/),h,7.4,219762,DB00814,Meloxicam
,24041210,apparent volume of distribution,"Carprofen plasma AUC, elimination half-life, apparent volume of distribution, and apparent oral clearance were 160.8 mg/L × h, 7.4 h, 0.42 L/kg, and 0.062 mL/h × kg, respectively.",Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041210/),h,7.4,219763,DB00814,Meloxicam
,24041210,apparent volume of distribution,"Carprofen plasma AUC, elimination half-life, apparent volume of distribution, and apparent oral clearance were 160.8 mg/L × h, 7.4 h, 0.42 L/kg, and 0.062 mL/h × kg, respectively.",Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041210/),[l] / [kg],0.42,219764,DB00814,Meloxicam
,24041210,apparent oral clearance,"Carprofen plasma AUC, elimination half-life, apparent volume of distribution, and apparent oral clearance were 160.8 mg/L × h, 7.4 h, 0.42 L/kg, and 0.062 mL/h × kg, respectively.",Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041210/),[ml] / [h·kg],0.062,219765,DB00814,Meloxicam
,27088740,maximum plasma concentration,Plasma concentrations after administration of 3 mg/kg PO meloxicam reached a mean maximum plasma concentration of 1.449 μg/mL at 2.35 hours with a terminal half-life of 1.832 hours.,Pharmacokinetics of a Single Dose of Oral and Subcutaneous Meloxicam in Caribbean Flamingos ( Phoenicopterus ruber ruber). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27088740/),[μg] / [ml],1.449,221330,DB00814,Meloxicam
,27088740,terminal half-life,Plasma concentrations after administration of 3 mg/kg PO meloxicam reached a mean maximum plasma concentration of 1.449 μg/mL at 2.35 hours with a terminal half-life of 1.832 hours.,Pharmacokinetics of a Single Dose of Oral and Subcutaneous Meloxicam in Caribbean Flamingos ( Phoenicopterus ruber ruber). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27088740/),h,1.832,221331,DB00814,Meloxicam
,27088740,maximum plasma concentration,"After administration of 1.5 mg/kg SC meloxicam, maximum plasma concentration was 4.059 μg/mL at 0.91 hour with a terminal half-life of 1.104 hours.",Pharmacokinetics of a Single Dose of Oral and Subcutaneous Meloxicam in Caribbean Flamingos ( Phoenicopterus ruber ruber). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27088740/),[μg] / [ml],4.059,221332,DB00814,Meloxicam
,27088740,terminal half-life,"After administration of 1.5 mg/kg SC meloxicam, maximum plasma concentration was 4.059 μg/mL at 0.91 hour with a terminal half-life of 1.104 hours.",Pharmacokinetics of a Single Dose of Oral and Subcutaneous Meloxicam in Caribbean Flamingos ( Phoenicopterus ruber ruber). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27088740/),h,1.104,221333,DB00814,Meloxicam
,26896943,Vdss,The volume of plasma MLX distribution at steady-state (Vdss) of the control group (Vdss: 263.0 ml/kg) was significantly greater (P < 0.05) compared to that of the surgery group (Vdss: 149.3 ml/kg).,The effect of surgery (Ovariohysterectomy) on the plasma disposition of meloxicam following intravenous administration in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896943/),[ml] / [kg],263.0,221891,DB00814,Meloxicam
,26896943,Vdss,The volume of plasma MLX distribution at steady-state (Vdss) of the control group (Vdss: 263.0 ml/kg) was significantly greater (P < 0.05) compared to that of the surgery group (Vdss: 149.3 ml/kg).,The effect of surgery (Ovariohysterectomy) on the plasma disposition of meloxicam following intravenous administration in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896943/),[ml] / [kg],149.3,221892,DB00814,Meloxicam
,26896943,AUC,The AUC values were higher (29.5 vs. 23.0 μg.,The effect of surgery (Ovariohysterectomy) on the plasma disposition of meloxicam following intravenous administration in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896943/),μg,29.5,221893,DB00814,Meloxicam
,26896943,AUC,The AUC values were higher (29.5 vs. 23.0 μg.,The effect of surgery (Ovariohysterectomy) on the plasma disposition of meloxicam following intravenous administration in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896943/),μg,23.0,221894,DB00814,Meloxicam
,26896943,CL,"h(2)/ml) and the CL values were lower (7.7 vs. 10.5 ml.h/kg) in the surgery group compared to the control group, respectively, but differences were not significant.",The effect of surgery (Ovariohysterectomy) on the plasma disposition of meloxicam following intravenous administration in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896943/),[h·ml] / [kg],7.7,221895,DB00814,Meloxicam
,26896943,CL,"h(2)/ml) and the CL values were lower (7.7 vs. 10.5 ml.h/kg) in the surgery group compared to the control group, respectively, but differences were not significant.",The effect of surgery (Ovariohysterectomy) on the plasma disposition of meloxicam following intravenous administration in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26896943/),[h·ml] / [kg],10.5,221896,DB00814,Meloxicam
,29905104,time to maximum plasma concentration (Tmax),"Meloxicam time to maximum plasma concentration (Tmax), maximum concentration (Cmax), and half-life (t1/2) after intramuscular administration were 1.00 hour, 8.03 μg/mL, and 31.87 hours, respectively, while oral administration produced a Tmax, Cmax, and t1/2 of 12.00 hours, 10.84 μg/mL, and 28.59 hours, respectively.",Pharmacokinetics of a Single Dose of Oral and Intramuscular Meloxicam in African Penguins ( Spheniscus demersus). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29905104/),h,1.00,222403,DB00814,Meloxicam
,29905104,maximum concentration (Cmax),"Meloxicam time to maximum plasma concentration (Tmax), maximum concentration (Cmax), and half-life (t1/2) after intramuscular administration were 1.00 hour, 8.03 μg/mL, and 31.87 hours, respectively, while oral administration produced a Tmax, Cmax, and t1/2 of 12.00 hours, 10.84 μg/mL, and 28.59 hours, respectively.",Pharmacokinetics of a Single Dose of Oral and Intramuscular Meloxicam in African Penguins ( Spheniscus demersus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29905104/),[μg] / [ml],8.03,222404,DB00814,Meloxicam
,29905104,half-life (t1/2),"Meloxicam time to maximum plasma concentration (Tmax), maximum concentration (Cmax), and half-life (t1/2) after intramuscular administration were 1.00 hour, 8.03 μg/mL, and 31.87 hours, respectively, while oral administration produced a Tmax, Cmax, and t1/2 of 12.00 hours, 10.84 μg/mL, and 28.59 hours, respectively.",Pharmacokinetics of a Single Dose of Oral and Intramuscular Meloxicam in African Penguins ( Spheniscus demersus). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29905104/),h,31.87,222405,DB00814,Meloxicam
,29905104,Tmax,"Meloxicam time to maximum plasma concentration (Tmax), maximum concentration (Cmax), and half-life (t1/2) after intramuscular administration were 1.00 hour, 8.03 μg/mL, and 31.87 hours, respectively, while oral administration produced a Tmax, Cmax, and t1/2 of 12.00 hours, 10.84 μg/mL, and 28.59 hours, respectively.",Pharmacokinetics of a Single Dose of Oral and Intramuscular Meloxicam in African Penguins ( Spheniscus demersus). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29905104/),h,12.00,222406,DB00814,Meloxicam
,29905104,Cmax,"Meloxicam time to maximum plasma concentration (Tmax), maximum concentration (Cmax), and half-life (t1/2) after intramuscular administration were 1.00 hour, 8.03 μg/mL, and 31.87 hours, respectively, while oral administration produced a Tmax, Cmax, and t1/2 of 12.00 hours, 10.84 μg/mL, and 28.59 hours, respectively.",Pharmacokinetics of a Single Dose of Oral and Intramuscular Meloxicam in African Penguins ( Spheniscus demersus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29905104/),[μg] / [ml],10.84,222407,DB00814,Meloxicam
,29905104,t1/2,"Meloxicam time to maximum plasma concentration (Tmax), maximum concentration (Cmax), and half-life (t1/2) after intramuscular administration were 1.00 hour, 8.03 μg/mL, and 31.87 hours, respectively, while oral administration produced a Tmax, Cmax, and t1/2 of 12.00 hours, 10.84 μg/mL, and 28.59 hours, respectively.",Pharmacokinetics of a Single Dose of Oral and Intramuscular Meloxicam in African Penguins ( Spheniscus demersus). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29905104/),h,28.59,222408,DB00814,Meloxicam
,16740106,area under the curve,"In horses and donkeys, mean +/- SD area under the curve was 18.8 +/- 7.31 microg/mL/h and 4.6 +/- 2.55 microg/mL/h, respectively; mean residence time (MRT) was 9.6 +/- 9.24 hours and 0.6 +/- 0.36 hours, respectively.",Comparative pharmacokinetics of meloxicam in clinically normal horses and donkeys. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740106/),[μg] / [h·ml],18.8,222892,DB00814,Meloxicam
,16740106,area under the curve,"In horses and donkeys, mean +/- SD area under the curve was 18.8 +/- 7.31 microg/mL/h and 4.6 +/- 2.55 microg/mL/h, respectively; mean residence time (MRT) was 9.6 +/- 9.24 hours and 0.6 +/- 0.36 hours, respectively.",Comparative pharmacokinetics of meloxicam in clinically normal horses and donkeys. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740106/),[μg] / [h·ml],4.6,222893,DB00814,Meloxicam
,16740106,mean residence time (MRT),"In horses and donkeys, mean +/- SD area under the curve was 18.8 +/- 7.31 microg/mL/h and 4.6 +/- 2.55 microg/mL/h, respectively; mean residence time (MRT) was 9.6 +/- 9.24 hours and 0.6 +/- 0.36 hours, respectively.",Comparative pharmacokinetics of meloxicam in clinically normal horses and donkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740106/),h,9.6,222894,DB00814,Meloxicam
,16740106,mean residence time (MRT),"In horses and donkeys, mean +/- SD area under the curve was 18.8 +/- 7.31 microg/mL/h and 4.6 +/- 2.55 microg/mL/h, respectively; mean residence time (MRT) was 9.6 +/- 9.24 hours and 0.6 +/- 0.36 hours, respectively.",Comparative pharmacokinetics of meloxicam in clinically normal horses and donkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740106/),h,0.6,222895,DB00814,Meloxicam
,16740106,Total body clearance (CL(T)),Total body clearance (CL(T)) was 34.7 +/- 9.21 mL/kg/h in horses and 187.9 +/- 147.26 mL/kg/h in donkeys.,Comparative pharmacokinetics of meloxicam in clinically normal horses and donkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740106/),[ml] / [h·kg],34.7,222896,DB00814,Meloxicam
,16740106,Total body clearance (CL(T)),Total body clearance (CL(T)) was 34.7 +/- 9.21 mL/kg/h in horses and 187.9 +/- 147.26 mL/kg/h in donkeys.,Comparative pharmacokinetics of meloxicam in clinically normal horses and donkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740106/),[ml] / [h·kg],187.9,222897,DB00814,Meloxicam
,16740106,Volume of distribution at steady state (VD(SS)),Volume of distribution at steady state (VD(SS)) was 270 +/- 160.5 mL/kg in horses and 93.2 +/- 33.74 mL/kg in donkeys.,Comparative pharmacokinetics of meloxicam in clinically normal horses and donkeys. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740106/),[ml] / [kg],270,222898,DB00814,Meloxicam
,16740106,Volume of distribution at steady state (VD(SS)),Volume of distribution at steady state (VD(SS)) was 270 +/- 160.5 mL/kg in horses and 93.2 +/- 33.74 mL/kg in donkeys.,Comparative pharmacokinetics of meloxicam in clinically normal horses and donkeys. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740106/),[ml] / [kg],93.2,222899,DB00814,Meloxicam
,16521861,maximal plasma concentrations,"After single oral dosing at 0.3 or 1.5 mg/kg, maximal plasma concentrations of meloxicam were achieved at 6 to 8 h and were 0.14 and 0.3 microg/ml, respectively.",Pharmacokinetics of meloxicam in rabbits after single and repeat oral dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16521861/),[μg] / [ml],0.14,224797,DB00814,Meloxicam
,16521861,maximal plasma concentrations,"After single oral dosing at 0.3 or 1.5 mg/kg, maximal plasma concentrations of meloxicam were achieved at 6 to 8 h and were 0.14 and 0.3 microg/ml, respectively.",Pharmacokinetics of meloxicam in rabbits after single and repeat oral dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16521861/),[μg] / [ml],0.3,224798,DB00814,Meloxicam
,16521861,elimination half-life,"The elimination half-life was approximately 8 h at both dose levels, suggesting that metabolism was not saturated.",Pharmacokinetics of meloxicam in rabbits after single and repeat oral dosing. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16521861/),h,8,224799,DB00814,Meloxicam
,29900779,peak plasma concentration,The peak plasma concentration of 598 ± 157.5 ng/ml occurred at 1.0 hr post dosing.,PHARMACOKINETICS OF MELOXICAM FOLLOWING A SINGLE ORAL DOSE IN MALAYAN FLYING FOXES ( PTEROPUS VAMPYRUS). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29900779/),[ng] / [ml],598,229129,DB00814,Meloxicam
,29900779,terminal half-life,"The terminal half-life was 1.1 ± 0.1 hr, which indicates that meloxicam is rapidly metabolized in this species.",PHARMACOKINETICS OF MELOXICAM FOLLOWING A SINGLE ORAL DOSE IN MALAYAN FLYING FOXES ( PTEROPUS VAMPYRUS). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29900779/),h,1.1,229130,DB00814,Meloxicam
,32615818,rate of absorption (T max),"MLX rate of absorption (T max) from EXT-SD, FUS-SD, and Mobic® was 1.5, 3.0, and 4.0 h, respectively.",A novel combination of Soluplus®/Poloxamer for Meloxicam solid dispersions via hot melt extrusion for rapid onset of action. Part 2: comparative bioavailability and IVIVC. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32615818/),h,1.5,230973,DB00814,Meloxicam
,32615818,rate of absorption (T max),"MLX rate of absorption (T max) from EXT-SD, FUS-SD, and Mobic® was 1.5, 3.0, and 4.0 h, respectively.",A novel combination of Soluplus®/Poloxamer for Meloxicam solid dispersions via hot melt extrusion for rapid onset of action. Part 2: comparative bioavailability and IVIVC. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32615818/),h,3.0,230974,DB00814,Meloxicam
,32615818,rate of absorption (T max),"MLX rate of absorption (T max) from EXT-SD, FUS-SD, and Mobic® was 1.5, 3.0, and 4.0 h, respectively.",A novel combination of Soluplus®/Poloxamer for Meloxicam solid dispersions via hot melt extrusion for rapid onset of action. Part 2: comparative bioavailability and IVIVC. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32615818/),h,4.0,230975,DB00814,Meloxicam
,10220944,elimination half-life,Meloxicam is completely absorbed from the gastrointestinal tract and has an elimination half-life of 24 hours in the dog.,[Pharmacodynamic and pharmacokinetic aspects of the non-inflammatory non-steroidal agent meloxicam in dogs]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10220944/),h,24,232769,DB00814,Meloxicam
,16197363,plasma half-life,Meloxicam has a plasma half-life of approximately 20 h and is convenient for once daily administration.,"Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16197363/),h,20,236078,DB00814,Meloxicam
,10971303,"Cpre,ss","The geometric mean lithium Cpre,ss was 0.65 mmol l(-1) when coadministered with meloxicam and 0.54 mmol l(-1) for lithium alone.",Steady-state pharmacokinetics of lithium in healthy volunteers receiving concomitant meloxicam. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10971303/),[mM] / [l],0.65,239036,DB00814,Meloxicam
,10971303,"Cpre,ss","The geometric mean lithium Cpre,ss was 0.65 mmol l(-1) when coadministered with meloxicam and 0.54 mmol l(-1) for lithium alone.",Steady-state pharmacokinetics of lithium in healthy volunteers receiving concomitant meloxicam. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10971303/),[mM] / [l],0.54,239037,DB00814,Meloxicam
,10971303,"Cmax,ss","Lithium Cmax,ss values were increased by 16% by coadministration of meloxicam, from 0.97 mmol l(-1) to 1.12 mmol l(-1).",Steady-state pharmacokinetics of lithium in healthy volunteers receiving concomitant meloxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10971303/),[mM] / [l],0.97,239038,DB00814,Meloxicam
,10971303,"Cmax,ss","Lithium Cmax,ss values were increased by 16% by coadministration of meloxicam, from 0.97 mmol l(-1) to 1.12 mmol l(-1).",Steady-state pharmacokinetics of lithium in healthy volunteers receiving concomitant meloxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10971303/),[mM] / [l],1.12,239039,DB00814,Meloxicam
,27597532,volume of distribution,"After i.v. administration, the volume of distribution, clearance and elimination half-life were 90.6 ± 4.1 mL/kg, 2.18 ± 0.25 mL/h/kg and 31.4 ± 4.6 h, respectively.","Pharmacokinetics of meloxicam after intravenous, intramuscular and oral administration of a single dose to African grey parrots (Psittacus erithacus). ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27597532/),[ml] / [kg],90.6,242319,DB00814,Meloxicam
,27597532,clearance,"After i.v. administration, the volume of distribution, clearance and elimination half-life were 90.6 ± 4.1 mL/kg, 2.18 ± 0.25 mL/h/kg and 31.4 ± 4.6 h, respectively.","Pharmacokinetics of meloxicam after intravenous, intramuscular and oral administration of a single dose to African grey parrots (Psittacus erithacus). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27597532/),[ml] / [h·kg],2.18,242320,DB00814,Meloxicam
,27597532,elimination half-life,"After i.v. administration, the volume of distribution, clearance and elimination half-life were 90.6 ± 4.1 mL/kg, 2.18 ± 0.25 mL/h/kg and 31.4 ± 4.6 h, respectively.","Pharmacokinetics of meloxicam after intravenous, intramuscular and oral administration of a single dose to African grey parrots (Psittacus erithacus). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27597532/),h,31.4,242321,DB00814,Meloxicam
,27597532,peak mean,The peak mean ± SD plasma concentration was 8.32 ± 0.95 μg/mL at 30 min after i.m. administration.,"Pharmacokinetics of meloxicam after intravenous, intramuscular and oral administration of a single dose to African grey parrots (Psittacus erithacus). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27597532/),[μg] / [ml],8.32,242322,DB00814,Meloxicam
,27597532,tmax,Oral administration resulted in a slower absorption (tmax = 13.2 ± 3.5 h; Cmax = 4.69 ± 0.75 μg/mL) and a lower bioavailability (38.1 ± 3.6%) than for i.m. (78.4 ± 5.5%) route.,"Pharmacokinetics of meloxicam after intravenous, intramuscular and oral administration of a single dose to African grey parrots (Psittacus erithacus). ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27597532/),h,13.2,242323,DB00814,Meloxicam
,27597532,Cmax,Oral administration resulted in a slower absorption (tmax = 13.2 ± 3.5 h; Cmax = 4.69 ± 0.75 μg/mL) and a lower bioavailability (38.1 ± 3.6%) than for i.m. (78.4 ± 5.5%) route.,"Pharmacokinetics of meloxicam after intravenous, intramuscular and oral administration of a single dose to African grey parrots (Psittacus erithacus). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27597532/),[μg] / [ml],4.69,242324,DB00814,Meloxicam
,27597532,bioavailability,Oral administration resulted in a slower absorption (tmax = 13.2 ± 3.5 h; Cmax = 4.69 ± 0.75 μg/mL) and a lower bioavailability (38.1 ± 3.6%) than for i.m. (78.4 ± 5.5%) route.,"Pharmacokinetics of meloxicam after intravenous, intramuscular and oral administration of a single dose to African grey parrots (Psittacus erithacus). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27597532/),%,38.1,242325,DB00814,Meloxicam
,27597532,bioavailability,Oral administration resulted in a slower absorption (tmax = 13.2 ± 3.5 h; Cmax = 4.69 ± 0.75 μg/mL) and a lower bioavailability (38.1 ± 3.6%) than for i.m. (78.4 ± 5.5%) route.,"Pharmacokinetics of meloxicam after intravenous, intramuscular and oral administration of a single dose to African grey parrots (Psittacus erithacus). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27597532/),%,78.4,242326,DB00814,Meloxicam
,27597532,concentrations,"At 24 h, concentrations were 5.90 ± 0.28 μg/mL for i.v., 4.59 ± 0.36 μg/mL for i.m. and 3.21 ± 0.34 μg/mL for p.o. administrations and were higher than those published for Hispaniolan Amazon parrots at 12 h with predicted analgesic effects.","Pharmacokinetics of meloxicam after intravenous, intramuscular and oral administration of a single dose to African grey parrots (Psittacus erithacus). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27597532/),[μg] / [ml],5.90,242327,DB00814,Meloxicam
,27597532,concentrations,"At 24 h, concentrations were 5.90 ± 0.28 μg/mL for i.v., 4.59 ± 0.36 μg/mL for i.m. and 3.21 ± 0.34 μg/mL for p.o. administrations and were higher than those published for Hispaniolan Amazon parrots at 12 h with predicted analgesic effects.","Pharmacokinetics of meloxicam after intravenous, intramuscular and oral administration of a single dose to African grey parrots (Psittacus erithacus). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27597532/),[μg] / [ml],4.59,242328,DB00814,Meloxicam
,31017959,elimination half-lives,"Both 1.0 mg/kg SC and IM treatments demonstrated elimination half-lives (mean ± SD) of 10.82 ± 2.46 and 12.63 ± 2.37 h, respectively.",Plasma pharmacokinetic profile and efficacy of meloxicam administered subcutaneously and intramuscularly to sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31017959/),h,10.82,248060,DB00814,Meloxicam
,31017959,elimination half-lives,"Both 1.0 mg/kg SC and IM treatments demonstrated elimination half-lives (mean ± SD) of 10.82 ± 2.46 and 12.63 ± 2.37 h, respectively.",Plasma pharmacokinetic profile and efficacy of meloxicam administered subcutaneously and intramuscularly to sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31017959/),h,12.63,248061,DB00814,Meloxicam
,32154277,Time to peak concentration (Tmax),"Time to peak concentration (Tmax) of meloxicam, flunixin, and S(-)-ketoprofen in plasma were 1.21, 0.85, and 0.59 h, compared to 2.81, 3.64, and 2.98 h in the ISF, respectively.","Comparative Plasma and Interstitial Fluid Pharmacokinetics of Meloxicam, Flunixin, and Ketoprofen in Neonatal Piglets. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154277/),h,1.21,254566,DB00814,Meloxicam
,32154277,Time to peak concentration (Tmax),"Time to peak concentration (Tmax) of meloxicam, flunixin, and S(-)-ketoprofen in plasma were 1.21, 0.85, and 0.59 h, compared to 2.81, 3.64, and 2.98 h in the ISF, respectively.","Comparative Plasma and Interstitial Fluid Pharmacokinetics of Meloxicam, Flunixin, and Ketoprofen in Neonatal Piglets. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154277/),h,0.85,254567,DB00814,Meloxicam
,32154277,Time to peak concentration (Tmax),"Time to peak concentration (Tmax) of meloxicam, flunixin, and S(-)-ketoprofen in plasma were 1.21, 0.85, and 0.59 h, compared to 2.81, 3.64, and 2.98 h in the ISF, respectively.","Comparative Plasma and Interstitial Fluid Pharmacokinetics of Meloxicam, Flunixin, and Ketoprofen in Neonatal Piglets. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154277/),h,0.59,254568,DB00814,Meloxicam
,32154277,Time to peak concentration (Tmax),"Time to peak concentration (Tmax) of meloxicam, flunixin, and S(-)-ketoprofen in plasma were 1.21, 0.85, and 0.59 h, compared to 2.81, 3.64, and 2.98 h in the ISF, respectively.","Comparative Plasma and Interstitial Fluid Pharmacokinetics of Meloxicam, Flunixin, and Ketoprofen in Neonatal Piglets. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154277/),h,2.81,254569,DB00814,Meloxicam
,32154277,Time to peak concentration (Tmax),"Time to peak concentration (Tmax) of meloxicam, flunixin, and S(-)-ketoprofen in plasma were 1.21, 0.85, and 0.59 h, compared to 2.81, 3.64, and 2.98 h in the ISF, respectively.","Comparative Plasma and Interstitial Fluid Pharmacokinetics of Meloxicam, Flunixin, and Ketoprofen in Neonatal Piglets. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154277/),h,3.64,254570,DB00814,Meloxicam
,32154277,Time to peak concentration (Tmax),"Time to peak concentration (Tmax) of meloxicam, flunixin, and S(-)-ketoprofen in plasma were 1.21, 0.85, and 0.59 h, compared to 2.81, 3.64, and 2.98 h in the ISF, respectively.","Comparative Plasma and Interstitial Fluid Pharmacokinetics of Meloxicam, Flunixin, and Ketoprofen in Neonatal Piglets. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154277/),h,2.98,254571,DB00814,Meloxicam
,32154277,apparent terminal half-life,"The apparent terminal half-life of meloxicam, flunixin and S(-)-ketoprofen were 4.39, 7.69, and 3.50 h, compared to 11.26, 16.34, and 5.54 h, respectively in the ISF.","Comparative Plasma and Interstitial Fluid Pharmacokinetics of Meloxicam, Flunixin, and Ketoprofen in Neonatal Piglets. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154277/),h,4.39,254572,DB00814,Meloxicam
,32154277,apparent terminal half-life,"The apparent terminal half-life of meloxicam, flunixin and S(-)-ketoprofen were 4.39, 7.69, and 3.50 h, compared to 11.26, 16.34, and 5.54 h, respectively in the ISF.","Comparative Plasma and Interstitial Fluid Pharmacokinetics of Meloxicam, Flunixin, and Ketoprofen in Neonatal Piglets. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154277/),h,7.69,254573,DB00814,Meloxicam
,32154277,apparent terminal half-life,"The apparent terminal half-life of meloxicam, flunixin and S(-)-ketoprofen were 4.39, 7.69, and 3.50 h, compared to 11.26, 16.34, and 5.54 h, respectively in the ISF.","Comparative Plasma and Interstitial Fluid Pharmacokinetics of Meloxicam, Flunixin, and Ketoprofen in Neonatal Piglets. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154277/),h,3.50,254574,DB00814,Meloxicam
,32154277,apparent terminal half-life,"The apparent terminal half-life of meloxicam, flunixin and S(-)-ketoprofen were 4.39, 7.69, and 3.50 h, compared to 11.26, 16.34, and 5.54 h, respectively in the ISF.","Comparative Plasma and Interstitial Fluid Pharmacokinetics of Meloxicam, Flunixin, and Ketoprofen in Neonatal Piglets. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154277/),h,11.26,254575,DB00814,Meloxicam
,32154277,apparent terminal half-life,"The apparent terminal half-life of meloxicam, flunixin and S(-)-ketoprofen were 4.39, 7.69, and 3.50 h, compared to 11.26, 16.34, and 5.54 h, respectively in the ISF.","Comparative Plasma and Interstitial Fluid Pharmacokinetics of Meloxicam, Flunixin, and Ketoprofen in Neonatal Piglets. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154277/),h,16.34,254576,DB00814,Meloxicam
,32154277,apparent terminal half-life,"The apparent terminal half-life of meloxicam, flunixin and S(-)-ketoprofen were 4.39, 7.69, and 3.50 h, compared to 11.26, 16.34, and 5.54 h, respectively in the ISF.","Comparative Plasma and Interstitial Fluid Pharmacokinetics of Meloxicam, Flunixin, and Ketoprofen in Neonatal Piglets. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154277/),h,5.54,254577,DB00814,Meloxicam
,28240949,maximum plasma concentration,RESULTS Mean ± SD maximum plasma concentration was 1.00 ± 0.88 μg/mL after oral administration.,Pharmacokinetics of meloxicam after intramuscular and oral administration of a single dose to American flamingos (Phoenicopertus ruber). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28240949/),[μg] / [ml],1.00,255454,DB00814,Meloxicam
,28240949,maximum plasma concentration,This was approximately 15% of the mean maximum plasma concentration of 5.50 ± 2.86 μg/mL after IM administration.,Pharmacokinetics of meloxicam after intramuscular and oral administration of a single dose to American flamingos (Phoenicopertus ruber). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28240949/),[μg] / [ml],5.50,255455,DB00814,Meloxicam
,28240949,time to maximum plasma concentration,Mean time to maximum plasma concentration was 1.33 ± 1.32 hours after oral administration and 0.28 ± 0.17 hours after IM administration.,Pharmacokinetics of meloxicam after intramuscular and oral administration of a single dose to American flamingos (Phoenicopertus ruber). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28240949/),h,1.33,255456,DB00814,Meloxicam
,28240949,time to maximum plasma concentration,Mean time to maximum plasma concentration was 1.33 ± 1.32 hours after oral administration and 0.28 ± 0.17 hours after IM administration.,Pharmacokinetics of meloxicam after intramuscular and oral administration of a single dose to American flamingos (Phoenicopertus ruber). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28240949/),h,0.28,255457,DB00814,Meloxicam
,28240949,half-life of the terminal phase,Mean half-life of the terminal phase after oral administration (3.83 ± 2.64 hours) was approximately twice that after IM administration (1.83 ± 1.22 hours).,Pharmacokinetics of meloxicam after intramuscular and oral administration of a single dose to American flamingos (Phoenicopertus ruber). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28240949/),h,3.83,255458,DB00814,Meloxicam
,28240949,half-life of the terminal phase,Mean half-life of the terminal phase after oral administration (3.83 ± 2.64 hours) was approximately twice that after IM administration (1.83 ± 1.22 hours).,Pharmacokinetics of meloxicam after intramuscular and oral administration of a single dose to American flamingos (Phoenicopertus ruber). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28240949/),h,1.83,255459,DB00814,Meloxicam
,23067209,terminal half-life,The mean terminal half-life was 4.99 ± 1.11 h.,Pharmacokinetics and adverse effects of oral meloxicam tablets in healthy adult horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23067209/),h,4.99,260041,DB00814,Meloxicam
,23067209,Cmax,"There was no significant difference between the mean Cmax , 1.58 ± 0.71 ng/mL at Tmax 3.48 ± 3.30 h on day 1, 2.07 ± 0.94 ng/mL at Tmax 1.24 ± 1.24 h on day 7, and 1.81 ± 0.76 ng/mL at 1.93 ± 1.30 h on day 14 (P = 0.30).",Pharmacokinetics and adverse effects of oral meloxicam tablets in healthy adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23067209/),[ng] / [ml],1.58,260042,DB00814,Meloxicam
,23067209,Cmax,"There was no significant difference between the mean Cmax , 1.58 ± 0.71 ng/mL at Tmax 3.48 ± 3.30 h on day 1, 2.07 ± 0.94 ng/mL at Tmax 1.24 ± 1.24 h on day 7, and 1.81 ± 0.76 ng/mL at 1.93 ± 1.30 h on day 14 (P = 0.30).",Pharmacokinetics and adverse effects of oral meloxicam tablets in healthy adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23067209/),[ng] / [ml],2.07,260043,DB00814,Meloxicam
,23067209,Tmax,"There was no significant difference between the mean Cmax , 1.58 ± 0.71 ng/mL at Tmax 3.48 ± 3.30 h on day 1, 2.07 ± 0.94 ng/mL at Tmax 1.24 ± 1.24 h on day 7, and 1.81 ± 0.76 ng/mL at 1.93 ± 1.30 h on day 14 (P = 0.30).",Pharmacokinetics and adverse effects of oral meloxicam tablets in healthy adult horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23067209/),h,1.24,260044,DB00814,Meloxicam
,23067209,Tmax,"There was no significant difference between the mean Cmax , 1.58 ± 0.71 ng/mL at Tmax 3.48 ± 3.30 h on day 1, 2.07 ± 0.94 ng/mL at Tmax 1.24 ± 1.24 h on day 7, and 1.81 ± 0.76 ng/mL at 1.93 ± 1.30 h on day 14 (P = 0.30).",Pharmacokinetics and adverse effects of oral meloxicam tablets in healthy adult horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23067209/),[ng] / [ml],1.81,260045,DB00814,Meloxicam
,20444036,ED(50),"Robenacoxib produced dose-related improvement in weight-bearing, pain and swelling as assessed objectively by forceplate analysis (estimated ED(50) was 1.23 mg/kg for z peak force) and subjectively by clinical orthopaedic assessments.",Analgesic and anti-inflammatory actions of robenacoxib in acute joint inflammation in dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444036/),[mg] / [kg],1.23,260970,DB00814,Meloxicam
,20444036,ED(50),All dosages of robenacoxib produced significant dose-related inhibition of COX-2 (estimated ED(50) was 0.52 mg/kg) but no inhibition of COX-1.,Analgesic and anti-inflammatory actions of robenacoxib in acute joint inflammation in dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444036/),[mg] / [kg],0.52,260971,DB00814,Meloxicam
,23438111,plasma concentration,"Initial mean ± SD plasma concentration of 17.3 ± 9.0 μg/mL was measured 5 minutes after IV administration, whereas peak mean concentration was 9.3 ± 1.8 μg/mL 15 minutes after IM administration.","Pharmacokinetics of meloxicam after intravenous, intramuscular, and oral administration of a single dose to Hispaniolan Amazon parrots (Amazona ventralis). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23438111/),[μg] / [ml],17.3,262485,DB00814,Meloxicam
,23438111,peak mean concentration,"Initial mean ± SD plasma concentration of 17.3 ± 9.0 μg/mL was measured 5 minutes after IV administration, whereas peak mean concentration was 9.3 ± 1.8 μg/mL 15 minutes after IM administration.","Pharmacokinetics of meloxicam after intravenous, intramuscular, and oral administration of a single dose to Hispaniolan Amazon parrots (Amazona ventralis). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23438111/),[μg] / [ml],9.3,262486,DB00814,Meloxicam
,23438111,plasma concentrations,"At 12 hours after administration, mean plasma concentrations for IV (3.7 ± 2.5 μg/mL) and IM (3.5 ± 2.2 μg/mL) administration were similar.","Pharmacokinetics of meloxicam after intravenous, intramuscular, and oral administration of a single dose to Hispaniolan Amazon parrots (Amazona ventralis). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23438111/),[μg] / [ml],3.7,262487,DB00814,Meloxicam
,23438111,plasma concentrations,"At 12 hours after administration, mean plasma concentrations for IV (3.7 ± 2.5 μg/mL) and IM (3.5 ± 2.2 μg/mL) administration were similar.","Pharmacokinetics of meloxicam after intravenous, intramuscular, and oral administration of a single dose to Hispaniolan Amazon parrots (Amazona ventralis). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23438111/),[μg] / [ml],3.5,262488,DB00814,Meloxicam
,23438111,Peak mean plasma concentration,Peak mean plasma concentration (3.5 ± 1.2 μg/mL) was detected 6 hours after oral administration.,"Pharmacokinetics of meloxicam after intravenous, intramuscular, and oral administration of a single dose to Hispaniolan Amazon parrots (Amazona ventralis). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23438111/),[μg] / [ml],3.5,262489,DB00814,Meloxicam
,23438111,Absolute systemic bioavailability,"Absolute systemic bioavailability of meloxicam after IM administration was 100% but was lower after oral administration (range, 49% to 75%).","Pharmacokinetics of meloxicam after intravenous, intramuscular, and oral administration of a single dose to Hispaniolan Amazon parrots (Amazona ventralis). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23438111/),%,100,262490,DB00814,Meloxicam
,23438111,Absolute systemic bioavailability,"Absolute systemic bioavailability of meloxicam after IM administration was 100% but was lower after oral administration (range, 49% to 75%).","Pharmacokinetics of meloxicam after intravenous, intramuscular, and oral administration of a single dose to Hispaniolan Amazon parrots (Amazona ventralis). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23438111/),%,49,262491,DB00814,Meloxicam
,23438111,Absolute systemic bioavailability,"Absolute systemic bioavailability of meloxicam after IM administration was 100% but was lower after oral administration (range, 49% to 75%).","Pharmacokinetics of meloxicam after intravenous, intramuscular, and oral administration of a single dose to Hispaniolan Amazon parrots (Amazona ventralis). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23438111/),%,75,262492,DB00814,Meloxicam
,23438111,Elimination half-lives,"Elimination half-lives after IV, IM, and oral administration were similar (15.9 ± 4.4 hours, 15.1 ± 7.7 hours, and 15.8 ± 8.6 hours, respectively).","Pharmacokinetics of meloxicam after intravenous, intramuscular, and oral administration of a single dose to Hispaniolan Amazon parrots (Amazona ventralis). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23438111/),h,15.9,262493,DB00814,Meloxicam
,23438111,Elimination half-lives,"Elimination half-lives after IV, IM, and oral administration were similar (15.9 ± 4.4 hours, 15.1 ± 7.7 hours, and 15.8 ± 8.6 hours, respectively).","Pharmacokinetics of meloxicam after intravenous, intramuscular, and oral administration of a single dose to Hispaniolan Amazon parrots (Amazona ventralis). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23438111/),h,15.1,262494,DB00814,Meloxicam
,23438111,Elimination half-lives,"Elimination half-lives after IV, IM, and oral administration were similar (15.9 ± 4.4 hours, 15.1 ± 7.7 hours, and 15.8 ± 8.6 hours, respectively).","Pharmacokinetics of meloxicam after intravenous, intramuscular, and oral administration of a single dose to Hispaniolan Amazon parrots (Amazona ventralis). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23438111/),h,15.8,262495,DB00814,Meloxicam
,27493016,ED50,"For weight bearing on the force plate, the ED50 of robenacoxib was 0.6-0.8 mg/kg.",Evaluation of the dose-response relationship of oral robenacoxib in urate crystal-induced acute stifle synovitis in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27493016/),[mg] / [kg],0.6-0.8,262914,DB00814,Meloxicam
,27493016,onset of action,"The onset of action and time to peak effect of robenacoxib were faster (respectively, 2-2.5 h and 3-5 h) than for meloxicam (respectively, 3 h and 6 h).",Evaluation of the dose-response relationship of oral robenacoxib in urate crystal-induced acute stifle synovitis in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27493016/),h,2-2.5,262915,DB00814,Meloxicam
,27493016,onset of action,"The onset of action and time to peak effect of robenacoxib were faster (respectively, 2-2.5 h and 3-5 h) than for meloxicam (respectively, 3 h and 6 h).",Evaluation of the dose-response relationship of oral robenacoxib in urate crystal-induced acute stifle synovitis in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27493016/),h,3,262916,DB00814,Meloxicam
,27493016,onset of action,"The onset of action and time to peak effect of robenacoxib were faster (respectively, 2-2.5 h and 3-5 h) than for meloxicam (respectively, 3 h and 6 h).",Evaluation of the dose-response relationship of oral robenacoxib in urate crystal-induced acute stifle synovitis in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27493016/),h,6,262917,DB00814,Meloxicam
,27493016,time to peak effect,"The onset of action and time to peak effect of robenacoxib were faster (respectively, 2-2.5 h and 3-5 h) than for meloxicam (respectively, 3 h and 6 h).",Evaluation of the dose-response relationship of oral robenacoxib in urate crystal-induced acute stifle synovitis in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27493016/),h,3-5,262918,DB00814,Meloxicam
,27493016,time to peak effect,"The onset of action and time to peak effect of robenacoxib were faster (respectively, 2-2.5 h and 3-5 h) than for meloxicam (respectively, 3 h and 6 h).",Evaluation of the dose-response relationship of oral robenacoxib in urate crystal-induced acute stifle synovitis in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27493016/),h,3,262919,DB00814,Meloxicam
,27493016,time to peak effect,"The onset of action and time to peak effect of robenacoxib were faster (respectively, 2-2.5 h and 3-5 h) than for meloxicam (respectively, 3 h and 6 h).",Evaluation of the dose-response relationship of oral robenacoxib in urate crystal-induced acute stifle synovitis in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27493016/),h,6,262920,DB00814,Meloxicam
,17598697,Maximum plasma concentrations (C(max)),"Maximum plasma concentrations (C(max)) of 1,146.9 ng/ml (test) and 1,064.8 ng/ml (reference) were achieved.",Pharmacokinetic and bioequivalence study of meloxicam tablets in healthy male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17598697/),[ng] / [ml],"1,146.9",264986,DB00814,Meloxicam
,17598697,Maximum plasma concentrations (C(max)),"Maximum plasma concentrations (C(max)) of 1,146.9 ng/ml (test) and 1,064.8 ng/ml (reference) were achieved.",Pharmacokinetic and bioequivalence study of meloxicam tablets in healthy male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17598697/),[ng] / [ml],"1,064.8",264987,DB00814,Meloxicam
,17598697,Areas under the plasma concentration-time curve (AUC(0-infinity),"Areas under the plasma concentration-time curve (AUC(0-infinity) of 34,499.0 ng x h/ml (test) and 33,784.3 ng x h/ml (reference) were determined.",Pharmacokinetic and bioequivalence study of meloxicam tablets in healthy male subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17598697/),[h·ng] / [ml],"34,499.0",264988,DB00814,Meloxicam
,17598697,Areas under the plasma concentration-time curve (AUC(0-infinity),"Areas under the plasma concentration-time curve (AUC(0-infinity) of 34,499.0 ng x h/ml (test) and 33,784.3 ng x h/ml (reference) were determined.",Pharmacokinetic and bioequivalence study of meloxicam tablets in healthy male subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17598697/),[h·ng] / [ml],"33,784.3",264989,DB00814,Meloxicam
,17598697,t(max),"Thus, t(max) showed values of 5.00 h for both test and reference.",Pharmacokinetic and bioequivalence study of meloxicam tablets in healthy male subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17598697/),h,5.00,264990,DB00814,Meloxicam
,17598697,plasma elimination half-life (t1/2),The plasma elimination half-life (t1/2) was 18.29 h (test) und 18.94 h (reference).,Pharmacokinetic and bioequivalence study of meloxicam tablets in healthy male subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17598697/),h,18.29,264991,DB00814,Meloxicam
,17598697,plasma elimination half-life (t1/2),The plasma elimination half-life (t1/2) was 18.29 h (test) und 18.94 h (reference).,Pharmacokinetic and bioequivalence study of meloxicam tablets in healthy male subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17598697/),h,18.94,264992,DB00814,Meloxicam
,30846026,Peak plasma concentrations,Peak plasma concentrations were 1057 ± 433 ng/mL at 4 ± 0 h for conventional meloxicam and 3238 ± 1480 ng/mL at 6.7 ± 4.1 h for SR meloxicam (SRM).,Preliminary Evaluation of Sustained-release Compared with Conventional Formulations of Meloxicam in Sheep (Ovis aries). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30846026/),[ng] / [ml],1057,265089,DB00814,Meloxicam
,30846026,Peak plasma concentrations,Peak plasma concentrations were 1057 ± 433 ng/mL at 4 ± 0 h for conventional meloxicam and 3238 ± 1480 ng/mL at 6.7 ± 4.1 h for SR meloxicam (SRM).,Preliminary Evaluation of Sustained-release Compared with Conventional Formulations of Meloxicam in Sheep (Ovis aries). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30846026/),[ng] / [ml],3238,265090,DB00814,Meloxicam
,30846026,Elimination half-lives,Elimination half-lives were 12.1 4.2 for CM and 15.2 ± 2.4 h for SRM.,Preliminary Evaluation of Sustained-release Compared with Conventional Formulations of Meloxicam in Sheep (Ovis aries). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30846026/),h,12.1,265091,DB00814,Meloxicam
,30846026,Elimination half-lives,Elimination half-lives were 12.1 4.2 for CM and 15.2 ± 2.4 h for SRM.,Preliminary Evaluation of Sustained-release Compared with Conventional Formulations of Meloxicam in Sheep (Ovis aries). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30846026/),h,15.2,265092,DB00814,Meloxicam
,8630630,elimination half-life (t1/2),The elimination half-life (t1/2) of meloxicam is approximately 20 h.,A review of the clinical pharmacokinetics of meloxicam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8630630/),h,20,268516,DB00814,Meloxicam
,8630630,total plasma clearance (CL),This is reflected in a total plasma clearance (CL) of 0.42-0.48 1/h.,A review of the clinical pharmacokinetics of meloxicam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8630630/),[1] / [h],0.42-0.48,268517,DB00814,Meloxicam
,16169293,recoveries,"The recoveries of piroxicam, meloxicam and tenoxicam ranged from 78.3 to 87.1%, with that of isoxicam being 59.7%.","Simultaneous determination of piroxicam, meloxicam and tenoxicam in human plasma by liquid chromatography with tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16169293/),%,78.3 to 87.1,268710,DB00814,Meloxicam
,16169293,recoveries,"The recoveries of piroxicam, meloxicam and tenoxicam ranged from 78.3 to 87.1%, with that of isoxicam being 59.7%.","Simultaneous determination of piroxicam, meloxicam and tenoxicam in human plasma by liquid chromatography with tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16169293/),%,59.7,268711,DB00814,Meloxicam
,28738003,half-life,"The half-life, maximum concentration, and time to maximum concentration of meloxicam in plasma samples were 2.8 hours, 7.21 μg/mL, and 2 hours, respectively.",Pharmacokinetics and egg residues after oral administration of a single dose of meloxicam in domestic chickens (Gallus domesticus). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28738003/),h,2.8,273944,DB00814,Meloxicam
,28738003,maximum concentration,"The half-life, maximum concentration, and time to maximum concentration of meloxicam in plasma samples were 2.8 hours, 7.21 μg/mL, and 2 hours, respectively.",Pharmacokinetics and egg residues after oral administration of a single dose of meloxicam in domestic chickens (Gallus domesticus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28738003/),[μg] / [ml],7.21,273945,DB00814,Meloxicam
,28738003,time to maximum concentration,"The half-life, maximum concentration, and time to maximum concentration of meloxicam in plasma samples were 2.8 hours, 7.21 μg/mL, and 2 hours, respectively.",Pharmacokinetics and egg residues after oral administration of a single dose of meloxicam in domestic chickens (Gallus domesticus). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28738003/),h,2,273946,DB00814,Meloxicam
